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Research ethics committees (RECs) are required by national and international ethical 
frameworks to provide independent ethics review and approval of biomedical research. South 
Africa has approximately 44 RECs registered with the National Health Research Ethics Council. 
However, despite more than a decade of existence, little is known about the review activities of 
such committees. The purpose of this study was to investigate the ethical issues typically raised 
by two purposively selected biomedical RECs in South Africa. A systematic random sample of 
REC minutes and decision letters from 2009 to 2014 were retrospectively analysed using the 
ethical framework developed by Emanuel, Wendler, Killen and Grady (2004). Furthermore, 
semi-structured interviews were conducted with nine REC members to explore their views of the 
ethical issues identified. Overall, the most frequent ethical issues identified were informed 
consent (top ranked), followed by respect for participants (ranked 2nd) and scientific validity 
(ranked 3rd). Interestingly, administrative issues such as researchers’ CVs and budgets were also 
frequently identified (ranked 4th) compared to other ethical issues such as collaborative 
partnership (ranked 5th), favourable risk/benefit ratio (ranked 7th) and fair participant selection 
(ranked 8th). The least frequent ethical issue was social value (ranked 10th). Data from semi-
structured interviews suggested that all nine REC members were not surprised by the frequency 
or ranking of ethical issues identified in this study. They felt that such ranking reflected what 
their RECs should be querying during ethics review. However, disparate views emerged 
regarding the frequency of scientific validity issues. Some REC members believed there was an 
over-emphasis on scientific validity, and that it was not within the remit of RECs to query the 
scientific validity of research proposals. Nevertheless, it was reassuring that almost all the issues 
identified in this study were in accordance with existing national and international guidance. This 
xv 
 
study provides important insights regarding the kinds of ethical issues raised by two SA RECs. 
The findings, however, may not be generalizable to the entire REC system, especially non-
biomedical RECs, but is likely to be relevant to other biomedical RECs operating in South Africa 





BACKGROUND OF STUDY  
1.0 Introduction  
The present study is an investigation of ethical issues raised by two South African biomedical 
research ethics committees (RECs) during ethics review of biomedical research involving human 
participants. This chapter provides the background and rationale for the study. First, a general 
background on the importance of health-related or biomedical research is provided. Thereafter, 
the relationship between research and ethics is described. This is then followed by a brief 
introduction on the researcher’s personal interest in the field of biomedical research ethics. This 
is followed by the problem statement and the research questions and objectives. Finally, the last 
section describes the motivation for the project and argues for its importance.  
 
1.1 The importance of biomedical research 
Biomedical research plays a critical role in advancing scientific knowledge for addressing public 
health challenges, informing evidence-based health policies, and enhancing the performance of 
public health systems (Department of Health, 2015; Senkubuge & Mayosi, 2013). If it were not 
for biomedical research, there would probably be no vaccines or chemotherapy drugs, or even 
organ transplants to save lives and reduce morbidity of many thousands of people daily in 
modern society. For example, it was through medical research that the world’s first human-to-
human heart transplantation was pioneered in 1967 by a South African surgeon named Christiaan 
Barnard. This medical procedure has since gone on to save millions of people’s lives around the 
world (Cooper, 2001).  
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In 2009, South African researchers at the Centre for the Aids Programme of Research in South 
Africa (CAPRISA) discovered through research that initiating  antiretroviral therapy at the same 
time as tuberculosis (TB) treatment when the immune system is still relatively intact reduces the 
risk of the human immunodeficiency virus (HIV) /TB related deaths by 56% (Abdool Karim, 
Morris & Moore, 2012). Implementing this life-saving policy, which is now endorsed by the 
World Health Organization (WHO), has resulted in about a hundred thousand more TB patients 
being initiated on antiretroviral therapy annually and is estimated to prevent 10 000 deaths a year 
in South Africa. Similarly in 2010, researchers at CAPRISA discovered through research that 
tenofovir gel, used as a vaginal microbicide, can prevent HIV infection in women. The findings 
influenced a change in the HIV/TB treatment policy in South Africa and worldwide as it was 
adopted by the WHO (Abdool Karim et al., 2012). These few examples highlight the importance 
of health-related research in improving lives and influencing policy.  
 
Furthermore, excellent scientific research and development (R&D) and innovation contribute to 
a country’s socio-economic growth through increased productivity and competitiveness in a 
knowledge-based global economy (Gumus & Celikay, 2015). Reports suggest that countries that 
have invested more in R&D yield higher added value and economic performance. A study 
involving 52 countries conducted between 1996 and 2010 found that R&D expenditure impacted 






The burden of mortality and morbidity associated with devastating infectious diseases (e.g. 
HIV/AIDS and TB) and non-communicable diseases (e.g. Diabetes) continues to increase 
considerably, particularly in less developed countries (Bygbjerg, 2012). According to the 
UNAIDS (2015), an estimated 36.9 million people globally were living with HIV at the end of 
2014. Sub-Saharan Africa accounted for more than half of the global prevalence of HIV with 
more than 25.8 million people living with HIV. Furthermore, women accounted for more than 
half the total number of people living with HIV in sub-Saharan Africa. Additionally, more than 
1.4 million new HIV infections occurred in Sub-Saharan Africa, accounting for 66% of new 
infections worldwide. In the same year, there were more than 790,000 AIDS related deaths and 
190,000 new HIV infections among Sub-Saharan African children (UNAIDS, 2015).  
 
In South Africa alone, a country at the epicentre of the global HIV/AIDS epidemic, there were 
more than 6.4 million people living with HIV in 2012, a 1.6% increase from 5.2 million in 2008, 
as well as 469,000 new infections and more than 450,000 AIDS-related deaths (Shisana et al., 
2014). The high burden of disease, including diseases associated with poverty and 
underdevelopment, along with non-communicable diseases, has created the need for a broad 
spectrum of biomedical research in South Africa and other low and middle income countries 
(LMICs) (Department of Health, 2015). Consequently, there has been massive growth of health-
related research in recent years sponsored wealthy countries and conducted in LMICs (Glickman 
et al., 2009). According to the online website of the South African National Clinical Trials 




Beyond this devastating impact on human lives, the high HIV/AIDS burden has undermined the 
achievement of key Millennium Development Goals (MDGs) in Sub Saharan Africa (Alban & 
Andersen, 2007; Fourie & Schoeman, 2010). There is thus a pressing need to find evidence-
based solutions through research in order to achieve the three health-related MDGs adopted in 
2000, i.e. reduction in child mortality (Goal 4); reduction in maternal mortality and access to 
reproductive health care (Goal 5); and combating HIV/AIDS, TB, Malaria and other diseases 
(Goal 6) (United Nations, 2014), and the health-related Sustainable Development Goals (SDGs) 
adopted in 2015, i.e., ensure healthy lives and promote well-being for all at all ages (Goal 3) 
(United Nations, 2015). One of the specific targets of the SGD goal 3 is to “Support the research 
and development of vaccines and medicines for the communicable and non-communicable 
diseases that primarily affect developing countries….” (United Nations, 2015, p.3). 
 
More concerning is the 10/90 gap, which implies that although 90% of the global disease burden 
is borne by developed countries, only 10% of all health research funding is used to address these 
diseases (Kilama, 2009). There is need therefore to develop and strengthen sustainable research 
capacity in developing countries through international and national collaboration. Significant 
strides have been made thus far in addressing the global health research inequity through 
partnerships with organizations such as World Health Organization (WHO) and Commission on 
Health Research for Development. The high burden of disease in South Africa and other Sub-
Saharan African countries has necessitated an increase in health-related research over the past 
few decades in order to accelerate progress against the HIV and TB co-pandemic and other non-
communicable diseases (Department of Health, 2015) and narrow the 10/90 global health 
disparities between developing and developed countries (Global Forum for Health Research, 
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2000). The recent Ebola outbreak in Western Africa has further highlighted the need for strong 
research capacity in Africa to adequately provide solutions to emerging infectious diseases 
(Pandor, 2014; Tomori, 2015).  
 
The importance of health-related research has been well articulated by several policy-makers 
internationally (Commission on Health Research for Development, 1990; Global Ministerial 
Forum on Research for Health, 2008; Ministerial Summit on Health Research, 2004). For 
example, the Ministerial Summit on Health Research (2004) and Global Ministerial Forum on 
Research for Health (2008) recommended that governments in LMICs should spend at least 2% 
of their national health budget on health research, although data suggests that government 
expenditure on health research, at least in South Africa, is still far below the 2% recommended 
(Paruk, Blackburn, Friedman & Mayosi, 2014). In 2013, the Abuja Special Summit on 
HIV/AIDS, Tuberculosis and Malaria, accentuated the need to enhance Africa’s research 
capacity, and develop novel and effective health solutions to address African health challenges 
(African Union Special Summit on HIV/AIDS, Tuberculosis and Malaria, 2013). More recently, 
the African Union adopted the Science, Technology and Innovation Strategy for Africa 2024 
(STISA-2024) as a blueprint to promote and enhance capacity for research on the African 
continent.    
 
The South African health research policy (Department of Health, 2001) emphasizes the 
importance of efficient health-related research in the country. The policy explicitly requires the 
establishment of Provincial Health Research Committees to coordinate and establish priorities 
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for local health research (Lutge & Mbatha, 2007). The need for health-related research in South 
Africa is clear. Given its high prevalence of HIV/TB, a thriving research infrastructure and 
expertise, and an enabling health research policy framework, South Africa has gained wide 
recognition as an international hub for health-related research (Department of Health, 2015). 
There are approximately 15 statutory research councils commissioned by Acts of Government to 
conduct various research for scientific and technological development (Scholes et al., 2008). 
Examples include the Council for Scientific and Industrial Research (CSIR), Human Sciences 
Research Council (HSRC) and Medical Research Council (MRC), constituted by Acts of 
Parliament in 1945, 1968, and 1969, respectively. These statutory research councils have been 
established to deliver outstanding health research to improve the lives of people in South Africa. 
In line with the Department of Health National Service Delivery Agreement (NSDA) for 2010-
2014, research councils such as the Medical Research Council have set priorities to undertake 
locally responsive and globally relevant world class biomedical research aligned to the NSDA 
four main goals: 1) increasing life expectancy, 2) decreasing maternal and child mortality 3) 
combating HIV/AIDS and decreasing the burden of disease from TB, and 4) strengthening health 
system effectiveness (MRC, 2012).  
 
Over the past decade, the landscape for biomedical research has evolved significantly in both 
scope and complexity and this continues to have profound ethical, policy and social implications 
on contemporary society.  Biomedical research has increasingly become more globalized, 
collaborative and multidisciplinary (da Silva, Amato, Guilhem & Novaes, 2016). Notably, the 
volume of clinical trials funded by more developed countries and conducted in low and middle 
income countries (LMICs) has increased (Glickman et al., 2009). According to a 2014 report by 
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the US Institute for Health Metrics and Evaluation, more than $31.3 billion was invested for 
funding health research in LMICs in 2013, five-times more than in 1990.  
 
Furthermore, given recent developments in the landscape of biomedical research, for example, 
genomics and whole-genome sequencing (Pinxten & Howard, 2014), biobanking (Dhai, 2013), 
data sharing (Bull et al., 2015; Denny, Silaigwana, Wassenaar, Bull & Parker, 2015) and linking 
personal medical record data with genomic sequence (ter Meulen, Newson, Kennedy & 
Schofield, 2011), the need for more effective and efficient research ethics oversight has become 
of paramount importance. On the one hand, these biomedical developments are phenomenal and 
significantly revolutionizing personal medicine and public health, but on the other hand, they 
raise numerous serious ethical issues and continuously frame ethical debates on issues such as 
informed consent, privacy and confidentiality, access to personal genetic information, the 
problem of incidental findings and the protection of personal genetic information stored in 
biobanks and databases and ownership of data and human biological materials (Millum, Sina & 
Glass, 2015).  
 
Well-capacitated RECs have a central role to play in ensuring that the research they review is 
relevant to local health needs, is ethically sound and protects the dignity and welfare of research 
populations while supporting evidence-based improvements in public health. There would thus 
appear to be a need to conduct more empirical research to determine the resources, capacity and 
functioning of African research ethics committees (RECs) in dealing with ethical issues raised by 
recent developments in biomedical research (Silaigwana & Wassenaar, 2015). 
8 
 
There have been concerns about inadequate ethics oversight and research ethics capacity in 
LMICs (Bhutta, 2002; Hyder, Dawson, Bachani & Lavery, 2009). A survey of ethics review 
practices in developing country (Africa, Asia and South America), found that about 44% of 
researchers indicated that their studies were not reviewed by an REC or health authority in the 
developing country and one third of those studies were funded by U.S. sponsors (Hyder et al., 
2004). A more recent study by Zielinski et al. (2014) surveyed 847 health research institutions in 
42 African countries and found that only 51% of respondent institutions reported that they had 
policies on research ethics and only 58% had written policies requiring that researchers obtain 
the informed consent of research participants.  
 
As the need for more health-related research in LMICs increases, so should research ethics 
capacity strengthening to ensure the protection of the rights and wellbeing of participants, while 
simultaneously contributing to the advancement of scientific knowledge (IJsselmuiden, Marais, 
Wassenaar & Mokgatla-Moipolai, 2012). It remains to be seen whether current research ethics 
systems in LMICs have kept pace with the increasingly challenging research milieu. However, 
several initiatives have made significant headway towards capacity building and enhancing 
research ethics systems in Sub-Saharan Africa (Ndebele et al., 2014a; Wassenaar, 2011) and 
other developing countries (IJsselmuiden et al., 2012; Oukem-Boyer, Munung, Ntoumi, Nyika & 
Tangwa, 2013). For instance, the Fogarty International Center, National Institutes of Health in 
the US invested approximately US$33 million between 2000 and 2012 to support and build 
research ethics capacity globally, with almost 40% (US$13 million) invested for research ethics 
capacity building in Sub-Saharan Africa alone (Ndebele et al., 2014a). Similarly, since 2007, the 
UK’s Wellcome Trust has spent approximately £2million (with most of the support directed 
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towards research ethics projects in Sub-Saharan Africa) in supporting and enhancing bioethics 
research, research ethics training, and workshops in developing countries. Likewise, the 
European Developing Countries Clinical Trials Partnership (EDCTP) has spent over €3.2 million 
to support more than 54 research ethics projects in Africa between 2005 and 2011 (Ndebele, 
Mwaluko, Kruger, Oukem-Boyer & Zimba 2014b).   
 
While such initiatives are laudable, it remains unclear what the optimal funding ratio should be 
for biomedical research versus research ethics. The aforementioned figures on research ethics 
spending by international organizations could probably still be far much lower than funding for 
clinical research. Considering that there is an increase in the amount and complexity of 
biomedical research conducted in Sub-Saharan Africa, more financial support towards research 
ethics capacity in Sub-Saharan Africa is still needed (Ndebele et al., 2014a). However, given that 
the REC capacity varies between countries, the optimal funding for research ethics capacity will 
inevitably vary between countries depending on their needs.  Initiatives to build research ethics 
capacity in developing countries should also focus on REC administrators (Kasule, Wassenaar, 








1.2 Research and Ethics  
Research ethics is a field concerning the principles, norms, standards and guidelines regulating 
the conduct of research (Ajuwon & Kass, 2008; Resnik, 2015). Research ethics aim to protect 
participants by ensuring that the goals of research do not supersede the rights, dignity, safety and 
welfare of research participants (Ajuwon & Kass, 2008). While biomedical research is 
unquestionably essential, it concomitantly presents potential risks (e.g. physical, psychological, 
and social) to the participant and society. There are many documented cases of unethical 
research where participants have been harmed by research, sometimes even dying as a result 
(Emanuel, Crouch, Arras, Moreno & Grady, 2003; Nuffield Council on Bioethics, 2002).  
 
This therefore necessitates ethical oversight mechanisms and processes for ensuring that such 
potential risks are carefully evaluated using established international and national ethical 
standards by an independent committee with no conflict of interests in relation to the proposed 
research (Council for International Organizations of Medical Sciences [CIOMS], 2002; WHO, 
2011; World Medical Association [WMA], 2013). The goals of research should not supersede 
the rights, dignity, safety and welfare of research participants. Research ethics is therefore aimed 
at protecting the rights, dignity and safety of human participants and ensuring that research is 
carried out in the least harmful way in accordance with fundamental ethical principles (Belmont 






The ethics of biomedical research in developing countries has generated considerable debate 
about the appropriate ethics standards (Angell, 1997; Benatar, 2002; Benatar & Fleischer, 2007; 
Bhutta, 2002; Fitzgerald, Wasunna & Paper, 2003; Levine, 2002; Macklin, 2004; Nuffield 
Council on Bioethics, 2002; Perrey, Wassenaar, Gilchrist & Ivanoff, 2009; Shapiro & Meslin, 
2001; Weijer, 1999). Some of the ethical issues may be exacerbated particularly in situations 
where individual research participants or communities may be vulnerable to risks of exploitation 
and harm if enrolled in certain research studies (Nuffield Council on Bioethics, 2002; 
Gbadegesin & Wendler, 2006; Horn, Sleem, & Ndebele, 2014). The main concern here is that 
research populations in developing countries may be predisposed to exploitation due to 
contextual factors such as low socio-economic background, power imbalances between 
researchers and participants, illiteracy and unfamiliarity with research (Dal-Ré, Ndebele, Higgs, 
Sewankambo & Wendler, 2014). Furthermore, participants and communities in less developed 
countries may be unfairly exposed to risks and burdens of research and yet may not have fair 
access to benefits derived such studies (Dal-Ré et al., 2014; Shapiro & Meslin, 2001; Weijer & 
Emanuel, 2000).  
 
Furthermore, ethical challenges may arise when investigators have to obtain valid informed 
consent from participants with high levels of cultural and language differences (Hanrahan et al., 
2015), and little or no understanding of clinical trial procedures such as randomization, double- 
blinding and placebo (Ndebele, Wassenaar, Masiye & Nkandu, 2014c). Moreover, investigators 
could be faced with  ethical complexities of designing or implementing appropriate levels of 
medical care and treatment for participants – the so-called standards of care, where local 
available standard of care is close to nothing, or endeavouring to integrate research results into 
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the healthcare system where the healthcare infrastructure is archaic and fragmented (Angell, 
1997; Emanuel et al., 2004; Fitzgerald et al., 2003; Levine 1998; Lindsey, Shah, Sibbery, Jean-
Philippe & Levin, 2013; Lurie & Wolfe, 1997; Macklin, 2004; Millum et al., 2015; Varmus & 
Satcher, 1997).  
 
The scope of research ethics has generally shifted beyond focusing only on the individual 
research participant, to more subtle concerns about social, cultural, political, and economic 
implications of proposed research on the entire community in which research is conducted 
(Emanuel et al., 2004). Of particular importance is the recognition for prior community 
consultation and engagement with local stakeholders in the design, conduct and implementation 
of the research and ensuring research has social value (Emanuel et al., 2004; Millum et al., 2015; 
Rivera & Borasky, 2010). A number of ethical guidelines have been produced specifically to 
address ethical issues in conducting biomedical research in developing countries (Nuffield 
Council on Bioethics, 2002). Although multiple international and national ethical guidelines 
exist, they do not always provide clear or unambiguous solutions to all the ethical complexities 
arising in the design and conduct of research in developing countries. The guidelines are 
sometimes contradictory and inconsistent and can be interpreted in varied ways (Emanuel et al., 
2004; Wassenaar, 2006).  
 
Research ethics committees (RECs), also known as institutional review boards (IRBs) in the US, 
can be described as multidisciplinary, independent groups of individuals appointed to conduct 
ethics reviews of research involving human participants (WHO, 2009). The primary 
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responsibility of RECs or IRBs is to protect the rights and welfare of human research participants 
(Amdur & Bankert, 2006).  The authors argue that while IRBs or RECs are there to protect the 
rights and welfare of human research participants, they cannot afford to spend time on activities 
not required for protection of human research subjects in compliance with federal research 
regulations. Specifically, they mention that “1) The IRB is not an editorial service, 2) the IRB is 
not the office of the medical director, 3) the IRB is not the medical records department or 
confidentiality committee, 4) the IRB is not the risk-management committee, 5) the IRB is not 
the office of patient financial services, and 6) the IRB is not a data safety monitoring board”     
(p. 28).  
 
The requirement for independent ethics review of research came about following several cases of 
unethical human research practices as those witnessed in the Nuremberg trials of doctors tried for 
crimes against humanity during World War II (Emanuel et al., 2003), other major concerns 
exposed by Beecher (1966), and as further publicized in the infamous Tuskegee syphilis studies 
(Brandt, 1978). The oversight of research involving human participants is an ethical and legal 
requirement in several countries worldwide (Department of Health and Human Services 
[DHHS], 2016; WHO, 2011). Since the Declaration of Helsinki guidelines were developed in 
1964, RECs have increasingly become common in the ethical oversight of biomedical research. 
Their primary task is to ensure the protection of participants by conducting ethical reviews of 
research in accordance with national (Department of Health, 2015) and international ethical 
standards (c.f., CIOMS, 2002, WHO, 2011; WMA, 2013). Several countries in Sub-Saharan 
Africa and internationally have implemented or are enhancing regulatory frameworks for 
research involving human participants to ensure adequate ethics oversight (DHHS, 2016). 
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In South Africa, the National Health Act No. 61 (2003) necessitates ethics reviews of all health-
related research by RECs registered with the National Health Research Ethics Council 
(NHREC), a national body which regulates the structure and functioning of local RECs 
(Department of Health, 2015). Currently, there are approximately 44 registered RECs in South 
Africa. While all ethics review activities of RECs in South Africa are, in principle, guided by the 
Department of Health (2015) guidelines, very little is known about the ethical issues raised by 
these committees in practice. This thesis provides a pilot study of the ethical issues typically 
identified during ethics review by two biomedical RECs in South Africa. 
 
1.3 Personal interest in biomedical research ethics  
The researcher’s interest in biomedical research ethics and the regulation of human research 
developed after receiving a Medical Education Partnership Initiative (MEPI) Research Ethics 
fellowship at the University of KwaZulu-Natal (UKZN), South Africa. This fellowship was 
aimed at PhD students to develop understanding and capacity in research ethics. During the 
fellowship, the researcher was involved in reviewing biomedical research proposals, observing 
meetings or deliberations of a biomedical REC and reading selected literature on research ethics.  
During literature search, the researcher noted that there was a dearth of information on the ethical 
issues that are raised by RECs reviewing biomedical research both locally and internationally. 
Therefore, this motivated the researcher and the supervisor to embark on a project which would 
utilize and study minutes and decision letters of a sample of biomedical RECs in order to provide 
empirical evidence on the ethical issues raised by a sample of South African RECs. Some of the 
burning questions that the researcher wanted to investigate included the following: 
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• What are the ethical issues typically raised by RECs during ethics review? 
• What are the views of REC members/ ethics experts regarding the ethical issues raised by  
RECs during ethics review of biomedical research? 
• Do the review activities of local RECs adhere to national ethics regulations and 
international guidance? 
Hence, these questions led to the conceptualisation of the present study which aims to provide 
empirical evidence on the issues raised by RECs during ethics review. 
 
1.4 Problem statement 
Despite their important work in ensuring the ethical acceptability of proposed research and 
protection of research participants, there is very limited empirical research on the ethical review 
activities of RECs (Silaigwana & Wassenaar, 2015). Although there is plentiful literature in 
developed countries such as the UK (Angell, Biggs, Gahleitner & Dixon-Woods, 2010; Angell, 
Bryman, Ashcroft & Dixon-Woods, 2008; Angell, Tarrant & Dixon-Woods, 2009; Dixon-
Woods, Angell, Tarrant & Thomas, 2008), Spain (Martin-Arribas, Rodriguez-Lozano & Arias-
Diaz, 2012) and US (Abbott & Grady, 2011; Lidz et al., 2012), not much has been published 
about the ethical issues raised by RECs in South Africa. The few available studies have generally 
focused more on the structure, functioning, resources and workload of RECs in Africa, including 
South Africa (Cleaton-Jones, 2012; Cleaton-Jones & Grossman, 2015; Cleaton-Jones & Vorster, 




Less attention, however, has focused specifically on the kinds of ethical issues identified during 
ethics reviews (Clarke, 2014; Cleaton-Jones, 2010; Tsoka-Gwegweni & Wassenaar, 2014). In 
principle, RECs are expected to apply national ethical guidelines and regulations (Department of 
Health, 2015) and other international standards as a foundation for their decisions when 
reviewing applications for ethics approval. However, very little is known about what RECs 
actually do in practice. Up to now, despite more than a decade of functioning since formal ethics 
review was legislated in South Africa (National Health Act, 2003), there are still gaps in what is 
known regarding the ethical issues raised by RECs. Furthermore, there have been very few, if 
any, studies exploring the views of South African REC members on the ethical issues arising in 
their typical review work. This is perhaps one critical gap necessitating further exploration in 
order to understand what local RECs are actually doing in practice. In view of their important 
work in protecting research participants, and the costs associated with operating RECs 
(Sugarman et al., 2005; Wagner, Cruz, & Chadwick, 2004), it is crucial to understand 
specifically the kinds of ethical issues that RECs raise when reviewing research protocols. As 
such, the overarching objective in this present study was to investigate the specific ethical issues 










1.5 Aims and objectives 
Given the few existing studies on the review activities of RECs in South Africa, this project 
aimed to describe the ethical issues raised by RECs. Specifically, the objectives of this study 
were: 
1. To identify the ethical issues typically raised.  
2. To apply the Emanuel et al. (2004) framework to evaluate the ethical issues raised.  
3. To qualitatively explore the views of REC members regarding the issues identified in 
(1) above. 
4. To determine whether findings in (1) align with national research ethics guidance. 
 
1.6 Research questions 
The specific research questions of this study were: 
1. What specific ethical issues are raised by two large biomedical RECs? 
2. Is the theoretical framework by Emanuel et al. (2004) compatible with the ethical 
issues and concerns raised by two large biomedical RECs in South Africa? 
3. What are the views of REC members regarding the ethical issues raised in (1) above? 





1.7 Scope of thesis 
This study investigated the ethical issues raised by two purposively sampled biomedical RECs in 
South Africa. It drew on three different data collection and analytic sections: 1) retrospective 
review of minutes and decision letters for the period 2009-2013; 2) semi-structured interviews 
with a random sample of RECs members from the two committees included in this study; and 3) 
comparative analysis of findings in objective (1) with existing national guidelines (Department 
of Health, 2015). While this thesis provides some crucial insights into the ethical issues raised by 
RECs during ethics review, it is beyond the scope of this thesis to provide definitive analyses of 
the entire ethics review system in South Africa. Furthermore, the present study did not aim to 
conduct an ethnographic study and discourse analysis of what transpires during REC meetings 
(de Jong, van Zwieten & Willems, 2012; Klitzman, 2015; Stark, 2012; Tolich, 2014). Similarly, 
it is also beyond the scope of this study to audit the biomedical RECs, or to make detailed 
recommendations relating to the weaknesses or potential problems or inadequacies of the South 
African ethics review system. What this thesis fundamentally aimed to achieve was to highlight 
the ethical issues typically raised by RECs and develop some perspective in understanding what 
REC members think about these kinds of issues and whether they fairly reflect their 
understanding of the core business of an REC. Ultimately, it is hoped that this thesis will provide 
preliminary insights into the kinds of ethical issues raised by two purposively sampled 






1.8 Contribution of this study to general knowledge  
The research question addressed by this thesis is largely descriptive and unsophisticated, and 
may simply be put as “What are the ethical issues raised by research ethics committees 
reviewing biomedical research in South Africa”. The answer to this question was simply not 
known at the time that this study was initiated. Answering this seemingly unsophisticated 
question will hopefully potentially facilitate better understanding of exactly what ethical issues 
are raised by RECs in their important work, contributing to growing scholarship on the activities 
and outcomes of RECs that typically occur ‘behind closed doors’ to quote Laura Stark’s (2012) 
ethnographic study of IRB decision making. This thesis reports on the ethical issues typically 
identified by a sample of two RECs in South Africa. Furthermore, it reports on the perspective of 
REC members regarding these ethical issues.  
 
As mentioned above, there has been relatively little research on the kinds of ethical issues raised 
by RECs in general and African RECs specifically, when reviewing biomedical research 
proposals. In a review of African RECs (Silaigwana & Wassenaar, 2015), only three studies 
(Clarke, 2014; Cleaton-Jones, 2010; Tsoka-Gwegweni & Wassenaar, 2014) out of 23 included 
studies, had addressed the actual ethical issues raised by RECs. This research therefore aims to 
assist in broadening knowledge of what ethical issues are typically raised by RECs, tests a 
conceptual framework for doing so (Emanuel et al., 2004), and hopefully contributes to better 
evidence-based understanding of what RECs do, what issues they typically raise, and how this 
might inform training or REC improvement programmes. Hence the study hopefully makes a 
useful empirical contribution to the scholarly literature on RECs, specifically revealing and 
discussing the ethical issues identified by such committees. The study hopes to generate data 
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which may hopefully be of interest to other researchers, scholars and even RECs themselves. As 
far as can be ascertained from available databases, the present study is the first doctoral project 
investigating RECs in South Africa. Therefore, by its very discussion of RECs and the ethical 
issues they raise, together with an analysis of the views of a sample of their members on these 
ethical issues, the present study is hopefully novel. Considering that RECs are notoriously 
known to be difficult to access for research purposes (de Jong et al., 2012; Klitzman, 2015; Stark 
2012), the present study hopefully provides a rare but important, glimpse into the kinds of ethical 
queries contained in the minutes and decision letters of two active biomedical RECs. 
Therefore, it is hoped that this study has potential significance because: 
1. The study will provide empirical evidence of the ethical issues raised by local RECs 
during review of health research. 
2. The study will contribute knowledge regarding the adequacy of the Emanuel et al. (2004) 
framework in addressing ethical issues identified by two SA RECs. 
3. Furthermore, the study has potential to provide a standardised methodology/approach for 
similar studies nationally and internationally. 
Understanding ethical issues raised by RECs is essential for several reasons. Firstly, it serves as 
an important process for accountability (O'Reilly, Dixon-Woods, Angell, Ashcroft & Bryman, 
2009), i.e., helping to provide evidence of what RECs (the guardians of research participants’ 
rights, safety and wellbeing) are actually doing. Second, it provides evidence of perhaps the 




1.9 Summary and overview of thesis 
In this chapter, an introduction on the biomedical research landscape and its importance in 
addressing public health challenges was briefly described. This was followed by a brief 
introduction to research ethics, some key historical drivers of the development of research ethics 
and its importance in protecting research participants. Furthermore, a problem statement and 
objectives of the study, research questions and the contribution of this study to general 
knowledge were articulated.  The subsequent chapters of the thesis provide more detailed 
information as outlined below. 
 
Chapter 2 reviews the literature on research ethics from a global context, followed by a focus on 
the South African context. Thereafter, literature critiquing mandatory ethics review is reviewed. 
The chapter then reviews empirical studies on ethical issues raised by RECs conducted 
internationally and concludes by reviewing empirical studies that have been conducted to 
investigate the ethical issues raised by African RECs.    
Chapter 3 gives a brief overview of the theoretical framework on which the present study was 
premised.  
Chapter 4 highlights the main aim of the study, the specific objectives and research questions. 
Chapter 5 describes the methodology used in this study - the study design, sampling and data 
analysis techniques used for the three work packages in this study. Furthermore, ethical 
considerations of the study are highlighted.  
Chapter 6 describes the results from the three work packages included in this study. Direct 
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quotes from the data, which have been anonymized, are used to illustrate the findings.  
Chapter 7 provides a discussion of the findings and interprets the results with reference to the 
theoretical framework and the published literature. 




















The main objective of this chapter is to present a review of literature on the ethical issues raised 
by RECs reviewing biomedical research. The chapter is divided into various sections as follows: 
• The first section of the literature review begins with the history and development of 
research ethics from an international context. It specifically reviews some of the scandals 
and tragedies of research with human participants that were foundational to the 
development of modern day research ethics.  
• The second section discusses some of the key international ethical guidelines including 
the Belmont Report’s fundamental ethical principles and their application.  
• The third section describes the South African research ethics review landscape. It 
commences with the history of the South African research ethics system. Thereafter, the 
South African legislative framework and national ethical guidelines for research are 
described.  
• The fourth section reviews literature critiquing mandatory REC ethics review. 
• The fifth section reviews literature on some of the ethical issues arising in biomedical 
research. The list of issues described in this chapter is by no means exhaustive. These 
issues have been purposively selected to facilitate discussion and interpretation of the 
findings of the present study. 
• The sixth section reviews and discusses previous empirical studies that have been 
conducted to investigate ethical issues raised by RECs internationally.  
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• The seventh section reviews and discusses previous empirical studies aimed at 
investigating ethical issues raised by African RECs. 
• The chapter concludes with a summary of the literature reviewed and some of the key 
findings from the previous studies. 
 
 
2.1 History and development of research ethics 
The field of research ethics has evolved over the past decades since the Nuremberg Code in 
1947, resulting in a plethora of ethical guidelines, codes, and regulations for research involving 
human participants. Historical events involving some unethical experiments involving human 
participants, for example, without their informed consent, withholding information and coercive 
influence over vulnerable populations, were largely responsible for the promulgation of some 
research ethics guidance (Beecher, 1966; Brandt, 1978; Emanuel et al., 2003; Katz, Capron & 
Glass, 1972). On the other hand, the globalization of research and dilemmas encountered in the 
dynamic health research milieu also led to the development of some research ethics guidelines, 
codes and regulations (Nuffield Council on Bioethics, 2002; Rivera & Borasky, 2010). While 
there are several cases of scandals and unethical research in the history of human research 
misconduct, the section below will outline some examples of studies that were ethically 
controversial and which led to the development of some key international ethical codes, 





2.1.1 Tuskegee Syphilis study (1932-72) 
The Tuskegee syphilis study began in 1932 and continued until 1972 and was commissioned by 
the United States Public Health Service (USPHS). The study apparently sought to investigate the 
natural course of latent, untreated syphilis in black males at a time when no treatment existed 
(Brandt, 1978). Approximately 400 African-American men with syphilis were recruited and 
assigned into the experimental group and another 200 uninfected men were assigned to the 
control group. It is reported that these men were enrolled into the study after misleading 
promises that they would receive new treatment (Brandt, 1978). Yet, even when safe and 
effective penicillin antibiotics were discovered and became widely available in the early 1950s, 
treatment for men infected with syphilis was still withheld from the patients, apparently because 
this would disrupt the natural history findings. Shockingly, the USPHS actually sought to 
prevent treatment on several occasions and a committee at the Center for Disease Control 
decided in 1969 that the study should be continued (Brandt, 1978). Sadly, the majority of the 
men in the experimental group suffered from severe morbidity and many died as a result of 
advanced syphilis.  The study was eventually halted by the US Department of Health Education 
and Welfare in 1972 after the atrocious details of the study were publicized nationwide. 
Consequently in 1997, Bill Clinton, then president of U.S, issued a public apology to a few men 
and the families of the deceased who had survived this atrocious (Clinton, 1997) and awarded 





Ethical violations of the Tuskegee study include enrolling participants without informed consent 
as the men were misinformed to believe that they would be receiving special treatment for 
syphilis (Heintzelman, 2003). Also, the researchers never gave the patients information on 
penicillin when it became available or a choice to voluntarily continue or withdraw from the 
study despite the availability of penicillin, an effective anti-syphilis drug. Furthermore, there was 
exploitation as the researchers recruited vulnerable African-American men of poor 
socioeconomic status with inadequate medical treatment and care (Heintzelman, 2003). Another 
ethical issue, perhaps more troubling, was the withholding of treatment to patients in dire need of 
treatment, for the purpose of research (Brandt, 1978). The investigators should have obtained 
voluntary informed consent from the men before enrolling them into the study. Furthermore, 
when it became available in the early 1950s, penicillin should have been provided to the infected 
men.  The direct result of the publicity of the Tuskegee Syphilis study was the establishment of 
the National Research Act (1974) which created the National Commission for the Protection of 
Human Subjects of Biomedical and Behavioral Research and in turn published the Belmont 
Report in 1978 (described in detail in subsequent sections). 
 
2.1.2 Nazi medical war crimes (1939-45)  
One of the most infamous examples in the history of research ethics is the experiments on Jews 
during the Nazi regime during World War II. In these experiments, thousands of concentration 
camp prisoners were subjected to numerous brutal experiments (Emanuel, et al., 2003). One 
example of these experiments was the high altitude (low pressure) experiments in which 
prisoners were put into low pressure tanks to determine how long they could survive with little 
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oxygen. Several people who did not die immediately were then put under water until they 
succumbed to death. Another example is the Malaria experiment whereby prisoners were 
deliberately infected with Malaria and then provided with different drugs purported to be 
antimalarial drugs (Emanuel, et al., 2003; Korda, 2006). Other examples of experiments 
included, but are not limited to, freezing experiments, mustard gas experiments, sulphanilamide 
experiments, typhus experiments, poison experiments, incendiary bomb experiments and 
sterilization experiments (Emanuel et al., 2003; Korda, 2006). Many of the prisoners subjected to 
these experiments succumbed and unfortunately died, often after prolonged suffering (Emanuel 
et al., 2003). After World War II, in response to these atrocities, 23 Nazi doctors and 
administrators were tried for the brutal atrocities they inflicted on thousands of concentration 
camp prisoners by the international military tribunals in Nuremberg 1947. Seven defendants 
were found guilty and sentenced to death, eight were sentenced to imprisonment from ten years 
to life, and the remaining seven were found not guilty (Emanuel et al., 2003). The Nuremberg 
Code (see section 2.2.1) was established in 1947 as a direct result of the trial.  
 
2.1.3 Willowbrook State School Hepatitis Study (1956) 
The Willowbrook state school hepatitis study, led by Dr Saul Krugman of New York University 
in 1956, involved more than 700 mentally ill children whom were deliberately infected with 
Hepatitis A virus ostensibly to investigate the children’s level of immunity against hepatitis, and 
to discover a cure for the disease (Krugman & Ward, 1958). The children did not receive 
treatment despite the discovery of an effective vaccine for Hepatitis in 1969 (Rothman, 1982). 
The study needlessly exposed vulnerable children to serious risks and most of them subsequently 
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developed symptoms such as swollen liver and yellowing of the skin. The researchers argued 
that 90% of children would still have been exposed to Hepatitis A at some point in their 
everyday life, i.e., the study did not expose these children to greater risks than those they would 
otherwise ordinarily have been exposed to due to the high incidence of the disease during those 
days (Rothman, 1982). 
 
Although informed consent was obtained from parents, and the study was approved and 
reportedly had a favourable risk/benefit ratio (Krugman & Ward, 1958), the study was ethically 
controversial (Robinson & Unruh, 2008). Firstly, the study did not adequately inform parents 
about the serious nature of risks posed by the experiments (Robinson & Unruh, 2008). 
Furthermore, mentally ill children who were institutionalized, constitute a vulnerable population 
whose autonomy is clearly diminished (or absent) with regard to giving valid and voluntary 
informed consent or assent (Robinson & Unruh, 2008).  From an ethical perspective, the study 
might have been considered for competent adults first before deliberately injecting live Hepatitis 
virus into vulnerable mentally ill children. Moreover, it can be argued that there was undue 
inducement as parents of the children may have been unduly influenced by being offered 
admission for their children into a new unit of the Willowbrook school (after the school had 
closed its admission for new students due to overcrowding in 1964) only if they agreed to 






2.1.4 Jewish Chronic Disease Study (1963) 
The legitimacy of research involving humans once again came under the spotlight after the 
Brooklyn Jewish chronic disease study in 1963.  The Jewish chronic disease study was 
conducted by three doctors who deliberately injected live cancer cells into twenty-two 
chronically ill and debilitated elderly patients supposedly to investigate a patient’s ability to 
reject foreign cells (Katz, Capron & Glass, 1972). Although the study had been approved by the 
board of the Jewish Chronic Disease Hospital, (Katz et al., 1972), it violated fundamental ethical 
principles for research with human beings. Firstly, the doctors/researchers did not inform the 
patients that they were being injected with live cancer cells, nor were the patients informed that 
this was an experimental procedure and not part of their routine therapy (Katz et al., 1972; 
Lerner, 2004).  That is, despite the doctors having obtaining verbal consent from the patients, the 
consent process was not truly informed because there was apparently no discussion with the 
patients to inform them about the study procedures and that they would be injected with cancer 
cells.  Moreover, because of their incapacitated physical and mental condition, some patients 
would probably not have been able to give valid informed consent. Therefore, these doctors 
should have sought valid informed consent from an authorized adult person with legal capacity 
to provide proxy consent after adequate disclosure of the nature of the study and the potential 
risks, including the procedure for injecting cancer cells. 
 
Furthermore, it is stated that the informed consent from the patients was not documented and nor 
was the study approved by the hospital’s research committee (Katz et al., 1972; Lerner, 2004). 
However, one of the doctors involved in the study – Chester Southam – argued that the study 
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presented no risk to the patients because there was scientific evidence suggesting that the 
injected cancer cells would cause an immune reaction that would lead to their expulsion from the 
patient’s body (Emanuel et al., 2003). Furthermore, the investigator argued that fully informing 
the patients about the study details, particularly the term cancer, would have caused them 
unnecessary risk of psychological distress. In other words, he did not inform the patients because 
he was trying to minimize the risk of psychological distress to the patients (Emanuel et al., 
2003). However, the New York Board of Regents in 1966 rejected both arguments and found the 
doctors guilty of fraud or deceit (Katz et al., 1972; Lerner, 2004). When Henry K. Beecher 
published his exposé of unethical research in the New England Journal of Medicine later in 1966, 
the Jewish chronic disease hospital scandal was among the twenty-two cases he cited (Beecher, 
1966). This work is discussed in more detail below (2.1.5). 
 
2.1.5 Henry Beecher’s expose (1966)  
In 1966, a US professor and anaesthetist Henry Beecher, published his article describing 
unethical medical research which had been conducted by medical doctors (Beecher, 1966). In 
summary, the article outlines 22 examples of studies in which patients were deceived or exposed 
to unnecessary risks without their consent. Of great concern was that several of these studies 
were conducted by esteemed researchers in well-known institutions, and were funded by 
reputable sponsors such as the US military, the National Institutes of Health and well-respected 
pharmaceutical companies. One such example was the study of cyclopropane anaesthesia and 
cardiac arrhythmias in which 31 patients were deliberately injected with toxic carbon dioxide 
into their closed respiratory systems and maintained for considerable periods ranging from two 
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to four and half hours until cardiac arrhythmias appeared (Beecher, 1966). Some of the ethical 
issues included, lack of informed consent, coercion or undue pressure on volunteers (or parents 
to volunteer their children), exploitation of vulnerable populations, withholding information 
about risks, withholding available treatment, exposing participants to undue risk that outweighed 
benefits, and the use of deception (Beecher, 1966). 
 
While most of the cases of unethical research involving human participants that led to the 
development of research ethics were predominantly of biomedical nature, there were also several 
cases of unethical research in the behavioural and social sciences. Perhaps one of most 
outstanding was the Milgram’s 1963 study of obedience to authority described below (2.1.6). 
 
2.1.6 The Milgram Study (1963) 
The Milgram study was a psychology experiment conducted by psychologist Stanley Milgram, 
that studied obedience to authority by instructing a group of approximately 40 male volunteers 
(“the teachers”) to administer potentially lethal electrical shocks to others (“the learners”) 
(Milgram, 1963,1965). Motivated by the defence testimony of the Nuremberg Trial accused, who 
stated that they were merely obeying orders, Milgram set out to determine under what conditions 
will people carry out the commands of an authority figure to inflict suffering on others, and 
whether and when will they refuse to obey such instructions (Milgram, 1963). The study 
involved the use of deception. The participants were misinformed about the true nature of the 
research study, by being deceived into thinking that they were involved in an experiment on the 
impact of punishment on memory (Milgram, 1963). The Milgram study is controversial because 
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of its lack of valid informed consent about the true nature and psychosocial risks of the 
experiment and its use of deception (although deception is now allowed by guidance and 
research ethics committees in certain justifiable instances). Furthermore, the study was unethical 
because of the potential risks of psychological distress on the participants after realizing they 
could have deliberately administered electrical shocks and caused suffering to another innocent 
human being (Won, 2012). 
 
2.1.7 Tearoom trade study (1970) 
The so-called tearoom trade study was conducted in the 1970s by Laud Humphreys towards his 
PhD, wherein he studied men who have sex with men in public toilets of city parks (Humphreys, 
1970). Such acts were illegal at that time and homosexuality was highly stigmatised. In the first 
component of the study, Humphreys apparently impersonated a “watch queen” who was on the 
lookout and would notify the men if somebody was approaching. Apparently, the aim of the 
study was to understand the relationship of these men’s clandestine homosexual activities in 
relation to their daily public lives. Humphreys sought to counter prejudice against 
homosexuality. In the second component of the study, Humphreys noted down the men’s vehicle 
licence plate numbers and tracked approximately fifty men to their home addresses through 
municipal records where he masqueraded as a social health researcher conducting interviews 
with the men in their homes to gather personal information on their marital status, sexuality and 
occupations (Humphreys, 1970).  These men were not informed of the fact that Humphreys was 
a researcher and therefore they became unwitting research participants.  After publishing his 
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findings, controversy arose. A major concern was the use of deception and invasion of privacy 
(Lenza, 2004).  
 
The current section has described some examples of controversial and unethical research 
involving humans that led to the development of modern day research ethics. While most of 
these scandals were in biomedical research, the literature review has also shown that there were 
also examples of unethical social science and behavioural research involving humans that caused 
ethical controversy (see 2.1.6 and 2.1.7). The next section describes some of the key 
international codes, declarations and guidelines that were developed as a result of the unethical 
research scandals described above. 
    
2.2 Key international research ethics codes and guidelines 
2. 2. 1 Nuremberg Code (1947) 
The Nuremberg Code (1947) was one of the first internationally recognized code of research 
ethics to be promulgated in response to unethical research conducted in humans. The Code 
outlined ten sets of principles for research involving humans including the need for voluntary 
consent, avoiding harm to research participants, and weighing up the risks against potential 





1. “The voluntary consent of the human subject is absolutely essential. 
2. The experiment should be such as to yield fruitful results for the good of society, 
unprocurable by other methods or means of study, and not random and unnecessary in 
nature. 
3. The experiment should be so designed and based on the results of animal 
experimentation and knowledge of the natural history of the disease or other problem 
under study, that the anticipated results will justify the performance of the 
experiment. 
4. The experiment should be so conducted as to avoid all unnecessary physical and 
mental suffering and injury. 
5. No experiment should be conducted, where there is an a priori reason to believe that 
death or disabling injury will occur; except, perhaps, in those experiments where the 
experimental physicians also serve as subjects. 
6. The degree of risk to be taken should never exceed that determined by the 
humanitarian importance of the problem to be solved by the experiment. 
7. Proper preparations should be made and adequate facilities provided to protect the 
experimental subject against even remote possibilities of injury, disability, or death 
8. The experiment should be conducted only by scientifically qualified persons. The 
highest degree of skill and care should be required through all stages of the 
experiment of those who conduct or engage in the experiment. 
9. During the course of the experiment, the human subject should be at liberty to bring 
the experiment to an end, if he has reached the physical or mental state, where 
continuation of the experiment seemed to him to be impossible. 
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10. During the course of the experiment, the scientist in charge must be prepared to 
terminate the experiment at any stage, if he has probable cause to believe, in the 
exercise of the good faith, superior skill and careful judgement required of him, that a 
continuation of the experiment is likely to result in injury, disability, or death to the 
experimental subject” (Nuremberg Code, 1947, pp. 181-182). 
 
Although the Nuremberg Code was published in 1947, there were other ongoing and later 
scandals and unethical medical research involving human beings carried out at leading research 
institutions and hospitals in the US (Beecher, 1966). The Nuremberg  Code did not have a great 
impact on the way in which clinical research was being carried out in other countries as it was 
seen as only being of direct application to the physicians that were on trial. According to Faden, 
Lederer and Moreno (1996), some researchers were against the Nuremberg Code for three main 
reasons namely 1) discrepancies between what investigators had come to know in real practice in 
research with patient-subjects and what they read in the lofty, idealized language of the 
Nuremberg Code,  2) others simply were not in agreement with some elements of the Code and 
3) others decried the notion of a “one-size-fits-all” standard to guide research in such a complex 
landscape of human experimentation.  
 
Therefore, after it was established, the Nuremberg Code had little effect in curbing unethical 
research practices in other developed countries such as the US (Faden et al., 1996). This was 
evident from the fact that despite the publication of the Nuremberg Code in 1947, many 
instances of unethical research conducted on vulnerable persons in other countries continued or 
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were initiated, often without their knowledge and voluntary informed consent (Beecher, 1966), 
which subsequently led to the creation of a number of key international ethical guidelines which 
are discussed in the next section. The Nuremberg Code enshrined voluntary informed consent 
above anything else. This later proved to be an unworkable impediment to research on certain 
populations (e.g. unconscious patients, psychotic patients and children). Emanuel et al. (2003) 
importantly point out that most codes were drafted driven by a scandal, causing them to be 
flawed in some way to prevent that particular scandal from recurring. 
 
2.2.2 Declaration of Helsinki (1964) 
The World Medical Association (WMA) published the Declaration of Helsinki in 1964, outlining 
ethical principles for medical research involving human subjects, including research on 
identifiable human material and data. This declaration, with very similar guidance to the 
Nuremberg Code, mainly focused on medical research intended for therapeutic purposes. 
Although the Declaration of Helsinki (1964) had many similarities to the Nuremberg Code 
(1947), the feature that distinguished it from the previously promulgated Nuremberg code, was 
the need for independent ethical review by RECs. Key issues addressed in the Declaration of 
Helsinki included: 
• Research with humans should be based on laboratory and animal experimentation 
• Research protocols should be reviewed by an independent committee 
• Informed consent is necessary 
• Research should be conducted by medically/scientifically qualified individuals 
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• Risks should not exceed benefits 
Since 1964, the Declaration of Helsinki has gone through several revisions (1975, 1983, 1989, 
1996, 2000, 2008) and most recently in 2013 during the 64th WMA General Assembly in Brazil 
(WMA, 2013). Briefly, the Declaration of Helsinki (2013) provides guidance on the following 
ethical issues: risks, burdens and benefits; vulnerable groups and populations; scientific 
requirements, research ethics committees; privacy and confidentiality; informed consent; use of 
placebo, post-trial access; public and dissemination of results; and unproven interventions in 
clinical practice (WMA, 2013). 
 
2.2.3 US National Research Act (1974) 
When the Tuskegee Syphilis study, which began in 1932 (described in section 2.1.1) was 
publicised and there was public outcry in 1972, the US Congress passed the National Research 
Act in 1974 (Emanuel et al., 2003). Subsequently, the National Research Act established the 
National Commission for the Protection of Human Subjects of Biomedical and Behavioural 
Research to identify the basic ethical principles that should underpin the conduct of biomedical 
and behavioural research involving human participants and to develop guidelines governing 
studies involving human participants to ensure the protection of human research participants. To 
that end, the US National Commission developed the Belmont Report (1979) (see next section), 
a foundational document guiding the ethics of human participants research in the United States. 
The National Research Act required prior IRB approval of biomedical and behavioural research 




2.2.4 The Belmont Report (1979) 
The Belmont Report is a statement of basic ethical principles and guidelines that provide an 
analytical framework to guide the resolution of the ethical problems arising from research with 
human subjects (Belmont Report, 1979). It was developed in 1979 by the US government 
appointed National Commission for the Protection of Human Subjects in Biomedical and 
Behavioural Research. The three basic ethical principles (respect for persons, beneficence and 
justice) and their applications are summarized in Table 1 below:   
 




Respect for persons Informed consent 
• Persons should be treated as 
autonomous individuals 
• There should be protection for 
persons with diminished 
autonomy. 
 
• Participants must freely choose 
whether or not to participate in 
research 
• The essential elements of the 
consent process are: 
• Information disclosure, 
• Understanding, and 
• Voluntariness. 
 
Beneficence Assessment of risks and benefits 
• There should be no harm to human 
participants  
• Proposed research should ensure 
that possible benefits are 
maximized possible harms 
minimized. 
 
• There should be systematic 
assessment of risks and benefits to 
ensure favourable risk/benefit ratio 
 
Justice Selection of participants 
• There should be fair distribution of 
research benefits and risks.  
• Selection of participants must be 
unbiased such that there is fair 





2.2.5 US Code of Federal Regulations “Common Rule”  
In 1981, the Department of Health and Human Services (DHHS) and the Food and Drug 
Administration (FDA) issued their regulations based on the Belmont Report. DHHS issued Code 
of Federal Regulations (CFR) Title 45 (public welfare), Part 46 (protection of human subjects). 
The US Federal Policy for the Protection of Human Subjects, also known as the “Common Rule” 
was published in 1991 (DHHS,1991; Williams, 2005). The regulations, 45 CFR part 46, (45 CFR 
46) consists of four subparts: subpart A, basic HHS policy for protection of human research 
subjects; subpart B, additional protections for pregnant women, human foetuses, and neonates; 
subpart C, additional protections for prisoners; subpart D, additional protections for children and 
subpart E,  registration of IRBs (45 CFR 46). The Common Rule led to the proliferation of IRBs 
to provide independent review of research involving human participants and requirements for 
obtaining and documenting informed consent (Emanuel et al., 2003). 
 
The current section has highlighted the key international ethics codes and guidelines that were 
developed as a result of research scandals such as the Tuskegee Syphilis study (see 2.1.1) and 
Nazi medical war crimes (see 2.1.2). In conclusion, the Nuremberg Code (1947), Belmont 
Report (1979), Declaration of Helsinki (1964) and Common Rule (1981) formed the foundation 
for modern day research ethics guidelines. Today, several international and national ethical 
guidelines have been developed.  Examples of other international ethical guidelines include the 
CIOMS (1993) guidelines and later revised in 2002 (and currently under revision), the 
International Conference on Harmonization-Good Clinical Practice (ICH-GCP) guidelines 
(1996), Nuffield Council on Bioethics (2002) guidelines on the ethics of research related to 
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healthcare in developing countries and WHO (2011) standards and operational guidance for 
ethics review of health-related research with human participants. 
  
Having described the development of research ethics from an international perspective, the focus 
of the next section is to highlight the history and development of the South African research 
ethics system. This is important considering that the current thesis was aimed at analysing ethical 
issues raised by two South African biomedical RECs. 
 
2.3 Research Ethics Review in South Africa 
2.3.1 History of ethics review in South Africa 
The history of ethics review in South Africa goes back to the mid-1960s. In 1966, John Hansen, 
professor of paediatrics at the University of the Witwatersrand, advocated for the establishment 
of the first-ever REC at his university. This REC has functioned continuously ever since 
(Cleaton-Jones & Wassenaar, 2010). From 1977, the number of RECs expanded with almost 
every South African university with a medical school having established its own REC. Similarly, 
the Department of Health, Medical Research Council, and South African Medical Association 
also established their own RECs. In 1995, a private REC named Pharma-Ethics REC was also 
established (Cleaton-Jones & Wassenaar, 2010). Currently, there are approximately 44 RECs 
operating in South Africa (NHREC, 2015). Some of the characteristics of the South African 
research ethics review system are that RECs are institutional and not regional as in some 
developed countries such as Sweden (Hedgecoe, Carvalho, Lobmayer & Raka, 2006); some are 
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private with no affiliation to any research institution (e.g. Pharma-ethics); some RECs were 
reported as  dominated by doctors and health professionals (Moodley & Myer, 2007). Since 2006 
there is a central national health research ethics council, the NHREC, which registers and audits 
all RECs in the country. 
 
2.3.2 Legislative Context 
Laws for the ethical conduct of research involving human participants exist in several countries. 
South Africa is no exception - all health-related research is regulated by legislation. Firstly, the 
South African Constitution Act (1996), states that “everyone has inherent dignity and the right to 
have their dignity respected and protected” (p. 6). Furthermore, in paragraph 12.2, the 
Constitution states that “everyone has the right to bodily and psychological integrity, which 
includes the right: (a) to make decisions concerning reproduction; (b) to security in and control 
over their body; and (c) not to be subjected to medical or scientific experiments without their 
informed consent” (p. 6). In other words, the Constitution’s Bill of Rights requires informed 
consent to be obtained from the research participant before participating in any research. 
Furthermore, research on human participants in South Africa is guided by the National Health 
Act No. 61 of 2003.  
 
The South African Research Ethics Committee (REC) system was legally established in 2005 in 
terms of the National Health Act 61 of 2003 (National Health Act, 2003).  The legislation passed 
in 2005 in most respects merely legalized and formalized the features of an earlier South African 
ethics review system which had operated since the first REC in 1966 (Cleaton-Jones & 
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Wassenaar, 2010), and made it absolutely clear that it was obligatory for a health-related 
research proposal to obtain ethics review and approval from an REC before commencement 
(Department of Health, 2015). According to the National Health Act No. 61 of 2003, all health-
related research projects must be submitted for approval by an REC registered with the 
NHREC.  Section 73 of the National Health Act (2003) explicitly states that, “(1) Every 
institution,  health agency and health establishment at which health research is conducted, must 
establish or have access to a health research ethics committee, which is registered with the 
National Health Research Ethics Council. (2) A health research ethics committee must  (a) 
review research proposals and protocols in order to ensure that research conducted by the 
relevant institution, agency or establishment will promote health, contribute to the prevention of 
communicable or non-communicable diseases or disability or result in cures for communicable 
or non-communicable diseases; and (b) grant approval for research by the relevant institution, 
agency or establishment in instances where research proposals and protocol meet the ethical 
standards of that health research ethics committee” (National Health Act, 2003, p. 74). 
Furthermore, the National Health Act provides for the establishment of the NHREC appointed by 
the Minister of Health. The functions of the NHREC are to:   
• “Determine guidelines for the functioning of health research ethics committees; 
• Register and audit health research ethics committees; 
• Set norms and standards for conducting research on humans and animals including norms 
and standards for conducting clinical trials; 
• Adjudicate complaints about the functioning of health research ethics committees and 
hear any complaint by a researcher who believes that he or she has been discriminated 
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against by a health research ethics committee; 
• Refer to the relevant statutory health professional council matters involving the violation 
or potential violation of an ethical or professional rule by a health care provider; 
• Institute such disciplinary action as may be prescribed against any person found to be in 
violation of any norms and standards, or guidelines, set for the conducting of research in 
terms of this Act; and 
• Advise the national department and provincial departments on any ethical issues 
concerning research” (National Health Act, 2003, p. 74). 
 
2.3.3 Research ethics guidelines in South Africa 
The first set of research ethics guidelines, entitled “Guidelines on Ethics for Medical Research” 
was produced by the South African Medical Research Council (SAMRC). These guidelines were 
not nationally binding on all researchers. In 2000, the national Department of Health produced 
Guidelines for Good Clinical Practice (GCP) which were updated in 2006 (Cleaton-Jones & 
Wassenaar, 2010; Department of Health, 2006). The section below briefly outlines the first South 
African national research ethics guidelines, i.e., the Department of Health (2004). (Note that the 
RECs studied in this study were at the time subject to the 2004 guidance, hence the 2004 
guidance is described in detail below, despite a later version being published in 2015 
(Department of Health, 2015). An online certificate-generating educational module based on the 




2.3.3.1 Department of Health guidelines (2004) 
 
The Department of Health (2004) guidelines were based on some of the key international 
guidelines previously discussed. These guidelines are underpinned by three fundamental 
principles, including respect for persons, beneficence, and justice.  The ethical principles 
contained in the Department of Health national guidelines (2004) are described below. 
 
• Respect and dignity 
The dignity, safety and well-being of participants should take precedence in all research 
involving human participants, i.e., the aim and goals of scientific research should not in any way 
override the an individual participant’s dignity, safety and welfare. Furthermore, appropriate 
consideration should be given to the local language and cultural values of the communities in 
which research is conducted (Department of Health, 2004). 
    
• Social value 
The research to be conducted should have a social value to the participants and the community as 
well. In other words, it should be relevant to the local health needs (Department of Health, 2004). 
The research should be of benefit to participants and ultimately be a value to the research 
community by translating the research findings into mechanisms for improving the health status 
and healthcare system of South Africa (Benatar & Singer, 2010; Department of Health, 2004).  
 
• Scientific Integrity  
In order to ensure that health research is conducted in an ethically appropriate manner, 
investigators and ethical reviewers should ensure that proposed research has scientific validity. 
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This encompasses an extensive literature review of previous similar studies, results from 
preclinical studies, as well as a rigorous and appropriate methodology which can help to provide 
answers to the questions the research intends to investigate (Department of Health, 2004).  
 
• Roles and responsibilities of the principal investigator 
According to the Department of Health (2004) guidelines, principal Investigators (PIs) bear full 
responsibility for the scientific and ethical aspects of the planned research study. Furthermore, 
research should be conducted by a local investigator who is competent and qualified in terms of 
education, knowledge, certification and experience. When the study is in progress after ethical 
approval has been obtained from the relevant REC and/ or MCC, the PI should continue to be the 
means of communication between the trial sponsor and the local RECs. This involves reporting 
adverse events that may occur to the research participants (Department of Health, 2004).  
 
• Informed consent 
Research participants should give both verbal and written informed consent (Department of 
Health, 2004). However, there are exceptions to this requirement, for example in emergency 
situations or where the individual lacks the mental capacity. In that case, a waiver of informed 
consent can be granted only if the local REC is convinced that there is reasonable justification 
for the research to commence without obtaining individual informed consent. Furthermore, 
informed consent should be free from coercion and undue influence and participants should have 
the right to freely refuse to consent or withdraw consent from participation at any time without 
any prejudice Where a participant (e.g. children) lacks the capacity to consent, consent should be 
obtained from the parent or a legally authorized guardian (Department of Health, 2004). 
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• Privacy and confidentiality 
Fundamentally, the privacy and confidentiality of research participants should be protected. This 
involves ensuring that personal identifying information including biological samples collected 
during the research process, are used, stored and or discarded in culturally appropriate manner 
that respects the privacy and confidentiality of the individual participants and the research 
community (Department of Health, 2004).  
 
• Inclusion and exclusion criteria 
There should be fair participant selection. Recruitment of participants must not unfairly exclude 
participants because of race, gender, age, sex, ethnicity or beliefs (Department of Health, 2004). 
 
• Risk and benefits 
The guidelines require that RECs should assess the risk and benefits of the study. Assessment of 
risk/benefit ratio should address the potential benefits and the associated physical, social and 
psychological risks of the study.  Furthermore, vulnerable populations whose participation in 
research may pose greater risk, for example pregnant women and infants, should be protected 
(Department of Health, 2004). 
 
• Dissemination of study results 
The dissemination of research findings or results to participants has widely gained recognition as 
an ethical research practice (Emanuel et al., 2004). According to the Department of Health 
guidelines, there is an obligation for researchers and investigators to disseminate research results 
in a timely and competent manner. However, there is need to ensure ethical dissemination in 
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order to protect vulnerable populations from risk of harm and stigmatization that may emanate 
from the findings (Department of Health, 2004).  
 
• Standard of care 
Standard care implies the provision of equal standards of medical care and healthcare facilities 
for all participants, equal respect and dignity for all participants, equal follow-up facilities (e.g. 
referrals and treatment for research related injuries) for all participants when the research study is 
completed and equal access to on-going medical care (Benatar & Singer, 2010; Shapiro & 
Benatar, 2005). The obligation to ensure the provision of equal standards of medical care to all 
participants during research is based on the fundamental ethical principles of beneficence - 
promoting the welfare of participants (Stobie & Slack, 2010) and reciprocal justice (Macklin, 
2006). Notwithstanding debates about the appropriate standards of care in developing countries 
such as South Africa (Essack, 2014; Ngongo et al., 2012; Slack, 2014), it is generally accepted 
that the obligation to provide optimal care and treatment to research participants is an ethical 
imperative. There should be transparent collaborative engagement and consultative process 
between trial sponsors and researchers, local governments, non-governmental organizations, 
communities in order to agree on who will provide care and treatment and how these will be 
financed and sustained (UNAIDS, 2012).   
 
• Standard of prevention in HIV prevention trials 
Standard of prevention refers to the comprehensive package of HIV risk reduction methods 
provided to participants in HIV prevention trials. One of the heated debated about HVTs is 
related to the question of what prevention methods or modalities need to be included as the 
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standard of prevention (Essack, 2014; Essack et al., 2010). Researchers are faced with ethical 
dilemmas when new HIV prevention methods such as pre-exposure prophylaxis (PrEP) prove to 
be significantly effective. The main concern in such a scenario is that a comprehensive standard 
of prevention package will seriously impact the results for trials of new HIV prevention 
interventions (Macklin, 2008, 2009). In this case, researchers are faced with a conflict between 
ensuring maximum HIV risk reduction in order to promote the welfare of the trial participants 
and the scientific goals of the research to obtain meaningful results. Secondly, the other ethical 
concern would be regarding the safety and the high risk of interactional or antagonistic effects 
when more and more HIV prevention methods become available and used in combination 
(Dawson, 2012). The UNAIDS/ WHO 2007 guidelines recommend that “researchers should 
engage appropriate stakeholders in tailoring the design, implementation and oversight of risk-
reduction interventions addressing the specific needs and risks of trial participants in a given 
community” (p. 46).  
 
• Safety monitoring 
The ethical guidelines necessitate monitoring of approved research in order to identify adverse 
events occurring during and after the research so that immediate remedial action can be taken to 
guarantee the safety and wellbeing of participants (Department of Health, 2004). In most cases, 
REC often require sponsors and the investigator to furnish in their protocol details about  the 
Data Safety Monitoring Board (DSMB) which should independently monitor and report any 
adverse events occurring during and after the trial. However, literature suggests that many RECs 
in developing countries do not have the resources to adequately monitor approved research 
(Boateng, Ndebele & Mwesiga-Kayongo, 2014).  
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2.3.3.2 Department of Health (2015) guidelines 
 
The Department of Health (2015) guidelines are an updated and revised version of the (2004) 
guidelines mentioned above. It must be noted that they were not yet in effect when the study 
described below was conducted; the RECs in question were subject to the Department of Health 
(2004) guidance. The principles of the Department of Health (2015) guidance are described 
below. 
 
• Relevance and value 
Research should be have relevance and be responsive to the health needs of populations of South 
Africa. The proposed research should describe the anticipated contribution to knowledge 
generation and, ideally how the results of the study can be translated into products, interventions 
or services likely to benefit and enhance the lives and wellbeing of people in South African.  
 
• Scientific integrity 
The study must have sound design and methodology that can reliably achieve the objectives of 
the study. The guidelines state that poor study design can expose participants to unnecessary risk 
and harm.    
 
• Role player engagement 
There should be meaningful prior engagement of relevant research stakeholders before 





• Favourable risk/benefit ratio 
The proposed study should have a favourable risk/benefit ratio. In other words, the potential risk 
of harm to a participant should be outweighed by the likelihood of benefit to the participant or 
the knowledge likely to be yielded from the research. 
 
• Fair selection of participants 
There should be fair and just selection of research participants based on objective criteria. No 
persons or groups should be included or excluded as research participants merely on the grounds 
discrimination, for example according to race and religion.  
  
• Informed consent 
Voluntary informed consent should be obtained from an individual before they can be enrolled 
into research.   
 
• Ongoing respect for enrolled participants 
This includes for example the need to guarantee the privacy and confidentiality of enrolled 
research participants. 
 
• Researcher competence and expertise 
Researchers must be appropriately qualified and competent to carry out the proposed research. 
Principal investigators should ensure that the safety and wellbeing of participants is guaranteed 
throughout the study. Furthermore it is the principal investigator’s responsibility to ensure that 
the research is of high scientific validity.  
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2.3.3.3 Department of Health (2006) Good Clinical Practice guidelines 
 
The Department of Health guidelines for good clinical practice (GCP) were first established in 
2000 and then revised in 2006 (Cleaton-Jones & Wassenaar, 2010). The guidelines describe the 
following guiding principles:  
 
• Study rationale and motivation 
The rationale and motivation of proposed research should ask relevant and important questions. 
  
• Study design 
The study design in the research proposal should demonstrate a high probability for providing 
answers to specific research questions.  
 
• Investigator competence 
The principal investigator should be technically competent to conduct the proposed research.  
 
• Balance of harm and benefit 
There should be a risk/benefit assessment to ensure that there is a favourable risk/benefit ratio.  
 
• Transparency 
Researchers have an ethical obligation to register the trial and report on the study results with 





• Privacy and confidentiality 
Measures should be implemented to protect the privacy and confidentiality of research 
participants.  
 
• Ethical review 
There should be prior independent ethical review of proposed research by local RECs. 
 
• Informed consent 
Researchers must ensure that voluntary informed consent is obtained from each prospective 
research participant before enrolling them into research. 
 
• Safety monitoring 
It is an ethical requirement to ensure ongoing monitoring of the safety of participants during and 
after a clinical trial. This involves monitoring and reporting and appropriate management of 
serious adverse events. 
 
• Multi-centre studies 
The design of multi-centre studies should be appropriate for the local setting. Furthermore, the 
study should ensure similar standards of care for both the sponsoring country participants and 
South African participants. Additionally, there should be appropriate incentives for trial 





This section has briefly described the South African research ethics system, highlighting its 
history, legislative context and the applicable national ethical guidelines used by RECs and 
researchers in ensuring that research with human participants conducted in the country is of high 
ethical and scientific standards.  While many countries, including South Africa, have 
implemented laws and guidelines mandating ethics review of research with human participants 
(Department of Health and Human Services, 2016), there have been numerous complaints and 
criticisms of mandatory ethics review (Mamotte & Wassenaar, 2009). The following section will 
review some of the literature on this debate.  
 
 
2.4 Resistance to mandatory REC ethics review  
Mandatory ethics review for human participant research does not always result in satisfaction, at 
least from researchers. While only a handful would categorically argue against the value of 
independent ethics review, there is considerable literature and scholarly commentary indicating 
researchers’ frustrations and complaints in navigating the ethics approval process by RECs 
(Abbott & Grady, 2011). For example, RECs are often criticized for being too bureaucratic 
(Israel, 2013), with cumbersome paperwork (Jamrozik, 2004) and stifling research (Snooks et al., 
2012). Furthermore, RECs have often been criticized for variability and inconsistency in 
interpreting ethical guidelines and the decisions they make when reviewing protocols (Abbott & 
Grady, 2011; Angell, Sutton, Windridge & Dixon-Woods, 2006; Edwards, Stone & Swift, 2007; 
Lux, Edwards & Osborne, 2000; Stark, Tyson & Hibberd, 2010). RECs have also been criticized 
for lacking appropriate ethics expertise and training to adequately review protocols, for too much 
tinkering with consent documents and requesting trivial amendments (Whitney et al., 2008), and 
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not adequately dealing with the main ethical issues that such committees were actually put in 
place to address (Emanuel et al., 2004; Iltis, 2009a) and idiosyncratic decision-making (Stark, 
2012; Tolich, 2014). 
 
Similarly, mandatory ethics review of social science has also been heavily criticized (de Vries, 
de Bruin & Goodgame, 2004; Schrag, 2011; Wassenaar & Mamotte, 2012). One of the criticisms 
levelled against RECs is the power that they have to reshape proposed research, in particular, 
although not at all exclusively, for qualitative research designs (Librett & Perrone, 2010; Tolich 
& Fitzgerald, 2006). Several reports describe how research proposals have been disapproved 
because of inappropriate interpretations of ethical norms that were applied incorrectly to the 
proposed research (Dingwall, 2008; Librett & Perrone, 2010). For instance, Librett and Perrone 
(2010) decry how their proposals were disapproved by an REC and how the review process 
fundamentally reshaped the original methodology and direction of the research. Furthermore, 
some have complained about how the medical model has extended into such areas as social 
science, a consequence of so-called “ethics creep” (Haggerty, 2004).   
 
Some social scientists have also criticized ethics review in disciplines such as journalism. For 
example, Dash (2007) in his paper titled, “Journalism and institutional review boards”, opposes 
any IRB oversight for academic work on journalism done by professors and journalism students 
in any academic institution, arguing that the tendency for IRBs to require anonymity for persons 
interviewed immediately reduces the credibility of any journalistic story. The main concern here 
is the perception by social scientists academics that they are being subjected to stringent rules 
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over how and what they can investigate, and hence infringing on their academic freedom 
(Dingwall, 2008; Hamburger, 2005; Hammersley, 2009; Hedgecoe, 2015; Katz, 2007; Scott & 
Fonseca, 2010; Tierney & Corwin, 2007).  
 
Another concern expressed by opponents of ethics review of social science research is the 
perception that social science research has relatively low risk or no risk and that these risks are 
different from the risks posed by biomedical research (Dingwall, 2008; Haggerty, 2004; 
Hammersley, 2009). Furthermore, RECs are sometimes viewed as a barrier which blocks 
responsive research as a result of the cumbersome administrative burden created by ethics 
application, considering the already limited time that academics have to conduct research within 
timeframes and funding periods. Opponents argue that this restrictive administrative burden 
placed on them drastically limits the capability of social science researchers to respond to and 
investigate rapid social changes, particularly during social crisis (Hemmings, 2006; Hammersley, 
2009).  
 
Another criticism raised by opponents of ethics review of qualitative research is that RECs lack 
an understanding of and sensitivity towards the unique research designs and methodological 
underpinnings of qualitative research studies (Librett & Perrone, 2010; Tolich & Fitzgerald, 
2006; Van Den Hoonaard, 2003; Wynn, 2011). The key concern here is that some ethical 
principles are difficult to implement, for example, in ethnographic study designs, which makes 
such qualitative methods less likely to be approved using a one-size-fits-all model of ethics 
review. For example, Van Den Hoonaard (2003) maintains that while anonymity is a widely 
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recognized ethical requirement highlighted in several research ethics guidance, it is a practically 
unattainable in ethnographic and qualitative research designs. In addition, some commentators 
argue that the informed consent requirements render ethnography generally impossible as it 
‘denaturalises’ the research settings and environment being researched, converting it into a 
formal research encounter instead of its intended goal, which is to explore people and culture as 
it occurs naturally (Murphy & Dingwall, 2007). Consequently, there have been suggestions that, 
owing to the substantial methodological differences between qualitative research and the 
positivistic paradigm, ethnographic studies be assessed for ethical suitability using a different 
review process to the quantitative positivistic approach (Librett & Perrone, 2010). 
 
An additional argument raised by opponents of ethics review of social science research is that 
there is substantial lack of consensus in research communities regarding ‘appropriate ethical 
practice’, criticizing the idea that RECs – a gathering of members constituted to review and 
approve research - are well suited to make determinations on ethical decisions (Hammersley, 
2009). He further argues that the interpretation of general ethical principles must be context-
dependent, i.e., consideration should be given to the specifics of a local research setting and 
methodological expertise. In his view it is not RECs who possesses this knowledge, rather it is 
the researchers themselves. For these reasons, Hammersley argues that RECs are unsuited to 
conduct ethics review. In his view, the regulatory framework on which RECs are grounded is 
counterproductive when, or because, it prevents researchers from the need and the practical 
process of reflecting on the ethical considerations raised by, and during, their own research 
(Hammersley, 2009). More recently, Dyck and Allen (2012) argued that mandatory ethics review 
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is in itself unethical because “review boards do not respect researchers or each other, lack merit 
and integrity, are not just and are not beneficent” (p. 1).  
 
While it is beyond the scope of this study to rebut arguments against mandatory ethics review of 
social science – or any research for that matter, the present researcher is of the view that some 
arguments by social scientists against ethics review may be misguided. For example, arguments 
by social scientists resisting ethics review of psychology research on the view that research 
ethics is meant only for biomedical research are “simplistic and overlook the fact that biomedical 
research and psychological research cannot be judged by different moral standards” (Wassenaar 
& Slack, 2016, p. 307). In addition, closer analysis of cases raised by critics suggest that 
complaints arise out of single cases, rather than out of consistent attempts to evaluate criticisms 
of REC processes across a representative sample of cases. 
 
Several proposals have been made to deal with some of the criticisms levelled against RECs 
(Emanuel et al., 2004; Klitzman, 2015). For instance, centralized ethics review (Abbott & Grady, 
2011) has been proposed to address the allegedly unnecessary delays and costs, and variations 
experienced by investigators submitting similar protocols in multi-site studies. Proponents of a 
centralized system of ethics review argue that this will result in more efficient reviews in 
multisite studies (Fitzgerald & Phillips, 2006). Under the new proposed changes to the US 





The current section has reviewed some of the literature critiquing mandatory ethics review. This 
section highlighted that while the importance of ethics review and protecting human participants 
is acknowledged, there are several complaints regarding mandatory ethics review of research, 
particularly by social scientists whom continue to debate the suitability and relevance of research 
ethics/and or ethics review  to social science research (Mamotte & Wassenaar, 2009). The next 
section reviews literature on the ethical issues of international biomedical research (Emanuel et 
al. 2004, 2008; Lavery et al., 2007).  For the purposes of this present study, that is, to facilitate 
clear discussion of the findings (see Chapter 7), these topics will be set out below as follows: 
collaborative partnership, social value, informed consent, vulnerability, scientific validity, 
favourable risk/benefit ratio, payment of research participants, standards of care, ancillary care, 
post-trial access, compensation for research-related injury, post-approval monitoring of studies 
and dissemination of results.  
 
 
2.5 Ethical issues in international biomedical research 
2.5.1 Collaborative partnership 
The principle of collaborative partnership in international biomedical research has gained wide 
recognition as an important ethical requirement (Emanuel et al., 2004; Lavery et al., 2007; 
Mamotte, Wassenaar, Koen & Essack, 2010; UNAIDS/AVAC, 2011). Advocates of 
collaborative partnership between key stakeholders in health research in developed countries 
with investigators, sponsors, researchers, policy makers and host communities argue that such 
consultation and engagement may help to minimize concerns about exploitation (Emanuel et al., 
2004). Such collaborative partnership involves ensuring that research stakeholders in the 
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developing country are allowed to determine for themselves whether proposed research 
sponsored by developed countries and conducted with human participants in developing 
countries is relevant and responsive to the host community’s health needs (Emanuel et al., 2004; 
Lavery et al., 2007).  This means that, first and foremost, there should be no exploitation of the 
research communities in less developing countries. That is, the host country in which research 
could be conducted ought to autonomously determine if the proposed research is acceptable and 
relevant to the health problems of the community (Emanuel et al. 2004; Lavery et al., 2007). This 
can be achieved through establishing meaningful partnerships and engagement with the research 
enterprise- including communities in assessing health problems to be solved, determining the 
significance of proposed research, as well as the actual planning and implementation of research, 
and incorporating results and products emanating from research into local healthcare system 
(Benatar & Singer, 2010; Emanuel et al., 2004; UNAIDS/AVAC, 2011).  
 
Furthermore, collaborative partnership involves strengthening of local research stakeholder 
capacity to synthesise and disseminate evidence to be used for policy making and health care. 
Furthermore, the local community’s values, culture, traditions, language as well as the social 
context, and differences thereof, should be respected (Dickert & Sugarman, 2005). Additionally, 
a collaborative partnership entails the sustainable development of local capacity so that there is 
equal and full partnership in order to circumvent pervasive inequalities between developed and 
less developed countries (Benatar & Singer, 2010).  
 
Weijer and Emanuel (2000) argue that the ethical goal of community engagement in research is 
to ensure the protection if research participants and communities. Other commentators have also 
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argued that the main goals for community engagement are to ensure protection, respect, 
empowerment and partnership building (Dickert & Sugarman, 2005; Participants in the 
community engagement and consent workshop, Kilifi, Kenya, 2013; Tindana et al., 2007).  
 
Dickert and Sugarman (2005) proposed four ethical goals that provide a framework which can be 
used by various stakeholders (researchers, sponsors, RECs, and communities) to evaluate 
community engagement processes. These include “(1) enhanced protection, (2) enhanced 
benefits, (3) legitimacy, and (4) shared responsibility”. First, community engagement processes 
must be designed and carried out in order to help identify risks for individual research 
participants and communities as well as to identify additional measures for ensuring the 
protection and safety of research participants. Furthermore, community engagement can enhance 
the protection of non-participants through the identification of potential risks for community 
members who are not enrolled in the research project.  
 
Community engagement, for example through community advisory boards (CABs), should help 
to enhance benefits to individual research participants in accord with the principle of 
beneficence. In addition, community engagement can also benefit local communities from which 
research participants are recruited.  Third, by allowing various stakeholders to express their 
views and concerns, community engagement may help to “confer ethical and political 
legitimacy” on a particular research study. However, achieving this goal may encounter a 
number of unresolved complex questions such as, what counts as a community? Who counts as a 
representative? What level of community support is needed to legitimize a particular study?  
Fourth, community engagement enables shared responsibility between researchers and the 
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community. For example, CABs may play an active role in assisting investigators to recruit 
participants and ensure that the informed consent process is conducted in a linguistically and 
culturally sensitive manner (Dickert & Sugarman, 2005).  
 
King, Kolopacket, Merritt and Lavery (2014) propose an ethical framework for community 
engagement which seeks to clarify what kinds of community engagement strategies contributes 
to the ethical quality of research. The framework is premised on the view that relationships 
between health researchers and community stakeholders in international health research studies 
are the foundation of meaningful engagement. The authors argue that it is primarily through the 
researcher-community stakeholder relationships that investigators are able to address three core 
ethical responsibilities: “1) identifying and managing non-obvious risks; 2) extending respect 
beyond the individual to the stakeholder community; and building legitimacy for the research 
project” (p. 3). In their view, King et al (2014) maintain that these three ethical goals collectively 
characterize a logical and comprehensive framework that elucidates the important role of 
community engagement in international health research, and may perhaps serve as a useful 
reference for the on-going debate about how to evaluate the quality and impact of community 
engagement.  
 
While the concept of community engagement has received much attention (Lavery et al., 2010; 
Marsh, Kamuya, Rowa, Gikonyo & Molyneux, 2008; Nakibinge et al., 2009; Newman, 2006; 
Newman & Rubincam, 2014; Newman et al., 2015; Participants, 2011; Tindana et al., 2007), 
there is a lack of consensus on the metrics for systematically evaluating community engagement 
(MacQueen et al., 2015). Furthermore, there is less empirical research on the salient aspects of 
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community engagement (Marsh et al., 2008, 2010) and there are unresolved questions about 
what makes a meaningful community engagement (King et al., 2014; MacQueen et al., 2015). 
Several authors in African countries, particularly at the Kenya Medical Research Institute-
Welcome Trust Programme have conducted empirical studies on community engagement. For 
instance, Marsh et al. (2008) reported a case study in which they attempted to initiate community 
engagement in Kilifi, Kenya.  They report that one of the important components of their 
community engagement strategy established through a series of consultative activities was the 
establishment of a representative local resident network in different geographic locations 
commonly involved in research, to supplement existing communication channels (Marsh et al., 
2008).  
 
A recent review of community engagement strategies used in research in three African countries 
(Botswana, South Africa, and Zimbabwe) found that there were various strategies used such as 
formative research activities, traditional or community leaders support, community stakeholder 
partnership, community sensitisation and education, community advisory mechanisms, and 
community empowerment (Musesengwa & Chimbari, 2016). Another review of the community 
engagement for biomedical and genomic research in Africa by Tindana et al. (2015) found that 
there was a lack of uniformity on how the concept of community engagement is defined in 
literature. The authors report found that there was the concept of community engagement was 
sometimes used interchangeably with community based participatory research to engage the 
target community and actively participating in the identification and planning of relevant 
research and disseminating the findings.  The review found that CABs were commonly used as a 
community engagement strategy (Tindana et al., 2015).  For genomic research, the review also 
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found that there was a range of strategies for community engagement such as the use of 
community representatives, CABs, and direct engagement with potential research participants 
and their communities (Tindana et al., 2015). 
 
Several empirical studies have been conducted to investigate the role of African CABs in 
community engagement (Morin, Maiorana, Koester, Sheon & Richards, 2003; Reddy, Buchanan, 
Sifunda, Shamagonam & Naidoo, 2010). One qualitative study conducted in South Africa aimed 
at investigating the views of investigators, CAB members, research staff and RECs found that 
there were differences in stakeholders’ views of the roles and responsibilities of CABs (Reddy et 
al., 2010). Another study by Morin et al. (2003) involving 6 research sites of the HIV Prevention 
Trials Network (HPTN) in US, Zimbabwe, Peru and Thailand found that there were two models, 
i.e. the “broad community” and “population-specific” models for the involvement of CABs in 
representing research participants in HIV prevention trials in these settings. Furthermore, the 
study found that CABs believed that their role was to act like a bridge between the researchers 
and trial participants. Additionally, the study found that CABs actively played a meaningful role 
in improving HIV prevention clinical trials by assisting in protocol development, recruitment, 
and retention, as well as involvement in identifying and resolving ethical issues in clinical trials 








2.5.2 Social Value 
Social value has gained wide recognition as a benchmark of ethical research (Emanuel et al., 
2004; Habets, van Delden & Bredenoord, 2014). According to Emanuel et al. (2004), social 
value in health research has four characteristics 1) specifying who the beneficiaries of research 
are, 2) outlining the potential value of the research for each of the prospective beneficiaries, 3) 
enhancing the value of research through, for example, dissemination of knowledge, product 
development, long term research collaboration and health systems improvements, and 4) 
ensuring that the conduct of research does not supplant the host country’s existing healthcare 
system (Benatar & Fleischer, 2007; Emanuel et al., 2004).  
 
Despite its acceptance as a benchmark of ethical research (Emanuel et al., 2004), there is 
considerable disagreement about the notion of social value, for example, how social value can be 
achieved and who is responsible for ensuring that it is attained (Lairumbi et al., 2008). Further 
unsolved questions include: Is social value a necessary requirement for ethical research?  What 
makes research socially valuable?  How does the social value of research relate to its scientific 
value?  Does the social value of research pertain to the potential value of study interventions, 
research studies or research programs?  Should social value be considered as a threshold 
condition for research to proceed, or should a given project’s social value be reasonable in 
relation to other considerations, such as the risks to participants? (Rid & Shah, 2015). In the 
absence of clear-cut guidance from existing research ethics guidelines, such questions are likely 
to continue posing challenges for sponsors, investigators, RECs and regulatory bodies 
particularly where the justification for the proposed research may not necessarily be for the 
benefit of individual participants, but for the general population (Lairumbi et al., 2008).  
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There is a growing literature exploring social value in African settings (Lairumbi et al., 2008; 
Lairumbi, Parker, Fitzpatrick & English, 2011a; Lairumbi, Parker, Fitzpatrick & English, 2012; 
Lairumbi, Parker, Fitzpatrick & Mike, 2011b). One study in Kenya found that stakeholders 
viewed social value as benefit-sharing, for example, through post-trial access to research 
products and medical care, technology transfer and building local capacity, and societal benefits 
emanating from the successful completion of research (Lairumbi et al., 2011a). In a separate 
study, Lairumbi et al. (2011b) reviewed existing research ethics guidelines and found 
considerable inconsistency in how guidelines address the issue of social value and benefits 
entitled to participants and host communities in international biomedical research. Another 
Kenyan study by Kamunya et al. (2014) found that research participants were gratified by the 
benefits, particularly health care benefits, derived from participation in research. Furthermore, 
research participants viewed fieldworkers and researchers as the gatekeepers and conduits of 
benefits. The same study found that fieldworkers and researchers had difficulty ignoring 
participant and community requests for more benefits, especially in situations of extreme poverty 
(Kamunya et al., 2014). 
 
Habets, van Delden and Bredenoord (2014) proposed that the concept of social value be limited 
to denote the anticipated improvement resulting from a particular intervention. The authors 
propose to use the concept “anticipated social value” which implies that the social value lies in 
the nature and magnitude of the improvement the intervention is expected to have on the 
wellbeing of patients, individuals in society, or society. Wenner (2015) criticized the existing 
guidelines for not distinguishing between those benefits which can justify the conduct of 
research in LMICs and those which cannot. The author argues that the justification for research 
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with human participants is primarily grounded in the value of the knowledge pursued, and that 
this social value of research generated knowledge should be contextualized, and that existing 
ethical guidance and frameworks on the concept of social value and benefits fails to appreciate 
that the value is highly context-dependent. The authors propose a framework for the assessment 
of benefits deriving from research assigned to host communities in developing countries in 
which the types of research conducted in such settings is limited (Wenner, 2015). 
 
2.5.3 Informed Consent 
Informed consent is widely recognized as the cornerstone for ethical clinical research involving 
human participants (Grady, 2015; Lindegger & Richter, 2000; Emanuel et al., 2004). Informed 
consent has its origins in the 1947 Nuremberg Code which states that “the voluntary consent of 
the human subject is absolutely essential” (p. 1). The principle of respect for persons underpins 
the requirement for informed consent (Belmont Report, 1979). Appelbaum, Lidz and Klitzman 
(2009) maintain that the informed consent process allows a potential research participant to make 
a meaningful choice whether or not to participate in research and should thus reflect the will or 
intention of the individual providing consent, not of other persons. The following are essential 
components of valid informed consent:  information disclosure, understanding and voluntariness 
(Lindegger & Richter, 2000).  
 
2.5.3.1 Information disclosure 
 
Complete, accurate and understandable information should be appropriately provided to 
participants prior to participation in clinical trials. In other words, participants should receive the 
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necessary information to make an informed choice about their participation. According to the US 
Common Rule, 45 CFR 46 guidance on informed consent,  the informed consent documents 
should have a clear description of information containing the following minimum requirements; 
(1) A statement that the study involves research, an explanation of the research, and the expected 
duration of the subject’s participation, a description of the procedures to be followed,  
identification of any procedures that are experimental, (2) a description of any reasonably 
foreseeable risks or discomforts to the research participant, (3) benefits anticipated from 
research, (4) any alternative procedures or treatments to study participation, (5) a statement 
describing the extent, if any, to which confidentiality of records identifying the research 
participant will be maintained, (6) an explanation as to whether any compensation and/or 
medical treatment are available if injury occurs and, if so, what they consist of, or where further 
information may be obtained, (7) contact details of the relevant persons to ask questions or report 
serious adverse events, and (8) A statement that participation is voluntary, refusal to participate 
will involve no penalty or loss of benefits to which the research participant is otherwise entitled, 
and the participant may discontinue participation at any time without penalty or loss of benefits 
to which the participant is otherwise entitled (DHHS, 1991). 
 
However, for the informed consent process to be truly ethical and valid, it demands more than 
just disclosure of the eight pieces of information (Flory & Emanuel, 2004). The information 
should be disclosed in a culturally and linguistically appropriate manner (Emanuel et al., 2004). 
Moreover, the need for additional community and familial consent procedures where it is 
culturally appropriate and necessary should be respected; however this should not override 
individual consent (Emanuel et al., 2004; Lindegger & Richter, 2000). 
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2.5.3.2 Comprehension of informed consent  
 
Understanding of consent information is a condition that must be adequately satisfied before 
potential research participants can give their informed consent (CIOMS, 2002; Department of 
Health, 2015, WMA, 2013). However, several empirical studies have suggested that participants 
often do not fully understand information provided during the informed consent process, both in 
developed (Falagas, Korbila, Giannopoulou, Kondilis & Peppas, 2009; Flory & Emanuel, 2004; 
Joffe, Cook, Cleary, Clark & Weeks, 2001; Sanchini, Reni, Calori, Riva & Reichlin, 2014; Smith 
& Fogarty, 2016; Tam et al., 2015) and developing countries (Afolabi et al., 2014; Chaisson, 
Kass, Chengeta, Mathebula & Samandari, 2011; Krosin, Klitzman, Levin, Cheng & Ranney, 
2006; Lynoe, Hyder, Chowdhury & Ekstrom, 2001; Molyneux, Peshu & Marsh, 2004; 
Molyneux, Wassenaar & Peshu, 2005; Naanyu, Some & Siika, 2014; Ndebele, Wassenaar, 
Masiye & Munalula-Nkandu, 2014c; Taiwo & Kass, 2009;  Pace et al., 2005a, 2005b).  
 
Participants’ understanding of the terms randomization, double-blinding, and placebo was 
investigated and it was found that the approximately 85% of respondents showed understanding 
of randomization, placebo use (72%), and double-blinding (68%). Overall, the study found that 
61% of respondents attained low scores on a collective understanding of all the three concepts 
(Ndebele et al., 2014c). Another study in Uganda assessed parents’ understanding of the trial and 
found that while a substantial percentage (77%) of respondents reported remembering being told 
about the study's purpose, the required number of visits (88%), the risks involved (61%), 
treatment allocation (84%), and their ability to discontinue their children's participation (64%). 
Only 18% could name the possible side-effects of the study drugs, and only 19% knew that 
children would be randomized to different treatment arms (Pace et al., 2005b). 
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Furthermore, reports have also suggested that research participants may often fail to understand 
that the trial may not benefit them personally even when they have been informed that they are 
participating in a research study which is not part of routine clinical care, the so-called 
therapeutic misconception (Lidz, Appelbaum, Grisso, & Renaud, 2004; Miller & Joffe, 2006). 
Several commentators have also raised concerns that the increasing length and complexity of 
participant information sheets and informed consent forms are impeding understanding (Franck 
& Winter, 2004; Pilgaard & Ravn, 2012; Taylor & Bramley, 2012). For instance, a study by 
Kass, Chaisson, Taylor and Lohse (2011) found that adult HIV trial consent forms had median 
length of 27 pages and the mean readability was 9.2 grade level. Klitzman (2013a) qualitatively 
studied 60 US IRB chairs on how they view and make decisions about informed consent. He 
found that IRBs encountered challenges and dilemmas regarding consent documents, particularly 
when deciding what and how much should be included in the consent forms. 
 
Several investigators have reported on mechanisms to help improve participant understanding of 
the informed consent information in settings where factors such as cultural background, illiteracy 
and language barriers hinder sufficient understanding of consent information by participants 
(Penn & Evans, 2010; Fitzgerald, Marotte, Verdier, Johnson & Pape, 2002; Flory & Emanuel, 
2004; Lindegger et al., 2006; Molyneux, Gikonyo, Marsh & Bejon, 2007; Ndebele, Wassenaar, 
Munalula-Nkandu & Masiye, 2012; Nishimura et al., 2013; Vallely et al., 2010. A study by 
Ndebele et al. (2012) implemented a mixed narrative intervention (such use of vignettes in 
explaining the trial concepts and colourful pictures to supplement written information) to 
improve participant understanding. Their intervention was effective in improving participant 
understanding of trial concepts, namely randomization, double-blinding and placebo.  
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Another study assessed the impact of three different interventions i.e., 1) enhanced standard 
consent forms,  2) context-specific consent forms,  and 3) context-specific counselling cards on 
participant understanding of informed consent by 297 pregnant women enrolled in an HIV 
prevention trial in Malawi. The study found that, both immediately post intervention and at 1-
week follow-up, participants assigned to groups 2 and 3 understood more about research 
concepts and study procedures compared with group 1, suggesting that context-specific 
approaches contributed to improved participant understanding of consent information when 
compared to enhanced standard consent form (Corneli et al., 2012).  Three consent interventions 
were developed and their effectiveness in improving participant understanding of the consent 
information was assessed. Group 1 participants received a bulleted fact sheet summarizing key 
study information, group 2 received the bulleted fact sheet in addition to engaging in a feedback 
question and answer (Q&A) session and the control group received standard consent procedures. 
The study reported that participants receiving the second intervention scored 7.6 % points higher 
on open-ended questions about understanding than participants in the control group, suggesting 
that both bulleted fact sheets and Q&A sessions can significantly contribute to improving 
participant understanding compared to standard consent (Kass et al., 2015). 
 
However, a study by Paris et al. (2015) assigned 241 patients to receive a standard informed 
consent document and 240 patients a modified informed consent. The authors reported that there 
was no difference between the two groups for the score of objective comprehension, suggesting 
that enhancing informed consent documents had no effect on participants' understanding. The 
authors noted that rate of enrolment in the clinical study was lower in the group that received the 
modified informed consent than for the standard informed consent. The authors concluded that, 
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“In attempts at improving potential participants' understanding of clinical research information, 
efforts and future trials should focus on other ways to improve comprehension” (Paris et al., 




Voluntary informed consent is a requirement in several ethical guidelines (Nuremberg Code, 
1947; Belmont Report, 1979; CIOMS, 2002; Department of Health, 2015; WMA, 2013). For 
instance, the Nuremburg Code (1947) states that, “The voluntary consent of the human subject is 
absolutely essential. This means that the person involved should … be so situated as to be able to 
exercise free power of choice, without the intervention of any element of force, fraud, deceit, 
duress, over-reaching, or other ulterior form of constraint or coercion” (p. 1).  
 
Although several international and national guidelines emphasize the need for voluntary consent, 
their definition of voluntariness is somewhat inconsistent and there is limited guidance on how to 
assess voluntariness (Mamotte & Wassenaar, 2015, 2016). Firstly, these guidelines generally 
regard voluntariness as the absence of coercion and undue inducement, yet fail to explicitly 
define either term or set out the critical features of such terms (Emanuel, 2005; Mamotte & 
Wassenaar, 2015). Such a deficiency in clarity could further exacerbate the ongoing controversy 
about coercion and undue influence in research (Emanuel, 2005; Klitzman, 2013c). Furthermore, 
some guidelines, for example the SA MRC (1993) and SA GCP (2006) regard financial 
incentives as factors undermining voluntariness, but without clear articulation of how these 




For some commentators, the use of incentives per se does not automatically constitute undue 
inducement. (Emanuel, 2005) argues that compensation is coercive only when it distorts a 
participant's reasoning to the extent that they take risks they would not ordinarily be willing to 
take. Similarly, Largent, Grady, Miller and Wertheimer (2012) argue that misplaced concerns 
about money ad inducements may inadvertently distort ethically acceptable incentives and 
impede valuable research.   
 
While there is a substantial body of literature on the concept of voluntariness (Appelbaum,  
2011; Appelbaum, Lidz & Klitzman, 2009; Mamotte & Wassenaar, 2015, 2016; Miller et al., 
2011; Nelson et al., 2011, Nelson & Merz, 2002; Pace & Emanuel, 2005), there is a lack of 
consensus in the ethical models or frameworks on the standards for assessing voluntariness of 
consent (Mamotte & Wassenaar, 2015). There are various conceptualizations of what exactly 
constitutes voluntary consent (Mamotte & Wassenaar, 2015, 2016). For instance, Beauchamp 
and Childress (2009) define voluntariness as when a person “wills the action without being under 
the control of another’s influence” (p. 132). Nelson et al. (2011) theorizes voluntariness as 
constituting intentional action and substantial freedom from internal (e.g. mental illness) and 
external controlling influences (e.g., payments, threats, deceit, manipulation, persuasion and 
coercion). Furthermore, the model posits that constraining situations (e.g., lack of resources, 
powerlessness and severe illness) may unintentionally cause a person to act involuntarily.   
 
However, some commentators have critiqued Nelson et al.’s (2011) approach. For instance, Bull 
and Lindegger (2011) argue that voluntariness must, in addition to external influences, take into 
consideration the participant’s subjective experiences of voluntary consenting, given the 
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complex political, cultural, social, and economic factors and power relations between researcher 
and participant, which may impact the voluntariness of decision-making process. Similarly, some 
authors also suggested that social norms and culture (e.g., decision-making by community 
leaders or family members) and social relationships (e.g., patient-researcher trust) are, indeed, 
common  contextual correlates of voluntary informed consent in Kenya and other low resource 
settings (Kamunya, Marsh & Molyneux, 2011), and  developed countries (Miller & Nelson, 
2012).  
 
Factors that have been implicated as possibly negating voluntariness include financial 
compensation in return for research participation (Kass, Maman & Atkinson, 2005; Koen, Slack, 
Barsdorf & Essack, 2008; Kwagala, Wassenaar & Ecuru, 2010; Mamotte & Wassenaar, 2016), 
recruitment of participants by their health care providers (Appelbaum, Lidz & Klitzman 2009), 
and  limited access to medical care and treatment (Kass et al., 2005; Mamotte & Wassenaar, 
2016; Nelson & Merz, 2002; Pace et al., 2005a).  For instance, a study conducted in Thailand by 
Pace et al. (2005a) reported that approximately 43 of 141 participants enrolled in randomized 
HIV treatment trial felt under pressure to participate because of their health status. Of these, 10 
respondents reported that the trial was the only way for them to access treatment (Pace et al., 
2005a).  
 
Another study reported that 75% of participants felt moderate or a lot of pressure to participate in 
the phase I study due to their growing cancer, whereas 7% said they felt pressure to participate 
from the study investigators and 9% felt such pressure from their families (Agrawal et al., 2006).  
A South African study by Barsdorf and Wassenaar (2005) assessing the perceptions on the 
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voluntariness of research participants found that black respondents perceived consent to be less 
voluntary than did white or Indian respondents. Another recent South African study assessing 
voluntariness in HIV clinical trials found high levels of perceived voluntariness with the majority 
of participants reporting an absence of controlling influences from other people. The authors 
reported that there was a significant association between lower perceived voluntariness and 
feeling of having no choice but to participate (Mamotte & Wassenaar, 2016).  
 
 
2.5.4 Vulnerability  
Vulnerability is a widely recognized ethical concern in biomedical research involving human 
participants (Ballantyne & Rogers, 2007; Coleman, 2009; DuBois, 2006; Horn, 2007; Horn, 
Sleem & Ndebele, 2014; Hurst, 2008; Iltis, 2009b; Lange, Rogers & Dodds, 2013; Macklin, 
2012; Tangwa, 2009). Several research ethics guidance (e.g., CIOMS, 2002; Department of 
Health, 2015; WMA, 2013) have a section on vulnerable populations and emphasize the need to 
protect vulnerable populations in research. For instance, the Declaration of Helsinki (2013) states 
that, “Some groups and individuals are particularly vulnerable and may have an increased 
likelihood of being wronged or of incurring additional harm. All vulnerable groups and 
individuals should receive specifically considered protection…” (p. 3). Although several 
international and national guidelines mention vulnerable populations, there is seemingly lack of 
consensus on the definition of vulnerability and standards for identifying and addressing the 
concept of vulnerability (Coleman, 2009; DuBois, 2006; Lange et al., 2013). Furthermore, there 
is little empirical research on the concept of vulnerability and what constitutes vulnerability 
(Lange et al., 2013; Levine et al., 2004). Macklin (2003) maintains that besides individuals or 
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groups,  the entire community or country can be vulnerable to exploitation particularly in 
international clinical research funded by wealthier countries and conducted with human 
participants in developing countries.   
 
RECs are required to ensure that investigators justify the recruitment of vulnerable populations 
and to ensure that there are additional measures in place to safeguard the rights, safety and 
wellbeing of vulnerable populations from coercion or undue influence (Horn et al., 2014). The 
National Bioethics Advisory Commission  (NBAC, 2001) proposed a framework involving six 
specific characteristics that might create vulnerability of an individual research participant, i.e., 
(i) cognitive or communicative vulnerability: cognitive incapacity may cause participants not to 
be able to sufficiently understand information, deliberate and make informed decisions, (ii) 
institutional vulnerability: people in dependent relationships with authority figures, e.g., students 
and prisoners may be exploited for convenience, hence negating or undermining their voluntary 
consent, (iii) deferential vulnerability: cultural or societal norms such as in the case of women 
whose cultural norm is to defer to the husband for decisions regarding participation in research 
may be vulnerable to exploitation , (iv) medical vulnerability: an individual suffering from a 
serious health condition for which there is no satisfactory standard treatment may have the 
perception that research is the only hope to which may negate the voluntariness of their 
participation in research , (v) economic vulnerability: conditions of poverty may cause less 
privileged participants to enrol in research when such research appears to offer benefits that are 
much needed and only available to the participant through research participation and (vi) social 
vulnerability: some societal groups or individuals may be viewed as less valuable by others such 
that researchers may unfairly treat them e.g., by giving them inadequate information during the 
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informed consent process or by recruiting them into a study with a risk/benefit ratio that would 
not be acceptable to more privileged people (DuBois, 2006).  
 
Kipnis (2001) offers a taxonomy delineating six types of vulnerability, i.e., cognitive (ability to 
understand and make decisions), juridic (being under a dependent relationship with a person with 
legal authority), deferential (customary obedience to medial or other authority), medical (having 
an illness without treatment), allocational (poverty educational deprivation) infrastructural 
(limitations of the research setting to carry out proposed research), and social vulnerability 
(belonging to a disadvantaged group). He argues that these six types of vulnerability may limit 
the ability to provide informed consent.  However, while accepting the usefulness of the 
taxonomy, Levine et al. (2004) criticize it for two reasons. First the taxonomy makes an 
assumption that everyone who fits in any of these categories is vulnerable. Second, the taxonomy 
implies that everyone capable of autonomous consent is not vulnerable (Levine et al., 2004). 
 
Ballantyne and Rogers (2007) argue that vulnerability exists as a spectrum rather than a simple 
(present or absent) dichotomy. They propose a conceptual framework outlining two types of 
vulnerability, i.e., extrinsic and intrinsic vulnerability. In their view, extrinsic vulnerability is 
caused by external situations, e.g., low socio-economic status or education,  while intrinsic 
vulnerability is as a result of internal characteristics of individuals themselves, e.g., medical 
illnesses, mental disabilities and extremes of age (for example in children and some elderly). The 
authors recommended that RECs should distinguish between intrinsic and extrinsic 
vulnerabilities, as these may require different mechanisms to protect the rights, dignity and 
safety of potential research participants (Ballantyne & Rogers, 2007).   
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Luna (2009) argues that vulnerability should not be a label assigned to certain subpopulations, 
but rather proposes a conceptual framework of "layers of vulnerability" (p. 128). In other words, 
Luna suggests that the notion of vulnerability is highly contextual and that RECs can only 
determine if participants are vulnerable by considering the contextual details of the proposed 
research (Luna, 2009). Dhai (2015) proposes a Vulnerability Assessment Scale to assist RECs 
and researchers identify research participants with vulnerabilities and develop focused 
safeguards for their protections. According to her scale, the REC would need to ask the 
following eight questions, i.e., “1) Has the essential minimum standard afforded all participants 
in light of universal vulnerability been met?  2) Has the baseline for respecting human dignity 
been met? 3) Will any participant be used in the research as a means to an ends she/he may not 
endorse? 4) Will all the research participants in this study be able to safeguard their own 
needs and interests? 5) If no, is there an increased likelihood of any of them being identifiably 
wronged as a result of their participation in the study? 6) Is there an increased likelihood of any 
participant being identifiably wronged to a greater degree than other participants? 7) Have the 
identifiable wrongs been recognised? and 8) Have special safeguards been developed to protect 
those participants in need of such safeguards?”  (p. 221). 
 
2.5.5 Scientific validity 
The obligation to conduct scientifically valid research is one of the fundamental ethical 
principles in research ethics (Emanuel et al., 2004). Almost all major international and national 
ethics guidance specifies that for studies to be ethical, they must be scientifically sound and have 
valid resigns that will properly answer the research question (Department of Health, 2015; 
Nuffield Council on Bioethics, 2002). According to the Emanuel et al. (2004) framework, the 
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design, sample, method, and analysis of the study should be rigorous, justifiable, feasible, and 
lead to valid answers to the research question. However, there is also much controversy and 
debate regarding the role of RECs in evaluating the scientific merit of research proposals with 
some critics arguing that scientific reviews falls outside the remit of RECs (Amdur, 2006; Angell 
et al., 2008; Edwards, 2010; Humphreys, Thomas & Martin, 2014a).  
 
Supporters of scientific review by RECs argue that one of the fundamental pillars of ethical 
research is the principle of scientific validity (Emanuel et al., 2004).  In other words, those 
supporting scientific review by RECs often argue that it is unethical to expose participants to 
risks and burden and enrol participants in research that is poorly designed and inconsistent with 
the expectations of good scientific methodology (Dawson & Yentis, 2007). As stated by the 
Nuffield Council on Bioethics (20002) “Research which is not appropriately designed will fail to 
provide answers to the questions posed by the research, and thus will have limited benefit or no 
benefit either to the participants, or to the wider community” (p. 102).  
 
This suggests that, regardless of whether it is quantitative or qualitative, proposed research 
should have scientific validity and rigor to avoid investing human and financial resources in a 
research study that will not yield any beneficial outcomes. The scientific validity of qualitative 
social science research should be assured and assessed using criteria appropriate to qualitative 
research. Furthermore, it is important for the PIs and research team to have suitable expertise and 
competence to undertake proposed research; otherwise this might easily undermine the scientific 
validity of a research study (Tsoka-Gwegweni & Wassenaar, 2014). Molyneux et al. (2009) 
argue that in social science research, the positionality of the researcher in relation to participants 
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might influence data quality. They argue that it is therefore also important to have well trained 
fieldworkers when conducting interviews and observations to ensure scientifically valid research. 
 
2.5.6 Favourable risk/benefit ratio 
The risk/benefit assessment of research protocols by RECs is an important component of ethics 
review in accordance with the ethical principles of beneficence and nonmaleficence (Emanuel et 
al., 2004; Weijer, 2000).  RECs are required to conduct a systematic, non-arbitrary assessment of 
the potential risks and benefits of a research protocol insofar as these are foreseeable (Belmont 
Report, 1979). The US Common Rule requires that in order for research to be approved, IRBs 
should ensure that “(1) Risks to subjects are minimized: (i) by using procedures which are 
consistent with sound research design and which do not unnecessarily expose subjects to risk, 
and (ii) whenever appropriate, by using procedures already being performed on the subjects for 
diagnostic or treatment purposes. (2) Risks to subjects are reasonable in relation to anticipated 
benefits, if any, to subjects, and the importance of the knowledge that may reasonably be 
expected to result. In evaluating risks and benefits, the IRB should consider only those risks and 
benefits that may result from the research (as distinguished from risks and benefits of therapies 
subjects would receive even if not participating in the research). The IRB should not consider 
possible long-range effects of applying knowledge gained in the research (for example, the 
possible effects of the research on public policy) as among those research risks that fall within 






While the importance of favourable risk/benefit ratio is highlighted by several international and 
national ethical guidelines and frameworks (Emanuel et al., 2004), there is considerable debate 
regarding when are research risks reasonable in relation to anticipated benefits (Weijer & Miller, 
2004), and what conceptual framework should guide the ethical analysis of risk (Weijer, 2000). 
There are two leading models that have been proposed for a systematic approach to risk/benefit 
assessment, i.e., the component analysis and the net risks analysis (Weijer, 2000; Weijer & 
Miller, 2004). According to Weijer (2000) a component-based approach to risk/benefit 
assessment involves analysis of both a) the magnitude of the harm and b) its probability of 
occurrence.  The component analysis approach is premised on the recognition that biomedical 
research often consists of a combination of therapeutic and non-therapeutic components, and as 
such there is need for separate moral standards for the assessment of individual study 
components or research intervention or procedure involved in a particular study instead of 
conducting a global risk benefit analysis profile of the overall study (Weijer, 2000).   
 
However, opponents of the component approach have argued that the approach is flawed for 
several reasons. They argue that, equipoise, one of the concepts of the component analysis 
approach, conflates ethics of research with ethics of clinical care (Miller & Brody, 2003). 
Furthermore, opponents argue that the component approach is inappropriately applied in the 
ethical analysis of placebo-controls (Emanuel & Miller, 2001). Wendler and Miller (2007) 
proposed the net risks test as an alternative approach for risk/benefit assessment. Similar to the 
component analysis, the net risks test’s emphasis is on consideration of the risks and benefits of 
individual research procedures or interventions instead of the overall study. However, there is a 
fundamental difference in the normative foundation of the net risks test which distinguishes it 
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from the component analysis. The net risks test is premised on the fundamental principle of non-
exploitation, a central concept in the ethics of clinical research. Thus, the primary objective of 
the net risks test (and risk/benefit assessment in general) is to safeguard the protection of 
research participants from being exposed to excessive risks of harm for the benefit of others.  
 
There are four ethical requirements articulated by the net risks test. First, the risks posed by each 
individual study procedure should be minimized, and the potential benefits of each procedure 
must be enhanced. Second, a research procedure should not pose an excessive increase in risk or 
an excessive decrease in potential clinical benefit for the participant when compared to available 
alternatives. In other words, this second requirement encompasses an assessment of whether a 
particular research procedure presents net risk to the individual research participant, followed by 
an assessment of whether these risks are excessive (Wendler & Miller, 2007). Net risks could 
occur in at least two scenarios. For instance, where the risks of a particular study procedure or 
intervention exceed its potential clinical benefits for the participant, then there is a net risk. An 
example of this scenario is in Phase I oncology trials, where the drugs often pose more risks to 
the participant than they offer potential benefits (Rid & Wendler, 2010). Another scenario of net 
risks occurs when a research procedure poses risks that do not exceed the procedure’s potential 
clinical benefits, but the procedure’s risk/benefit profile is lower than the risk/benefit profile of 
one or more of the available alternatives. For example, some older generation drugs offer a 
favourable risk/benefit ratio, but then it is lower than the risk/benefit ratio of newer drugs with 
which they have been replaced. Where a particular study procedure poses net risks to participants 
(as in the examples above), the net risks test necessitates that these risks are sufficiently low (Rid 
& Wendler, 2010).  
82 
 
The third requirement of the net risks test is that where a study procedure poses net risk, this 
should be justified by the knowledge expected to be gained from using that particular study 
procedure. This requirement is important in ensuring that the net risks to an individual research 
participant, on the provision that they are not excessive, are reasonable in relation to potential 
societal benefits (Wendler & Miller, 2007). The last requirement of the net risks test is that the 
‘cumulative’ net risks of all the combined research procedures (regardless of whether each 
procedure poses low net risks to participants) in a study should not be excessive (Wendler & 
Miller, 2007, p. 484).  
 
Critics of the net risk test argue that the approach has limitations in that it fails to align the ethics 
that govern clinical research with those of clinical care, subsequently allowing research that 
violates patients’ rights to appropriate care (Weijer & Miller, 2007). Another criticism of the net 
risks test is that it permits any level of risk, as long as the anticipated benefits to society are 
reasonable, and thus may undermine the public trust of the medical research enterprise (Weijer & 
Miller, 2007). Furthermore, the net risks test is criticized for its apparent lack of definition of 
‘excessive’ risk, hence leaving it to the discretion of RECs to make the determination of what 
risks are excessive (Weijer & Miller, 2007). This may cause variability in how RECs make 
decisions regarding the risk/benefit ratio of a study (Shah et al., 2004).  
 
Bernabe, van Thiel, Raaijmakers and van Delden (2012) argue that both procedure-level 
approaches conflate the various risk/benefit assessment tasks of RECs.This conflation, the 
authors claim, makes the REC’s task of assessing the risk/benefit of a research “confusing, if not 
impossible” (p.8). Rid (2014) argues that the current model for risk/benefit assessment is not 
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comprehensive and arguably places too much emphasis on informed consent as a condition of 
acceptable net risk to participants. Rid proposes that the scientific and social value of biomedical 
research is likely to be fundamental to the acceptability of exposing participants to net research 
risks. This implies that when a particular study is scientifically valid and socially valuable, then 
it may be justifiable to expose participants to net risks of research (Rid, 2014).    
 
2.5.7 Payment of research participants 
It is common practise to offer participants payments for their participation in biomedical research 
(Dickert, Emanuel & Grady, 2002; Fry et al., 2005; Grant & Sugarman, 2004; Ripley, Macrina & 
Markowitz, 2006). In order to help IRBs and investigators, several approaches to payments have 
been proposed (Ackerman, 1989; Anderson & Weijer, 2002; Dickert & Grady, 1999; Macklin, 
1981).  For instance, Dickert and Grady (1999) described the market model, wage payment 
model and reimbursement model. The wage model is recommended by Dickert and Grady 
(1999) for three main reasons: (1) it reduces concerns about undue inducement, (2) it 
standardises payment schedules, and (3) it establishes a system in which payment is based on the 
contribution made by each participant, consistent with the principle of justice, i.e., equals should 
be treated equally.  
 
However, there is considerable debate regarding the ethics of paying research participants 
(Grady, 2005a; Gordon, Brown, Kratocvil, Schonfeld & Prentice, 2006; Horn, 2008; Koen et al., 
2008). McNeill (1997) argues that it is unethical to offer payment to participants, claiming such 
payments may cause participants to not be able to adequately assess the risks of participating in 
research. He further argues that offering payments to participate in research would further 
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increase the inequity of research conducted on the impecunious for the benefit of the well-off.  
The main concerns raised by some commentators in relation to payment of participants are 
coercion and undue inducement which undermine free and voluntary consent (Grady, 2001, 
2005a). In a paper titled The paradoxical case of payment as benefit to research subjects,  
Macklin (1989) argues that ‘‘the reason for holding that it is ethically inappropriate to pay 
patients to be research subjects is that it is likely to be coercive, violating the ethical requirement 
that participation in research should be fully voluntary” (p. 3).  
 
Some commentators have also argued that payments do not constitute coercion and undue 
inducement (Emanuel, 2004; Emanuel 2005; Emanuel, Currie, & Herman, 2005; Grady, 2005a; 
Largent et al., 2012; Largent et al., 2013; Wertheimer & Miller, 2008). For instance, Emanuel 
(2005) argues that in order for an inducement to be undue, there are four necessary conditions 
that must be met. First, a desirable good has to be offered in return for a specified action. Second, 
the offered good must be so excessive that it cannot be resisted. Third, the offer has to result in a 
person making a poor judgment in relation to the specified action. Finally, the person’s poor 
judgment must result in a high probability that they will experience serious harm that threatens 
their interests. In his view, undue inducements apply only when risks are undoubtedly 
unreasonable. The author concludes that if a research proposal fulfils all the other ethical 
requirements and an efficient and competent REC has found the risk/benefit ratio to be 
favourable, then undue inducement cannot occur as long as the risk of serious harm that is 
precluded, even if participants exercise poor judgment (Emanuel, 2005). Similarly, Emanuel and 
Miller (2007) argue that instead of relying on financial considerations as indicators of ethical 
problems, ethical analysis should focus on relevant substantive issues, such as the research 
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design, the risk/benefit ratio and the informed consent process.  
 
Horn (2008) argues that determination of whether or not to pay participants is dependent on 
several factors, such as the nature of the study, degree of risk involved, profile of participants, 
funding source, and issues related to the potential public health implications of the study. 
Payment should thus be considered on a case-by-case basis. Generally, the literature on the ethics 
of paying research participants has concluded that while issues may arise, offering payments to 
participants does not constitute coercion or undue inducement (Emanuel, 2004, 2005; Emanuel et 
al., 2005; Grady, 2001, 2005a; Largent et al., 2012, 2013; Wertheimer & Miller, 2008). 
 
Little is known about how RECs view and deal with such issues (Ripley et al., 2006, 2010). A 
qualitative study by Klitzman (2013c) explored how IRBs view and make decisions about 
coercion and undue influence  and found that IRBs often encountered difficulties with defining 
the concepts of coercion and undue inducement, especially in deciding about participant 
compensation. Another study by Largent, Grady, Miller and Wertheimer (2012) explored the 
views of IRB members about whether payments constitute coercion and undue inducement. They 
found that the majority (61%) of respondents expressed concern that payment of any amount 
might influence participants’ decisions or behaviours regarding research participation. The 
authors reported that there was variation in how IRBs viewed coercion and undue influence to 
the extent that these inconsistences could needlessly interfere with important research (Largent et 
al., 2012, 2013). In 2012, The South African NHREC developed guidelines for the ethical 
payment of research participants. The proposed model is payment for time, inconvenience and 
expenses (NHREC, 2012).  
86 
 
2.5.8 Standard of Care 
The growth of externally-sponsored clinical research in developing countries has, over the recent 
years, fuelled debates about the issue of standard of care, i.e., the level of treatment that should 
be offered to participants assigned to the control group (Ehni, 2006; Lavery et al., 2007; Lie, 
Emanuel, Grady & Wendler, 2004; Miller & Silverman, 2004; Schüklenk, 2004; Schüklenk & 
Ashcroft, 2000; Selgelid, 2005; Wendler, Emanuel & Lie, 2004). At the centre of the standard of 
care debate is the question of what standard reference point should be used to compare the 
efficacy of an investigational drug? Should it be the best current treatment or should it be the 
universal standards of care or should it be the locally available standard of care – even if it is 
close to nothing? (Hawkins, 2008). Distinguishing between these two viewpoints of standard is 
essential and leaves the concept of standard of care subject to different interpretations (Macklin, 
2004).  
 
The standard of care debate came to the fore following a number of cases of placebo-controlled 
trials of zidovudine (AZT), referred to as the ACTG 076 regimen - AIDS Control Trial Group 
076 protocol - for the prevention of perinatal transmission of HIV infection in different 
developing countries, namely Côte d’Ivoire, Uganda, Tanzania, South Africa, Malawi, Thailand, 
Ethiopia, Burkina Faso, Zimbabwe, Kenya, and the Dominican Republic (Annas & Grodin, 
1994; Selgelid, 2005). A brief history of AZT is given here: in 1994, clinical research in wealthy 
developed countries showed that treatment with zidovudine (AZT) significantly reduced by one-
third, from 25% to 8%, the risk of mother-to-child transmission of HIV in the developed world 
(Connor et al., 1994). After these persuasive results were published, AZT received the U.S Food 
and Drug Administration’s (FDA) approval and became the standard of care for the prevention 
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of HIV transmission from infected pregnant women to babies in wealthy developed countries 
(Schüklenk, 2000). However, AZT was expensive, costing approximately US $800 per 
pregnancy, and thus unaffordable in poor developing countries such as those in Sub-Saharan 
Africa where governmental healthcare budgets are often less than $10 per person per year  
(Resnik, 2001). Yet it is in those less developing countries where the prevalence of HIV is high 
with approximately more than 60% of new HIV infections and 90% of all maternal-foetal HIV 
transmission occurring in sub-Saharan Africa (UNAIDS, 2015). Therefore it is clear that Sub-
Saharan Africa is where safe, effective and affordable HIV prevention interventions are much 
needed.  
 
In 1994 international agencies such as the US National Institutes of Health, WHO and UNAIDS 
designed placebo-controlled controlled trials aimed at testing the effectiveness of a short-course 
treatment of AZT (which would cost only $80 per infected woman), compared to the standard of 
care in developing countries, of no intervention at all to prevent HIV infection of new-born 
babies (Lavery et al., 2007; Schüklenk, 2000). In these trials, control participants were offered 
placebo treatments, despite the existence of effective AZT therapy in developed wealthy 
countries (Angell, 2000; Lavery et al., 2007). Lurie and Wolfe (1997) heavily criticized these 
placebo-controlled trials (Angell, 1997). Their primary argument was the use of double standards 
for poor and wealthy populations, implying that researchers from developed countries were using 
trial designs (i.e., placebo controlled trials) for HIV pregnant woman in developing countries 
when the very same design would have been deemed unacceptable in the sponsoring developed 




However, other commentators argued that the critics failed to understand the scientific, social 
and economic contextual complexities of the AZT trials in developing countries (Forster, 
Emanuel & Grady, 2001; Lie et al., 2004; Varmus & Satcher, 1997). For instance, Resnik (1998) 
argued that these placebo-controlled trials for AZT in 1997 were morally justifiable based on the 
local standards of care for those countries. In other words, it was ethically permissible to provide 
placebo to the control group since no alternative treatment was available locally.  
 
Furthermore, supporters of the placebo controlled AZT trials maintained that the use of placebo 
control posed potential benefits rather than risks to the trial participants. Considering that no 
treatment was the standard of care for the prevention of mother to child transmission of HIV in 
those developing countries where AZT trials were conducted, proponents argued that participants 
assigned to the control arm were not deprived of any treatment they would otherwise have 
received (Selgelid, 2005; Varmus & Satcher, 1997). That is to say, if the participants had not 
enrolled in the AZT trials, ordinarily they would not have received any interventions to prevent 
HIV transmission to their babies in any case, given the existing economic and infrastructural 
constraints of the local contexts. Indeed, the participants who were assigned to the treatment arm 
in addition to free HIV counselling, benefited by receiving treatment that could reduce the risk of 
HIV transmission to their babies. On the other hand, those in the placebo group also benefited 
from free HIV counselling and education. In addition, they were not harmed because they were 
not denied any effective treatment entitled to them had they not participated in the AZT trial 





Abdool Karim (1998), in his South African viewpoint paper published in the American Journal 
of Public Health, argued that the use of placebo in the AZT trials in South Africa was ethically 
justifiable given the local economic and infrastructural constraints. Abdool Karim was 
emphasizing one of the arguments in defence of the AZT placebo controlled trials –that no 
locally available therapy was being withheld from participants in the placebo control group. 
 
While many commentators advocate for best available standard of care worldwide to research 
participants (Angell, 1997, 2000; Lurie & Wolfe, 1997; Rothman & Michels, 1994; Shapiro & 
Meslin, 2001), others argue that this may impede valuable research in developing countries 
(Studdert & Brennan, 1998). Wendler et al. (2004) proposed a framework delineating the 
conditions under which it is acceptable to provide research participants with less than the best 
methods. They recommend that IRBs or RECs should apply a default of requiring the best 
interventions available anywhere in the world, in all cases. However, the authors concede that 
there are exceptions to this default requirement in certain circumstances, specifically when 
proposed research satisfies four conditions:  “(1) scientific necessity: investigators must use less 
than the worldwide best methods to answer the scientific question posed by the trial, (2) 
relevance for the host community: answering the scientific question posed by the trial will help 
address an important health need of the host community, (3) sufficient host community benefit : 
the trial will produce a fair level of benefit for the host community, and (4) participant and host 
community nonmaleficence: participants and the host community will not be made prospectively 





Lignou (2011) argued that the fundamental human right to health and the moral principle of 
justice should form the moral basis for the standard of care debate in developing countries. 
Similarly, Marouf and Esplin (2015) argued that the duty of justice and the basic human right to 
health as international human rights principles are pertinent to the standard of care debate in 
developing countries, particularly where limited resources mean that the local standard of care is 
no care at all. The authors maintain that applying a human rights framework may help define a 
middle ground that recognizes the practical challenges arising in providing the best worldwide 
intervention while also setting a minimum standard of care for control groups. In the authors’ 
view, the framework of human rights law, in particular the core obligations of the right to health, 
might help establish a minimum standard of care (Marouf & Esplin, 2015). 
 
2.5.9 Ancillary care 
Ancillary care refers to medical care that research participants need during a trial, but which is 
not related to the research question (Richardson & Belsky, 2004). Investigators conducting 
research with participants in developing countries where there is inadequate healthcare access 
often encounter ethical dilemmas of having to provide additional healthcare beyond the scope of 
their research projects (Participants in the 2006 Georgetown University workshop on the 
ancillary care obligations of medical researchers working in developing countries, 2008; 
Richardson, 2007). A number of case studies have been reported where researchers discover 
unmet health needs not related to the study in which participants have been enrolled. For 
example, Dickert and Wendler (2009) mention a project conducted to investigate whether 
children with severe Malaria develop hypertension, with the aim of understanding morbidity and 
mortality related to Malaria. The investigators found that the children also had unmet health 
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problems such as eye infections, upper respiratory infections and one heart defect requiring 
surgery. In another example described by Merritt, Taylor and Mullany (2010), researchers 
enrolled 17,306 mother-infant pairs into the Nepal Newborn Washing Study, a community-based 
trial to test the efficacy of a one-time chlorhexidine skin cleansing for promoting infant survival 
in a district of Nepal where the majority of participants are impoverished, more than 95% of 
mothers give birth at home, with very limited access to antenatal, obstetric, postnatal, and 
neonatal care. In that study, researchers encountered other unmet health needs of participants 
such as high prevalence of hookworm infections among pregnant women, unhygienic home birth 
environments, and common treatable diseases among infants (Merritt et al., 2010).  
 
The scenarios above highlight challenging ethical questions regarding ancillary care. Do 
researchers have a responsibility to provide ancillary care? When do researchers have a duty or 
responsibility to provide medical care beyond their research scope to research participants? What 
is the nature and extent of researchers’ obligations to respond to such needs? (Belsky & 
Richardson, 2004; Merritt, 2011). Unfortunately existing guidelines say little, if anything, about 
ancillary care and thus provide limited guidance on the questions raised above (Belsky & 
Richardson, 2004; Krubiner, Syed & Merritt, 2015; Participants, 2008). Those that do mention 
ancillary care obligations emphasize the need for planning and engagement with various 
stakeholders in order to share responsibilities (CIOMS, 2002; HPTN, 2009; Nuffield Council on 
Bioethics, 2002; UNAIDS/WHO, 2007; UNAIDS/AVAC, 2011).  For instance, the Nuffield 
Council on Bioethics (2002) states that, “During research into some diseases, participants may 
develop a condition that is related to the condition under study or an entirely unrelated 
condition…We recommend that before research begins, agreement should be reached about the 
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standard of care that should be provided to participants in research who already have or who 
develop diseases other than the disease being studied” (p. 139).  
 
The debate about ancillary care has been viewed from two extreme endpoints. On one hand, 
some commentators believe that researchers in developing countries have an obligation to 
provide ancillary care needs of participants (Belsky & Richardson, 2004). Advocates for 
ancillary care obligations invoke principles such as social justice (Shapiro & Benatar, 2005), 
reciprocity (Macklin, 2006), and beneficence (Stobie & Slack, 2010). On the other hand, 
opponents argue that researchers have no obligation to provide ancillary care because medical 
research – aimed at generating scientific knowledge – is different from medical care (Belsky & 
Richardson, 2004). Furthermore, investigators may not have the expertise to address all the 
ancillary care needs of participants. Moreover, costs for providing ancillary care can exceed the 
planned budget for the study and this may jeopardise the study (Dickert & Wendler, 2009).  
Additionally, concerns about fairness may emerge when research participants receive priority 
care for other unmet needs while nonparticipants do not have access to medical care. This is 
particularly true if the provision of ancillary care utilizes the already scarce healthcare resources 
of the host country (Dickert & Wendler, 2009). In addition, placing the obligations for ancillary 
care provision on investigators could be seen as misplaced responsibility which is unfair to 
investigators, particularly if that responsibility does not reflect the nature of their work or 






Some commentators have reported practical examples demonstrating the feasibility of providing 
sustainable ancillary care to trial participants through shared responsibilities amongst various 
stakeholders – e.g., sponsors, researchers, local healthcare providers and NGOs (Participants, 
2008). An example is a trial of preventive regimens for tuberculosis in HIV infected adults in a 
poor township in South Africa. As part of ancillary care obligations, researchers and local 
healthcare providers collaborated and provided all participants with free HIV care and follow-up. 
Another example of ancillary care involves a trial of vaginal microbicide in sex workers in 
Benin. The researchers organized for sponsors to provide healthcare to participants with extra 
uterine pregnancy not related to enrolment in the trial (Participants, 2008). Ancillary care 
obligations will vary from one study to another, hence RECs need to exercise caution and make 
recommendations based on a case-by-case review of protocols. For instance, an observational 
study in which the participant will be assessed only once, will present different practical ethical 
challenges compared to an interventional study with long term assessment of participants 
(Participants, 2008).  
 
There is a considerable body of literature on ancillary care (Dickert & Wendler, 2009; Merritt 
(2011); Oslon, 2015; Richardson & Belksy, 2004). Several frameworks have been proposed to 
assist investigators in making ancillary care determinations (Belsky & Richardson, 2004; Bright 
& Nelson, 2012; Brownsword, 2007; Dickert et al., 2007). For instance, Richardson and Belsky 
(2004) proposed a partial-entrustment model which is premised on the notion that the 
relationship between participant and researcher involves a partial and limited entrustment of 
participants' health to researchers. In other words, when participants allow investigators to access 
their personal health information and perform research procedures, they entrust certain aspects of 
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their health needs to researchers, and can be affected by how investigators use such personal 
information, hence they become vulnerable. As a result of this vulnerability and entrustment, 
investigators have an obligation to assume some responsibility for certain health aspects of 
participants related to the study procedures. So, for example, in the Malaria case study described 
earlier, participants allow investigators to perform certain procedures and entrust investigators 
with their health needs. Consequently, according to the partial-entrustment model, the 
investigators have an obligation to address only Malaria-related needs of the participants 
(Richardson & Belsky, 2004).  
 
However this partial-entrustment model has been criticized by some commentators for its 
problematic restraint on the scope of health needs for which investigators can be obligated to 
provide ancillary care (Dickert & Wendler, 2009; Olson, 2015).  For instance, Dickert and 
Wendler (2007) argue that there should be no restriction on the scope of ancillary care 
obligations to the specific aspects of participants’ health needs. They argue investigators have an 
obligation to provide ancillary care to a variety of health needs even sometimes they are not 
related to study procedures. The authors maintain that the obligation to provide ancillary care is 
limited by the “depth of the investigator's relationship with participants and the resource 
demands of providing such care” (Dickert & Wendler, 2009, p. 425). Similarly elsewhere, the 
authors criticize the partial-entrustment model and argue that several factors, for example, the 
existence of need, the capacity to help, and particularly the investigators’ level of engagement 
such as duration and intensity of interactions with participants, are essential factors in 




Tshikala et al. (2008) criticized Belsky and Richardson’s model on ancillary care obligations. 
For instance, it is argued that not providing ancillary care for a serious but not urgent medical 
need would be unacceptable. Yet this would be acceptable according to the model proposed by 
Belsky and Richardson (2004). Weijer and Le Blanc (2006) argued that researchers do not have a 
moral obligation to provide ancillary care. The authors concluded by saying “…our analysis 
concludes that there is as of yet no robust moral argument supporting a moral obligation to 
provide treatment to participants in HIV prevention trials who seroconvert” (Weijer & Blanc, 
2006, p. 806).  However, the authors also recommend that there should be moral negotiation to 
allow meaningful researcher-community negotiation on the expected benefits of research 
participation including ancillary care (Weijer & Blanc, 2006).   
 
Bright and Nelson (2012) proposed a capacity-based model for identifying ancillary care 
obligations that entail giving considerations to the urgency, the capacity of the local healthcare 
infrastructure and the capacity of the research infrastructure to provide ancillary care. Pratt et al. 
(2013) suggest that the need to meet ancillary care obligations derives from the health capability 
paradigm which requires the delivery of ancillary care to trial participants for a limited and 
specified subset of conditions that cause severe morbidity and mortality. The model is based on 
the idea that every person has a duty of justice to do what they can to bring individuals 
worldwide up to the optimal level of health achieved globally.  This theory gives priority to 
addressing shortfalls in the health of people who are worst-off in the sense that they are farthest 





Olson (2015) proposes a relationship-based approach. In this view, this approach provides a 
principled basis for differentiating investigators’ obligations from those of clinicians’ without 
putting restrictions on the scope of ancillary care needs for which investigators may have a 
responsibility (as in the partial-entrustment model). Furthermore, the relationship-based 
approach locates ancillary care obligations in a variety of morally pertinent factors of the 
researcher-participant relationship, such as the engagement level between researchers and 
participants, and weighs these factors against each other. The author argues that the duration and 
intensity of engagement between researchers and participants is important for determining 
investigators responsibilities on ancillary care (Oslon, 2015).   
 
There are few empirical studies that have reported on the current practices regarding the 
provision of ancillary care (Krubiner, Syed, & Merritt, 2015; Taylor et al., 2011). A recent 
review of existing institutional guidance on health researchers’ ancillary-care responsibilities in 
low-resource settings found that many institutions (34/57) as well as international and national 
ethical guidelines (54/71) did not mention ancillary care responsibilities (Krubiner et al., 2015). 
Another qualitative survey of researchers' practices regarding the provision of ancillary care in 
public health intervention research found that investigators conducting research in the 
community setting were more likely to identify and plan for the ancillary care needs of potential 
research participants in advance prior to commencement of the research project, while those 
affiliated with a permanent facility were more likely to provide ancillary care to research 
participants on an ad hoc basis (Taylor et al., 2011). Some commentators supporting ancillary 
care have argued that the provision of ancillary care is one way in which trial participants can 
receive direct benefits from their participation in research. Slack (2014) investigated whether 
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recommendations regarding ancillary care in HIV vaccine trials in existing ethical guidelines 
were being achieved, and whether stakeholders encountered challenges. She concluded that all 
five sites surveyed had mostly met the guideline recommendations for engaging host community 
in which research is conducted, and recommendations for “moral negotiation” were met to a 
lesser extent. 
 
2.5.10 Post-trial access 
There is increasing international concern about what happens to participants and host 
communities once the research is over. The requirement to ensure post-trial access to treatment 
for research participants is widely highlighted by key international and national guidelines 
(CIOMS, 2002; WMA, 2013; UNAIDS/WHO, 2012). For example, the Declaration of Helsinki 
(2013) recommends that “In advance of a clinical trial, sponsors, researchers and host country 
governments should make provisions for post-trial access for all participants who still need an 
intervention identified as beneficial in the trial…” (p. 7).  
  
The issue of post-trial access when a research study completes has generated considerable debate 
in the research ethics literature (Grady, 2005b; Millum, 2011; Sofaer & Strech, 2011; Zong, 
2008). At the heart of the debate is the key question: what, if anything, is owed to research 
participants after their participation in a clinical trial ends and whether sponsors and investigators 
have an obligation to provide ongoing treatment to participants or host community after the trial 





A systematic review by Sofaer and Strech (2011) assessed the reasons why post-trial access to 
trial drugs should, or need not be provided to research participants. The authors identified a 
range of reasons broadly based on morality, legality, interests/incentives, or practicality of 
offering post-trial access. Proponents of post-trial access invoke the ethical principles of 
beneficence (an obligation to help others further their important and legitimate interests), 
nonmaleficence (an obligation not to inflict ham on others) (Grady, 2005b; NBAC, 2001) and 
justice (NBAC, 2001; Macklin, 2006; Shapiro & Benatar, 2005).  
 
The NBAC (2001) supported post-trial access based on the principle of justice as reciprocity, 
implying that because participants enrolled in research assume some risk and burdens for 
altruistic reasons for the good of society and scientific advancement, certain things are owed to 
them in return for their participation. According to NBAC (2001), “justice as reciprocity is 
concerned with what people deserve as a function of what they have contributed to an enterprise 
or to society. In the context of clinical trials, justice as reciprocity could mean that something is 
owed to research participants even after their participation in a trial has ended, because it is only 
through their acceptance of risk and inconvenience that researchers are able to generate findings 
necessary to advance knowledge and develop new medical interventions” (p. 59). 
 
However, Merritt and Grady (2006) question the reciprocity-based justification for offering 
priority access to ART trial participants when ART must be rationed. They argue that justifying 
the provision of ART on the principle of reciprocity depends on several variables, including the 
quantity of ART available, the number of people in the country who need ART, and whether the 
country’s concurrent allocation policy selects specific subpopulations (such as HIV-infected 
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mothers of young children) for priority. They conclude that the reciprocity-based justification for 
giving ART trial participants priority over equally needy HIV-infected citizens is relevant only 
under some circumstances, at best. In other words, they are cautioning against the prioritizing the 
provision of post-trial access to trial participants based on reciprocal justice without giving due 
consideration to the possible burden on people who did not participate in the trial (Merritt & 
Grady, 2006). 
 
While the principle of providing post-trial access is recognized by various research ethics 
guidelines (CIOMS, 2002; Department of Health, 2015; UNAIDS/WHO 2012; WMA, 2013), 
there is little empirical research about how RECs, investigators and research participants deal 
with issues of post-trial access in practice. One study in the US surveyed 65 IRB/REC chairs, 
117 investigators, and 500 research participants in a multinational HIV trial in 25 countries to 
assess their views about post-trial access to interventions proven effective in the study. The 
authors reported that 29% of IRB/REC chairs, 42% of researchers and 83% of research 
participants believed the study product should be guaranteed for every HIV-infected person in 
the world if proven effective (Pace et al., 2006). They also found different views in terms of 
availability of the product, with most European and Latin American research participants saying 
it should be provided freely, while North American, Australian, and Thai participants felt it 
should be provided at a price affordable to the average person. Furthermore, REC chairs and 
researchers believed that the “reasonable availability” requirement (CIOMS, 2002, p. 51) is 
meant for people in the country where the study was conducted and meant a drug should be 
available at a price the average person could afford and that host country governments had 
primary responsibility for making it available (Pace et al., 2006).  
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Another US study investigating how closely researchers followed NIH guidance on post-trial 
access found that all 18 research protocols included plans for post-trial access for trial 
participants and more than 13 of the 18 (70%)  had specific mechanisms for post-trial access, but 
none guaranteed long-term sponsor funding after the trials (Shah, Elmer & Grady, 2009). The 
views and attitudes of trial participants in the US about whether or not, and why, they should 
receive post-trial access were investigated and it was found that the majority of respondents 
believed that various stakeholders (investigators, sponsors, health insurers, and others) have a 
shared obligation to facilitate post-trial access to the trial drug (or to a therapeutic equivalent) if 
it benefited the participant. Furthermore, the same study found that while some believed post-
trial access obligations include providing transition care (referrals to non-trial physicians or other 
trials, limited follow-up, short-term drug supply) or care for long-term adverse events, others 
said, that there should be no post-trial access obligations on drugs or care. Additionally, they 
found that participants frequently expressed reasons such as health needs, cost, reciprocity, free 
choice, and sponsor self-interest to justify their views on post-trial access (Sofaer et al., 2009).  
 
A systematic review by Cohen, O'Neill, Joffres, Upshur and Mills (2009) investigating the extent 
to which registered international RCTs report the use of standard of care and post-trial 
obligations found that out of 312 studies identified, only 4 (1.3%) mentioned provisions for post-
trial access. Of those, one stated that the post-trial drug would be provided by the governments of 
the respective countries; another mentioned that participants who became infected with HIV 
during the trial would be provided with free HIV counselling and education and access to 
required healthcare, as well as free antiretroviral drugs, if clinically indicated. The same study 
noted, however, that there was no mentioning of who will offer these provisions and who will 
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ensure that these are provided (Cohen et al., 2009).  Another US study by Ciaranello et al. (2009) 
investigated how details about post-trial access were included in the trial’s protocols and 
informed consent forms. They found that post-trial access was mentioned in 14 of 31 trials 
(45%), access to medications in 12 of 31 (39%) and access to medical care in 5 of 31 (16%) 
trials.  
 
The views of  HIV/AIDS clinical trial participants, researchers and research administrators were 
investigated in Kenya and it was found that most research participants expressed a desire for 
post-trial access to drug therapy, most often life long, after their participation in a clinical trial.  
Furthermore, participants felt that subsidisation of drug therapies and education were essential 
forms of compensation for clinical trial participation. Similarly, clinician researchers and 
administrators believed that there was a moral obligation from researchers to facilitate continued 
post-trial access of the drug to participants (Shaffer et al., 2006).  The views of twenty-nine 
South African community members regarding the provision of treatment in HIV prevention trials 
were investigated and the study reported that most respondents believed that researchers should 
facilitate access of treatment and care to participants. The same study found that respondents felt 
that researchers can help through referrals until such time that participants are capable of 
accessing care and treatment on their own (Barsdorf et al., 2010). In a study aimed at 
investigating post-trial access in HIV prevention trials, it was reported that , found that while all 
nine biomedical prevention trials they analysed had offered post-trial access, there was 
considerable variation in the mechanisms, duration and timeliness of post-trial access (Haire & 




2.5.11 Compensation for research-related injury 
There is wide ethical consensus that research participants should be provided with medical care 
and compensation for research-related injury (Cleaton-Jones, 2014; Cleaton-Jones et al., 2006; 
Mamotte, Wassenaar & Singh, 2013; Resnik, 2006; Slack, Singh, Strode & Essack, 2012).  
RECs have an obligation to ensure adequate provision of free or compensated medical care for 
research-related injury (Cleaton-Jones, 2014; Cleaton-Jones et al., 2006; Vasgird, 2006).  
Advocates supporting compensation for research-related injury invoke principles of beneficence, 
distributive justice, compensatory justice and reciprocity (Childress, 1976; Pike, 2014; Resnik, 
2006; Vasgird, 2006). Furthermore, some commentators have argued that participants are 
morally entitled to compensation (U.S. Presidential Commission for the Study of Bioethics, 
2011) and participating in research ought not to leave participants worse off than they were prior 
to enrolling in a research (Beauchamp & Childress, 2001).  
 
Several international (cf. CIOMS, 2002; HPTN, 2009), and national guidelines (Department of 
Health, 2015; Uganda National Council for Science and Technology, 2014), recommend or 
require that participants receive compensation for research-related injuries. For example the 
Ugandan guidelines for research involving humans as research participants explicitly states that, 
“the sponsor should provide care until complete cure or stabilization of a research related injury. 
The injured research participant shall be given the best care available within the country for the 
research related injury. Research participants shall not be required to waive their legal rights for 
redress in courts of law” (Ugandan National Council for Science and Technology, 2014, p. 20). 
Furthermore, some guidelines recommend that where no compensation will be provided, this 
should be explicitly stated during the informed consent process (HPTN, 2009). Where such 
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compensation will be provided to participants, the consent process should adequately describe 
the nature of the compensation available to research participants for harms incurred during the 
study, the medical treatment to be provided for research-related injury and information about 
possible compensation for physical, social and economic harms attributable to research 
participation (HPTN, 2009). 
 
However, according to US Federal policy, compensation is not mandatory for US sponsored 
studies (e.g., NIH sponsored research) and this has been criticized by several commentators both 
in the US (Henry, Larkin & Pike, 2015; Pike, 2014) and developing countries such as in Africa 
(Cleaton-Jones et al., 2006; Cleaton-Jones, 2014; Mamotte, Wassenaar & Singh, 2013). The 
failure to provide compensation is particularly problematic for research conducted in developing 
countries where injured research participants are unlikely to have health insurance and therefore 
cannot afford to pay for care for research-related injury (Mamotte et al., 2013). Commentators 
have proposed a systematic no-fault compensation in the US in order to bring US law in 
alignment with international ethical norms regarding compensation and ensure that injured 
research participants are adequately protected (Henry et al., 2015; Pike, 2014). 
 
While compensation for research-related injury is widely accepted as an ethical practice in 
research with human participants, it remains a subject of ongoing debate (Mamotte et al., 2013; 
Pandya & Desai, 2013 ) and few empirical studies have examined the issue (Bavdekar & Thatte, 
2009; Mamotte et al., 2013; Thatte, Kulkarni-Munshi & Kalekar, 2009). A retrospective study of 
138 protocols submitted to two RECs in India found that 46 (33.33%) of protocols mentioned the 
provision of free treatment for a trial-related injury, 42 (30.43%) did not have any policy 
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regarding the provision of treatment for research-related injury, whereas others included 
statements that intended to provide treatment, but with certain restrictions. In relation to 
informed consent documents, 33 (23.91%) stated that compensation would not be provided while 
65(47.10%) did not mention anything about compensation for research-related injury (Bavdekar 
& Thatte, 2009). The author concluded that informed consent documents submitted to Indian 
RECs sometimes do not conform to national guideline requirement for compensation of 
research-related injury (Bavdekar & Thatte, 2009). Another Indian study by Thatte et al. (2009) 
found that almost half (47%) of investigators expressed either ignorance or misunderstanding of 
the legal requirements for compensation and depended on sponsors to manage these issues. On 
the other hand, most (74%) of REC members expressed awareness of the requirements. While 
fewer than half of investigators (40%), and REC members (30%) and all sponsors had policies to 
manage compensation issues, the policies mainly addressed the provision of immediate free 
medical care or reimbursement of expenses incurred for the acute management of an adverse 
event. None of the policies included compensation for loss of time/wages, death, physical 
disability or long term incapacitation. Furthermore, informed consent and insurance documents 
did not adequately address issues regarding compensation, with only insurance certificates 
submitted to RECs (Thatte et al., 2009).  
 
A South African study by Mamotte et al. (2013) surveyed RECs and investigators regarding the 
practice of compensation for research injury in US NIH-funded research, despite contrary NIH 
policy, described above. They found that nine of 12 principal investigators provided financial 
compensation to cover treatment for research-related injuries, and the other three did not. 
Furthermore the study found that more than half (9/14) of the REC chairs mentioned that their 
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REC reviewed compensation plans for research-related. Of those, eight REC chairs indicated that 
their ethics application form consisted of a section specifically requesting details regarding 
medical care and/or financial compensation for research-related injuries. Only a few chairs stated 
that while their REC considers the issue, their ethics application form does not specifically ask 
for information regarding compensation for research injury (Mamotte et al., 2013). 
 
2.5.12 Post-approval monitoring of research  
RECs are required to ensure there is monitoring of research and adverse events in order to ensure 
ongoing protection of participants safety and wellbeing (Boateng, Ndebele & Mwesiga-
Kayongo, 2014; Department of Health, 2015). Accordingly, RECs need assurance that as the 
study progresses, the risks are minimized, the benefits are maximized and the risk/benefit ratio of 
the study continues to be favourable (Kratochvil, Prentice, Epperson & Gordon, 2006). Data 
safety and monitoring boards (DSMBs) play a crucial role in monitoring participants’ safety data 
and adverse event monitoring in a clinical trial (McCutchan, 2006; Musesengwa, 2014). RECs 
can monitor research in several ways including through continuing reviews of approved research, 
reviewing informed consent processes, adherence to protocols, and unapproved activities (Heath, 
1979). Monitoring of research by RECs is important in avoiding research scandals, and in 
enhancing public trust in the biomedical research enterprise (Weijer, Shapiro, Fuks, Glass & 
Skrutkowska, 1995).  
 
While some ethical guidelines necessitate post-approval monitoring of research by RECs, there 
is limited guidance on the frequency, scope or operational methods for monitoring research 
(Ochieng, Ecuru, Nakwagala & Kutyabami, 2013). Furthermore, existing reports suggests that 
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while post-approval monitoring of research is considered necessary and important, there is 
inadequate monitoring taking place because of limited resources and expertise to efficiently 
conduct monitoring of approved research, and lack of clear frameworks for undertaking site 
monitoring (Ochieng et al., 2013).   
 
A qualitative study with 14 REC members in Nigeria found that there was inadequate monitoring 
of approved research protocols to ensure strict compliance by researchers due to financial 
constraints (Agunloye, Salami & Lawan, 2014).  Similarly, a recent review of empirical research 
on the structure, functioning and outcomes of African RECs found that many RECs had limited 
financial resources and capacity to monitor approved research (Silaigwana & Wassenaar, 2015). 
 
There are divergent views in the research ethics literature concerning whether RECs should 
actively monitor research (Christakis, 1988). Those who support post-approval monitoring by 
RECs argue that such monitoring enhances protection of research participants. For example, 
Robertson (1982) maintained that an "IRB should monitor the consent process, test subject 
understanding, and modify its requirements accordingly” (p. 31). Furthermore, he recommended 
that IRBs should take steps to monitor investigator compliance with consent requirements, on a 
sample or comprehensive basis, and hold accountable investigators who do not comply 
(Robertson, 1979).  
 
Some commentators argue that monitoring of REC decisions and approved research can rapidly 
result in the transformation of the ethics review system from a review and advisory body into 
some kind of policing system and could erode the trust between researchers and RECs (Levine, 
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1980). Similarly, Heath (1979) argues that, "IRB activity to ensure adherence to an approved 
protocol would invade the trust established between the IRB and an investigator…The IRB 
members seem ill-suited for this job” (p. 3). 
 
Heath (1979) proposes a framework of monitoring which involves four concepts: (1) continuing 
review; (2) review of the consent process: (3) review for adherence to an approved protocol; and 
(4) review to identify unapproved activities. Continuing ethics review is one approach that can 
be used by RECs to ensure that there is ongoing protection of the rights and wellbeing of 
research participants throughout the course of a research study. RECs can conduct continuing 
reviews through either a passive or active process. Passive continuing review involves the 
reviewing research reports about the project's status compiled by the principal investigators. The 
report would typically include information such as details about participant enrolment, serious 
adverse events, protocol violations, and other problems encountered during the study. Active 
continuing review, on the other hand, could encompass formal review of the informed consent 
process, data and safety-monitoring by DSMBs, and periodic review of study-related 
documentation (Boateng et al., 2014; Musesengwa, 2014).  
 
There have been few empirical research studies investigating how RECs implement continuing 
reviews in practice. A study by McNeil, Berglund and Webster (1990) reported that of 101 
Austrian RECs they surveyed, only less than half said they monitored approved research. A 
separate 2008 survey of 103 Canadian RECs by Norton and Wilson (2008) found that 88% 
performed continuing ethics review while the other 12% did not. Furthermore, the study found 
that the most common type of continuing ethics review were reviews of ongoing study reports 
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completed by the investigator (84%), adverse events reported by the investigator (81%),  end-of-
study reports completed by the researcher (76%) and informed consent documents and the 
informed consent process (50%) (Norton & Wilson, 2008). 
 
Ochieng et al. (2013) proposed a model for monitoring which includes seven elements: 
regulatory issues (availability of study related documents), site facilities (availability and the 
amount of space compared to the participant population), informed consent process and 
documentation (observe the process of obtaining consent), participant’s welfare, reporting and 
management of adverse events, study related training and working practices. 
 
 
2.5.13 Dissemination of study results 
The dissemination of research results to participants is widely recognized as an ethical research 
practice according with the principles of respect for persons and beneficence (Dixon-Woods, 
Jackson, Windridge & Kenyon, 2006; Emanuel et al., 2004; Fernandez, Kodish & Weijer, 2003; 
Keens, 2006; Miller, Giacomini, Robert & Christensen, 2008; Shalowitz & Miller, 2008). 
Fernandez et al. (2003b) argue that offering research results to participants is an ethical 
imperative and that “fulfilling respect for participants obligates the researchers to offer to 
provide a summary of research results on completion of the study” (p. 9).  RECs often require 
researchers to furnish plans of how they will disseminate results of their research (MacNeil & 
Fernandez, 2007). Indeed, a Canadian study of examining the policies of Canadian university 
based research ethics boards (REBs) regarding returning results to research participants found 
that of the 34 REBs surveyed, only 2 (9.1%) had a policy that governed the return of research 
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results while on a study, and seven (31.8%) following the completion of a study. No REBs had 
specific guidelines describing how participants should be informed of results (MacNeil & 
Fernandez, 2007). A 2014 study of one South African REC found that of the total 144 ethical 
queries raised under the principle of respect for participants, 17.3% concerned dissemination of 
study results to participants (Tsoka-Gwegweni & Wassenaar, 2014). 
  
While several commentators have advocated for the dissemination of research results to 
participants (Fernandez et al., 2003b; Partridge, Burstein, Gelman, Marcom & Winer, 2003; 
Partridge & Winer, 2009; Partridge et al., 2005; Shalowitz & Miller, 2005), it remains unclear 
what is the scope and limits of researchers’ responsibility in offering results to participants 
(Shalowitz & Miller, 2008). For instance current ethical guidelines are inconsistent about (1) 
whether investigators should proactively re-contact participants, (2) the type of results to be 
offered, (3) the need for clinical relevance before disclosure, and (4) the stage of research at 
which results should be offered (Shalowitz & Miller, 2008).   
 
There are number of empirical studies on the views of participants on receiving research findings 
(Partridge et al., 2003; Shalowitz & Miller, 2008). Empirical findings suggest that most 
participants wish to receive results of their trial participation (Dixon-Woods et al., 2006; 
Partridge et al., 2003; Snowdon et al., 1998). Other studies have also reported on the views of 
investigators (Fernandez et al., 2003; Partridge et al., 2004) and RECs (MacNeil & Fernandez, 
2006, 2007) regarding the provision of research results to participants. Fernandez et al. (2003) 
surveyed 150 principal investigators and found 69.3% supported or strongly supported the 
development of a guideline mandating provision of research results to participants. However the 
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respondents raised some seemingly trivial impediments to offering results to participants, namely 
difficulties of preparing lay summaries, time constraints, the cumbersome task of contacting 
participants, and potential distress for the participants. There was variation regarding when 
results should be offered with 30% favouring after the study was closed while 24% felt it should 
be at the time of publication of results. It would seem prudent to do so only after peer-review of 
the main findings. 
 
Another study by Partridge et al. (2004) surveyed 796 oncology physicians and nurses and found 
that more than half (62.4%) indicated that they offer trial results to participants less than 20% of 
the time. The majority (72.4%) of responders felt that most of their patients wanted to be 
informed of the study results, and 79.7% of responders indicated willingness to offer results to 
most study participants in the future, believing that in most cases their patients want to know 
results of the trial and provided that routinely offering results would not cause negative effects 
on patients. Surprisingly, few (16.2%) responders felt that an obligation to offer results to 
research participants would make such patients less likely to enrol in studies (Partridge et al., 
2004), suggesting that PIs might be resistant to the extra post-trial workload even though 
beneficence would be maximised. A study of Canadian REB chairs found that 94.8% of REB 
chairs supported offering research results to participants after study completion. While only 
19.5% of chairs mentioned that a policy or guideline governing the return of research results to 
participants existed at their institution, most chairs (72.0%) supported the idea of their REB 
instituting a set of guidelines recommending that researchers offer results to participants in a lay 




This section has attempted to outline some of the typical ethical issues in biomedical research, 
noting that these issues, reviewed for the purpose of this thesis, are by no means exhaustive. The 
issues highlighted above were purposively selected from the framework (Emanuel et al., 2004, 8) 
on which the current study is premised with the goal of facilitating the discussion of findings/ 
results of the present study. Having described some of the typical ethical issues arising in 
biomedical research, the next section focuses on studies conducted in both developed and 
developing countries aimed at investigating RECs and the ethical issues typically raised during 
their review activities. 
 
2.6 Studies evaluating ethical issues raised by RECs internationally 
There is substantial literature on ethical issues raised by developed country RECs. Several papers 
suggest that UK RECs frequently raise concerns about informed consent (Angell, Biggs, 
Gahleitner & Dixon-Woods, 2010; Boyce, 2002; Dixon-Woods, Angell, Tarrant & Thomas, 
2008). One study found that, of the 339 applications reviewed by a REC in UK, 85% had queries 
about the participant information sheet (such as inadequate information, jargon, poor clarity, 
need for proofreading) and 50%) had queries about study design (Boyce, 2002). 
 
A study of cancer trials reported that RECs mostly raised the issue of informed consent (96%), 
followed by risks to participants (95%) and scientific design (76%) (Dixon-Woods et al., 2008).  
In a similar study investigating issues raised in research involving human tissues, informed 
consent was the most frequently raised (Angell, Tarrant & Dixon-Woods, 2009). Similarly, 
informed consent, recruitment, care and protection of participants, scientific design and 
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confidentiality were the most frequent issues in applications involving research with children 
(Angell et al., 2010). Another study of four RECs in UK found that modifications to the 
participant information sheets were the most common queries raised (57%), followed by requests 
for further information in the protocol (33%), study design (22%) and informed consent form 
(21%) (Kent, 1999). Other issues such as missing information, slip-ups and discrepancies were 
also frequently identified by UK RECs (Angell & Dixon-Woods, 2008, 2009). A study in Brazil 
reported that the most frequent issues were related to methodology and statistics (77.1%), 
inadequate language and/or difficulty of understanding the informed consent form (32.2%), lack 
of detailed information about the study in the informed consent form (25.8%). Further issues 
raised in the same study were incorrect or incomplete documentation, funding/budget issues and 
details about the entire research team (Bueno et al., 2009). Similarly, the most frequent issues 
identified by Novaes et al. (2009) were related to informed consent (30%), methodology (20%), 
CVs (12%) and budget (9%).  
 
A separate study in Thailand reported that out of 291 protocols, the most frequent queries were 
research methodology (80.7%), participant information sheet (62.2%), recruitment of 
participants (60.1%) and informed consent/assent form (51.2%). Furthermore, of the 44 studies 
involving minority populations in Thailand, the main issues identified included: participant 
information sheet and consent forms (86.4%), research methodology (84.1%), inclusion-
exclusion criteria (72.7%) and treatment and care for participants (65.9%)  (Adams et al., 2013). 
Elsewhere, Adams et al. (2015) found that issues of informed consent were most common for 
drug trials (93.3%) and biomedical studies (89.5%) while issues concerning privacy and 
confidentiality tended to be highest for laboratory and epidemiology studies. Overall, the most 
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common issues were scientific issues about specimen and data collection (60%), participant 
information sheet (56%) and informed consent (50%).  
 
Queries related to informed consent were frequently identified (98%), in particular requests for 
changes in the informed consent documents (88%) when compared to other ethical criteria in the 
Common Rule (Lidz, et al., 2012). A separate study in the US found that stakeholders ranked the 
following as the most important aspects of REC reviews: (1) favourable risk/benefit ratio; (2) 
risk minimization; (3) clarity of consent; (4) protection of vulnerable populations; and (5) 
privacy and confidentiality (Geisser, Alschuler & Hutchinson, 2010). Another study in Canada 
found that REC members identified scientific merit, risk/benefit, quality of information sheets 
and consent process, confidentiality, participant selection and financial arrangements as 
important ethical criteria (Meslin et al., 1994). Elsewhere, a study of a REC in Spain reported 
that 56.8% of the comments raised in applications reviewed were related to informed consent 
and confidentiality, 18.9% concerned the principles of beneficence and non-maleficence and the 
remaining concerned process errors such as incomplete documentation (Martin-Arribas, 
Rodriguez-Lozano & Arias-Diaz, 2012). The most frequent issues raised by RECs in a study in 
the Netherlands were related to participant information and consent forms (80.5%), methodology 
and statistical analyses (70.8%), and supporting documentation, including trial agreements and 
certificates of insurance (68.1%) (van Lent, Rongen & Out, 2014). A recent study in Finland 
found that the most frequent reason for not approving research proposals were concerns about 
participant autonomy and informed consent (70.8%), followed by requests for more 
information/documents (34.2%) and scientific quality (31.5%) (Hemminki, Virtanen & 
Regushevskaya, 2015).  
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This section has reviewed international empirical studies that have been conducted aimed at 
investigating the ethical issues raised by RECs worldwide. The next section now focuses on local 
studies that have been conducted to investigate ethical issues raised by African RECs. 
 
2.7 Studies reviewing ethical issues raised by RECs in Africa 
There is relatively limited empirical data on the ethical concerns raised by African RECs 
(Cleaton-Jones, 2010; Clarke, 2014; Klitzman, 2008; Langat, 2005; Sathar, Dhai & van der 
Linde, 2013; Tsoka-Gwegweni & Wassenaar, 2014). Cleaton-Jones (2010) found that of the 369 
protocols reviewed by a REC at the University of Witwatersrand, the top ranked issues were 
related to informed consent (55%), followed by missing or incomplete information (43%), 
confidentiality (17%) and sample size (15%). Likewise, informed consent (27.4%), scientific 
validity (21.3%), fair participant selection (13.9%), and respect for participants (13.8%), were 
the most frequent issues raised by a different REC (Tsoka-Gwegweni & Wassenaar, 2014). 
Similarly, Clarke (2014) found that of the 53 protocols reviewed by a REC, the most frequently 
raised issues were related to study design (21.8%), methodology (20.4%), statistical validity 
(9.9%) and informed consent (9.2%). Ethical queries about informed consent form (25.4%), 
methodology and statistics (24.3%), scientific rationale (15.9%), sample size (13.7%) and 
inclusion/exclusion criteria (6.5%) were also frequently raised by a REC in Nigeria (Eyelade, 





The views of South African REC members regarding the content and process of HIV vaccine 
trials (HVT) suggested that most members believed that participants poorly understood the 
consent forms, risks and benefits of participating in HVT trials (Klitzman, 2008). Also, REC 
members frequently differed on the minimum standard of care for participants who acquired HIV 
infection during the trial; 63% believed it should be the best treatment available worldwide while 
11% felt it should be the best available nationally (Klitzman, 2008).  
 
Langat (2005) retrospectively analysed research protocols submitted to two Kenyan RECs in 
order to identify ethical issues regarding the storage, reuse and exporting of human tissue. He 
found that most investigators did not recognize the need for informed consent to storage and 
reuse of samples as most of them neither requested permission nor informed participants of plans 
to re-use stored samples (Langat, 2005). Another study involving a retrospective audit of 
protocols submitted to a South African REC evaluated whether ethical issues in collaborative 
research using human biological materials (HBMs) had not been adequately addressed. The 
authors concluded that both the REC and researchers did not sufficiently engage with the ethico-
regulatory challenges in research involving collection, storage and export of HBMs (Sathar et al., 
2013). Concerns about the collection and storage of human biological samples for future use 
were also raised by Egyptian RECs (Matar & Silverman, 2013). Nine RECs stated that export of 
samples would require national security clearance, whereas two of 13 RECs absolutely 
prohibited exportation of biological samples out of Egypt (Matar & Silverman, 2013).  
Furthermore, similar studies found that REC members were concerned with social value of 
studies under review (Milford et al., 2006), maximising benefits for local communities and 
ensuring appropriate informed consent process  (Henderson et al., 2007).  
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2.8 Summary  
This chapter reviewed the history and development of research ethics, including key 
international guidelines. It also reviewed the South African research ethics system. This was the 
followed by a section reviewing criticism of RECs. Thereafter, literature on ethical issues in 
biomedical research was reviewed. The chapter concluded with reviewing published studies 
aimed at investigating ethical issues raised by RECs in developed countries and in Africa. This 
chapter highlighted that modern-day research ethics was mostly born out of scandals and 
tragedies of research with human participants (Emanuel et al., 2003). The reviews also suggested 
that South Africa and other LMICs have since implemented and strengthened their research 
ethics systems by creating laws and ethical guidelines that enable them to conduct their own 
ethical review of research activities of both local and international collaborative research in order 
to protect the rights, dignity and safety of human participants.  Furthermore, from the literature 
reviewed, it is evident that a significant amount of literature exists on the ethical issues raised by 
conducting biomedical research, particularly in international collaborative research sponsored by 
wealthy countries and conducted with human participants in less developed countries. Examples 
of such issues are collaborative partnership, social value, informed consent, standards of care and 
post-trials access, to name a few. Regarding the types of ethical issues raised by RECs, the 
literature review has showed that RECs raise an array of issues – although informed consent was 









3.0 Introduction  
This chapter includes a brief discussion of the theoretical framework underpinning this present 
study. The theoretical framework developed by Emanuel, Wendler, Killen and Grady (2004)  is a 
synthesis of pre-existing international guidance and  is widely recognized and very influential in 
research ethics (Tsoka-Gwegweni & Wassenaar, 2014). This framework provides a 
comprehensive model for researchers and RECs to ensure ethical conduct of research in 
developing countries. According to Emanuel et al.’s (2004) framework, for health research in 
developing countries to be ethical, consideration must be given to the following principles; (1) 
collaborative partnership, (2) social value, (3) scientific validity, (4) fair selection of study 
participants, (5) favourable risk benefit ratio, (6) independent review, (7) informed consent and 
(8) on-going respect for participants and the community. These are summarised briefly below. 
 
3.1 Collaborative partnership 
Collaborative partnership involves a holistic approach of establishing meaningful and sustainable 
local partnerships and establishing trust between researchers and the host community (Emanuel 
et al., 2004). The local country in which research would be conducted ought to autonomously 
determine if the proposed research is acceptable and relevant to the health problems of the 
community (Emanuel et al. 2004). This can be achieved through community engagement to 
assess health problems to be solved, determine the significance of proposed research, as well as 
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incorporating research results and products into local health-care system (Benatar & Singer, 
2010; Emanuel et al., 2004). Also, collaborative partnership involves strengthening of local 
research stakeholder capacity to synthesise and disseminate evidence to be used for policy 
making and health care. Furthermore, there should be fair beneficiation from rewards (such as 
intellectual property rights, royalties, publications and authorship) emanating from the conduct 
of research, and the local values and cultural differences should be respected (Emanuel et al., 
2004). The UNAIDS/AVAC (2011) guideline is an example of a “gold standard” on 
collaborative partnerships in biomedical research. The guidelines refers to community 
stakeholder engagement as a process through which stakeholders responsible for implementing 
trials build “transparent, meaningful, collaborative and mutually beneficial relationships” with 
“interested or affected” individuals or groups (UNAIDS/AVAC, 2011, p. 2). 
 
3.2 Social value 
The principle of social value is based on the premise that health research should generate 
knowledge that will ultimately contribute to the improvement in health needs of the participant 
and the research population. Therefore, it is imperative from the onset that consideration of who 
will benefit (e.g. participants, local community, host country) from the research should be 
specified (Emanuel et al., 2004). Research without social value not only wastes resources, but 
also needlessly exposes participants to risks and burdens for participation in research without any 
reasonable prospective value (Emanuel et al., 2004). Furthermore, the value of proposed research 
should be enhanced through appropriate dissemination of results, and use of generated 
knowledge and /or products to improve the health-care system. However, precautions should be 
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taken to prevent research that will result in depleting resources of the local health-care system 
(Emanuel et al., 2004). 
 
3.3 Scientific validity 
Scientific validity, in its broadest sense, is an important requirement for any meaningful research. 
In order to conduct a scientifically valid research, the study design should be such that the 
research objectives are accomplished within high quality, acceptable scientific standards (e.g. 
adequate sample size, statistical validity, objective outcome measurement) (Emanuel et al., 
2004). Furthermore, the study should be feasible and realizable within the context of the local 
research community, i.e., consideration should be given to the social, political, or cultural 
context of the host community in which research would be conducted (Emanuel et al., 2004). 
 
3.4 Fair participant selection 
Fair participant selection is centred on the fundamental principle of justice. There should be fair 
and equitable selection of participants, i.e., selection of the study population should be relevant 
to the research objectives. For example, under-privileged participants should not be selected 
because of their poverty, to be exposed to risks and burdens of high-risk studies, whilst wealthy 
populations are preferentially enrolled in low risk studies (Emanuel et al., 2004). Additionally, 
vulnerable populations should be identified and protected. For example, proposed research 
involving vulnerable populations such as prisoners, refugees or persons engaged in illegal 
activities e.g., sex work or drug use, must be based on valid scientific justification, and not 
because of social marginalization or prejudice. Where the reasons for their inclusion are valid, 
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additional mechanisms such as privacy and confidentiality, and freedom to participate or 
withdraw from a study, should be implemented in order to protect such vulnerable populations 
(Emanuel et al., 2004). 
 
3.5 Favourable risk/benefit ratio 
Rooted in the fundamental principle of non-maleficence and beneficence, risk/benefit assessment 
ensures that the study has a favourable risk benefit ratio. In the case where the potential risks are 
outweighed by benefits to participants, then these risks must be justified by the social value of 
the research (Emanuel et al., 2004). In order to justify risks, benefits to participants should be 
assessed in terms of the direct benefit of the interventions being tested to the participant’s health, 
or indirectly through scientific knowledge likely to be generated from the study or improvements 
in the health of the local community in general (Emanuel et al., 2004). The context of an 
individual (e.g. health background, genetic, social, environment) must be taken into 
consideration when determining a favourable risk-benefit ratio for the respective participant. 
Similarly, the net risks to a community (e.g. stigmatization resulting from genetic study that 
identifies genotype conferring undesirable traits to the community) should be justified in light of 







3.6 Independent review 
Consistent with international and national guidance, the Emanuel et al. (2004) framework 
emphasizes the need for independent ethics reviews mandated by local laws and regulations 
(Emanuel et al., 2004). For example in South Africa, approval by a REC and the Medicines 
Control Council (MCC) is required for clinical trials of drugs (Department of Health, 2015).  
 
3.7 Informed consent 
Informed consent is one of the cornerstones of ethical research involving human participants 
(Emanuel et al., 2004). Central tenets for valid informed consent processes include the following 
components: information disclosure, understanding, voluntariness to decide without coercion, 
capacity to consent (Lindegger & Richter, 2000). The information should be disclosed in a 
culturally appropriate manner (Emanuel et al., 2004). Furthermore, there is need to involve local 
community stakeholders in establishing an effective informed consent process that is locally 
acceptable; however, this should not override individual consent (Emanuel et al., 2004; 
Lindegger & Richter, 2000). Importantly, the participants should have the freedom not to 
participate or to withdraw from the trial without any penalties (Emanuel et al., 2004). 
 
3.8 Respect for participants and the community 
Respect for participants is an important ethical principle underpinning several ethical guidelines. 
The Emanuel et al. (2004) framework emphasizes the need to protect the privacy and 
confidentiality of research participants. Furthermore, there should be plans to ensure the timely 
and appropriate (culturally and linguistically) dissemination of results and information arising 
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from the study to the participants and their communities. Additionally, participants should be 
provided with medical care and interventions, including research-related injuries, and access to 
such interventions after the study - so-called post-trial access (Emanuel et al., 2004).  
 
3.9 Summary 
The above section has described the theoretical framework (Emanuel et al., 2004) on which the 
present study is based. The framework’s eight principles of ethical research involving human 
participants have been described. These are (1) collaborative partnership, (2) social value, (3) 
scientific validity, (4) fair selection of study participants, (5) favourable risk-benefit ratio, (6) 
independent review, (7) informed consent and (8) on-going respect for participants and the 
community. Having described the important theoretical framework on which this study is 
premised, and highlighted the eight key benchmarks of ethical research, the following chapter 











AIMS AND OBJECTIVES 
The general aims of this study were to examine ethical issues raised by two South African 
biomedical RECs based on the theoretical framework outlined in the Chapter 3. 
The specific study objectives were: 
1. To identify the ethical issues typically raised by two South African biomedical RECs.  
2. To apply the Emanuel et al. (2004) framework to evaluate the ethical issues raised.  
3. To qualitatively explore the views of REC members regarding the issues identified in 
(1) above. 
4. To determine whether findings in (1) align with national research ethics guidance. 
 
The specific research questions were:  
1. What specific ethical issues are raised by two South African biomedical RECs? 
2. Is the theoretical framework by Emanuel et al. (2004) compatible with the ethical 
issues and concerns raised by two large biomedical RECs in South Africa? 
3. What are the views of REC members regarding the ethical issues raised in (1) above? 







5.0 Overview of methods and study design 
In line with the overall objective to investigate the ethical issues raised by RECs reviewing 
biomedical research protocols and to explore REC members’ views on, and understanding of 
these ethical issues, this project was designed in three work packages. 
  
Work package 1 comprised a retrospective audit of records from two biomedical RECs located 
at two different universities in South Africa. The data were extracted, anonymized and coded 
using a predetermined theoretical framework (Emanuel et al., 2004).  This enabled both 
deductive and inductive content analysis of themes emerging from the data, whilst also yielding 
the frequency and ranking of ethical issues identified. Data from each REC were analysed, 
compared and then combined. 
 
Work package 2 consisted of qualitative semi-structured interviews with REC members in order 
to explore their views and understanding of the ethical issues identified from work package (1) 
above. 
 
Work package 3 was included in order to determine whether the findings from the work 
packages above align with national and international research ethics guidance. This included a 
review of national guidance (Department of Health, 2015), and a comparison with themes 
identified in work packages (1) and (2) above. 
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The implementation of the most appropriate design which adequately answers the research 
questions and objectives for this project was of critical importance. As such, the study adopted a 
largely qualitative study design encompassing document review and semi-structured interviews. 
The purpose of incorporating a mixture of research methods and data sources was to explore the 
types of ethical issues from a variety of different perspectives. This approach may be viewed as a 
form of triangulation (Kelly, 2006), a term used to refer to the process of comparing the results 
from either two or more different data collection methods (in this case, document analysis and 
semi-structured interviews) or, more simply, two or more data sources (in this case, records from 
two different RECs and semi-structured interviews with different REC members). According to 
Patton (2002), there are four types of triangulation: data triangulation (the use of various sources 
of data), investigator triangulation (the use of multiple coders, and comparing codes), theory 
triangulation (the use of multiple perspectives to interpret the study data) and methodological 
triangulation (the use of a variety of research methods within the study).  
 
5.1 Methodology for work package 1 – analysis of REC minutes 
This work package comprised a retrospective audit of minutes from two South African 
biomedical RECs. The aim of the audit was to identify the types of ethical issues raised by RECs 
reviewing biomedical research, with a twofold purpose: The intention was to review records for 
projects reviewed by both RECs for a five-year period (2009-2014). The researcher (in 
consultation with the contact person in each REC) estimated that an analysis of records over this 
five-year period would suffice to identify the types of ethical issues raised by both RECs.  
Furthermore, it was assumed that reviewing data from the past five years would yield a 
reasonable sample size considering that it was predominantly qualitative content analysis.   
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5.1.1 Sampling Strategy  
After obtaining gatekeeper permissions, records for all research reviewed by the two RECs 
between 2009 and 2014 were accessed from the respective REC administrators. Purposive 
sampling was used to select minutes and decision letters for initial applications reviewed by full 
committee members (i.e., only more than minimal risk studies reviewed at full REC meetings 
were included). Thus, expedited studies that are reviewed by one or two REC members and then 
ratified by the committee were not included. Furthermore, applications for recertification, 
responses to queries, and amendments were excluded. While outright approval does not 
necessarily imply that there were no ethical issues identified in the research proposal, only 
studies given conditional approval or rejected were purposively selected since these indicate that 
REC has raised at least some issue(s) with the research proposal. A systematic random sampling 
technique was then used to select every 3rd case yielding a total of 180 protocols for analyses. 
Data were extracted in de-identified format to maintain confidentiality, onto a data collection 
sheet (Appendix 1). From the minutes of the 180 protocols reviewed by the two biomedical 
RECs during the years 2009 to 2014, REC queries were extracted and categorised. Two 
independent coders assessed REC minutes for each protocol to identify, code, and rank the 
frequency of ethical issues raised by the two RECs according to the eight principles and 
benchmarks described by Emanuel et al. (2004). The agreement between the two coders was 






5.1.2 Data analysis  
Qualitative content analysis was chosen as the most suitable approach because it enables the 
researcher to interpret meaning from the content of the text data (Hsieh & Shannon, 2005).  The 
Emanuel et al. (2004) framework was used to code and deductively analyse data. In order to 
identify salient emergent themes not described in the framework, inductive analysis was also 
applied (Hsieh & Shannon, 2005). The data were coded into eight broad themes based on the 
Emanuel et al. (2004) framework and an additional two emergent categories. Coding each 
protocol involved careful reading and re-reading of each query contained in the RECs’ minutes 
and decision letters, and identifying the primary, central ethical issue. Where more than one issue 
emerged, these were coded into the primary category under which it seemed to best fit. Given the 
huge volume of the data set, it was impractical to have a second coder for all the data. However, 
a few random cases (n=20) were verified by a second coder with expertise in the Emanuel et al. 
(2004) framework and REC activities. The coding was discussed and any differences were 
resolved by consensus.  
 
 
5.2 Methodology for Work package 2- Semi-structured interviews 
5.2.1 Rationale for method 
Semi-structured interviews allow in-depth understanding of how individuals experience or 
understand a particular phenomenon in their context (Patton, 2002). Unlike quantitative methods 
that focus on breadth, representativeness and generalizability, semi-structured interviews do not 
necessarily aim to have a representative sample, but rather focus on depth, insight and 
transferability of findings. The second work package of this present study, (i.e., exploring views 
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of REC members regarding ethical issues identified in work package 1), is best answered using 
semi-structured interviews. However, the main disadvantage of such interviews is that the quality 
and amount of data may be influenced by the interviewer’s qualitative interviewing skills. 
 
 5.2.2 Participant sampling strategy 
The researcher first approached the REC chairs at each respective site to request assistance with 
recruitment of REC members. At REC 1, the chair (after informing REC members about my 
study during one of their monthly meeting) granted the researcher access to the names and 
contact details of all REC members. Thereafter, a recruitment email was sent to each member 
inviting them to volunteer to participate. Initially, four out of 22 members responded and 
expressed willingness to participate. Follow-up reminder emails were sent to the remaining 
members who did not respond to the first email. Another three members responded, but two 
withdrew, citing time constraints and commitment to other activities. A third and final follow-up 
email was sent to members who had not previously responded. There was no further response. A 
total of five members from REC 1 consented to participate in the study. Various attempts were 
made to recruit members from both RECs, but most of these attempts were met with silence and 
refusals. This was not to be unexpected as reports have suggested that RECs are reluctant to be 
researched (de Jong et al., 2012; Klitzman, 2015; Stark, 2012).  
  
At REC 2, the chair recommended that a group email be sent to all members inviting them to 
participate in the study. Members were requested to indicate their willingness to have their 
contact details shared with the researcher for follow-up direct contact from the researcher. Two 
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members initially consented to participate. After a month, reminder emails were sent to the 
members who had not initially responded. A further two responded and consented to participate. 
A third and final reminder email was sent to members who had not responded to the previous 
emails, but there was no further response. A total of four members from REC 2 agreed to have 
their contact details shared, and participate in the study. Overall, 9 members consented to take 
part in this project. Each member was then provided with graphs summarizing the data from 
work package 1(Figure 9). Semi-structured interviews lasting between 30-45 minutes were 
conducted face-to-face or by telephone using a semi-structured interview guide (Appendix 2). 
Probes, clarifications and follow-up questions were used to elicit broader views from 
respondents. The interviews were recorded and transcribed verbatim. 
 
5.2.3 Data analysis 
Thematic analysis was used to code and analyse the narrative data from the transcripts and 
identify salient themes emerging from the data (Hsieh & Shannon, 2005). This method allows a 
consistent examination of themes contained in the data. Data were analysed both inductively and 
deductively to identify themes grounded in the data. Emerging codes and themes were sought by 







5.3 Methodology for work package 3- Comparison of findings with national 
ethics guidance 
Thematic content analysis (Hsieh & Shannon, 2005) of national department of health guidelines 
(Department of Health, 2015) was conducted to identify emerging themes. These were compared 
to the findings in work package 1 to determine the level of congruence.  
 
5.4 Reliability and Validity 
Reliability refers to the degree to which a measure of a concept is stable or trustworthy (Bryman, 
2004). Validity entails ensuring that an instrument measures the construct it is designed to 
measure (Bryman, 2004). Several strategies were implemented to maximize the reliability and 
validity of findings of the present study. First, the coding of minutes was done by two 
independent coders to ensure inter-coder reliability. The coding framework was discussed and 
any disagreements resolved by consensus, where appropriate. Furthermore, the interview guide 
for the qualitative interviews was developed in consultation with an ethics expert and qualitative 
researcher. This was then pilot tested with a sample of six experts before the actual data 
collection. Pilot testing ensured that the broad questions in the interview guide were in line with 







5.5 Ethical Considerations 
Following the Emanuel et al. (2004) framework for determining whether research is ethical, the 
following ethical issues applied to this study. 
 
5.5.1 Collaborative partnership  
Collaborative partnership requires that a researcher develop research in collaboration with the 
relevant local stakeholders so as to ensure that local context is respected (Emanuel et al., 2004). 
Taking this into consideration, the two biomedical RECs sampled in this study were selected 
based on prior consultation with relevant stakeholders knowledgeable in research ethics systems 
at the respective universities. Furthermore, gatekeeper permissions were also obtained from the 
relevant institutional authorities. In order to avoid revealing the identities of the RECs, the 
gatekeeper permission letters are not included in the Appendices section, but they are on record. 
 
5.5.2 Social value  
The principle of social value requires that proposed research should benefit the participants and 
community (Emanuel et al., 2004). In light of this, it is hoped that the present study has potential 
social value because its findings may generate novel empirical data on the actual issues typically 
raised by two busy South African biomedical RECs. Such information might inform training of 





5.5.3 Scientific validity  
Scientific validity requires that proposed research uses high quality and scientifically valid study 
design and methodology in order to achieve the objectives of the study. In view of that, a full 
description of the research questions and methodology was addressed, including issues of 
validity and reliability. Furthermore, to ensure high quality results, data analysis was conducted 
by two independent coders with vast experience in empirical research ethics.  
 
5.5.4 Fair selection of participants  
This principle necessitates unbiased selection of participants based on the research objective. 
Firstly, the REC minutes or decision letters sampled were randomly selected. Second, the two 
participating RECs, and REC members, were purposively selected based on availability and 
willingness to participate, without any bias or unfair predetermined inclusion/exclusion criteria. 
 
5.5.5 Favourable risk/benefit ratio  
The principle of favourable risk/benefit ratio requires identification and minimization of 
potential risks, and maximising benefits (Emanuel et al., 2004). The present study did not have 
any direct risk associated with participation. The potential risk of harm to the reputation of either 
of the RECs and their host institutions is offset by anonymization. It is hoped that this minimal 
risk study has the potential of generating useful information that might benefit RECs and 




5.5.6 Independent ethics review  
This principle necessitates competent and independent review of research proposals by an 
accredited REC. Accordingly, this study received ethical approval from the two participating 
RECs. To maintain anonymity and confidentiality, the full ethics approvals obtained from the 
participating RECs are omitted from the Appendices, but are available on request for audit 
purposes.   
 
5.5.7 Informed consent  
The principle of informed consent requires that a participant should give voluntary informed 
consent before participating in a study. Therefore, written informed consent was obtained from 
REC members for their participation in semi-structured interviews.  The members were informed 
that participation was voluntary and that they could freely choose to refuse or withdraw from the 
study at any time without any penalty. They were also free not to answer any questions they 
chose not to answer. 
 
5.5.8 Ongoing respect for participants  
According to Emanuel et al. (2004), the principle of respect for participants entails, among other 
things, protecting the confidentiality of participants and communities, providing participants with 
information that arises in the course of the research study and informing participants of the study 
results. In view of this and as mentioned above, the identities of the two RECs and REC 
members sampled in this study were kept anonymous and confidential in order to prevent 
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stigmatization and discrimination. Furthermore, the results from this study will be communicated 
to the participating RECs. Care will be taken to avoid revealing the identities of the two RECs in 
future publications in journals. 
 
5.6 Summary  
This chapter described the research methodology used in this study. The primary purpose of this 
study was to investigate the ethical issues raised by two South African biomedical RECs. 
Specifically this study aimed to determine the ethical issues raised by RECs using the Emanuel 
et al. (2004) framework, explore the views of REC members regarding the ethical issues raised 
and to determine the alignment of the issues identified above with existing South African 
national ethics guidance (Department of Health, 2015). The data collection and analysis process 












     RESULTS 
 
6.0 Introduction  
The section describes the main findings of the study. The results are divided into the three 
different work packages described in Chapter 5. Briefly, work package (1) focuses on the ethical 
issues identified through retrospective review of minutes and decision letters from the two RECs.  
Thereafter, work package (2) focuses on the views and perspectives of REC members regarding 
the issues identified in work package 1 above. The final work package (3), concludes by 
comparing the findings from work packages above with principles in the national guidance 
(Department of Health, 2015).    
 
6.1 Results for Work package 1 
6.1.1 Characteristics of the study sites 
REC 1 has 22 members, while REC 2 has 44 members. The membership of the two RECs is 
varied, constituting both males and females from various disciplines – mostly clinicians and 
medical professionals, epidemiologists, public health specialists, social scientists, ethicists and 
one or two lay members - thus complying with the national guidelines (Department of Health, 
2015). Both RECs meet on a monthly basis. The REC application forms, informed consent 
template and other documents relevant to ethics applications and standard operating procedures 
(SOPs) are available publicly online. Applicants have to submit these before a specified deadline 
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for consideration in the following month’s meeting. For non-expedited, i.e., more than minimal 
risk studies, the focus of the present study, the proposal is assigned to primary and secondary 
reviewers, and occasionally to a third assigned reviewer. During the convened scheduled 
meeting, the chair declares the session open after quorum and requests any members to declare 
conflict of interests (so that they do not take part in the review process if there is any conflict of 
interest). The primary reviewer then presents a written synopsis of the study and then presents 
ethical issues identified in the proposals. These issues are also tabled in writing. The secondary 
and third reviewers repeat this process but without the synopsis. Thereafter the full committee 
discusses the ethical merits of each proposal on the meeting’s agenda and the administrator 
records the discussion points and integrates them with the written reviews that comprise the 
minutes from which the decision letters are compiled and sent to the applicants.  In this study, 
the researcher was given gatekeeper permission to access the minutes and decision letters from 
the two participating RECs. To preserve anonymity and confidentiality, the minutes and letters 
are not provided in the appendices but are available for audit purposes. 
 
6.1.2 Characteristics of studies sampled 
The characteristics of the studies sampled in this study are summarised in Table 2 below. At 
REC 1, most of the research proposals sampled in this study were clinical trials (53%) while the 
remaining (47%) were observational studies. At REC 2, half of the studies were clinical trials 
(50%) and the other 50% were observational studies (Table 2). The type of review caseload of 
both RECs was thus nominally similar. Overall, clinical trials constituted the majority (52%) of 
protocols reviewed by the two RECs included in this study. In terms of the subject area, 
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aggregated data from both RECs shows that the majority of research protocols were in the field 
of HIV/AIDS (45%) and TB (31%) With regard to the type of research participants, the research 
protocols sampled in this study consisted of mostly adults (48%), followed by children (31%) 
(Table 2). 
Table 2: Characteristics of protocols sampled in this study 
 REC 1 (n=90) REC 2 (n=90) Total 
Type of study    
 Clinical trials 










Area of research    
                    HIV/AIDS 
                    TB 
                    Cancer 
                    Heart disease 
                    Diabetes 
                    Others/ unspecified                                                                  
45 (50%) 
22 (24%)  
          8 (9%)                    
          6 (7%)                     
          5 (6%)                     
          4 (4%) 
                     













Participants    
                    Adults 
                    Children 
                    Pregnant women 


















6.1.3 Approval decisions on protocols reviewed 
Table 3 below shows the initial decision outcomes of the studies reviewed. Of the 90 protocols 
included in this study that were submitted for initial review at REC 1, 84% were conditionally 
approved while the other 13% were not approved and 2% was deferred.  On the other hand, 93% 
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were conditionally approved and 7% not approved. At both RECs, none of the protocols 
reviewed received full approval at initial review (Table 3).  
Table 3: Initial review outcomes of proposals included in this study 
Initial review outcome      REC 1 (n=90) REC 2 (n =90) Total (n=180) 
Conditional approval 76 (84%) 84 (93%) 160 (89%) 
Not approved 12 (13)% 6 (7%) 18 (10%) 
Deferred 2 (2%) 0 (0%) 2 (1%) 
Full approval 0 (0%) 0 (0%) 0 (0%) 
 
6.1.4 Ethical issues raised in the protocols sampled 
The section below describes the findings regarding the ethical frequency and percentages of 
ethical issues raised by the two RECS. In the sections which follow, data from REC 1 will be 
presented first, followed by data from REC 2, followed by a comparison of the two data sets.  
 
6.1.4.1 Emanuel et al. (2004) ethical issues raised by REC 1 
 
There were a total of 1274 queries raised in 90 protocols sampled at REC 1. The most frequent 
Emanuel et al. (2004) ethical issues raised by REC 1, ranked in descending order of frequency, 
included queries related to informed consent (23.9%), respect for participants (18.9%) and 
scientific validity (18%). Other ethical issues raised by REC 1 in the protocols sampled for this 
study included collaborative partnership (8.1%), fair participant selection (4.8%), favourable 
risk-benefit ratio (4.5%) and independent ethics review (3.5%). The least frequently raised issues 
were about social value (1.3%) (Table 4 and Figure 1).   
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Table 4: Emanuel et al. (2004) ethical issues raised by REC 1 




Percentage of queries 
(%) 
Rank of frequency 
Informed consent  305 23.9 Highest 
Respect for participants 241   18.9  
Scientific  validity 229               18  
Collaborative partnership 103               8.1  
Fair participant selection 61               4.8  
Favourable risk-benefit ratio 57 4.5  
Independent ethics review 44 3.5  
Social value 17 1.3 Lowest 
 
 






























Emanuel et al. (2004) ethical issues 
Figure 1: Ethical issues raised by REC 1 
140 
 
6.1.4.2 Emanuel et al. (2004) ethical issues raised by REC 2 
At REC 2, there were 510 queries raised in 90 protocols sampled in this study. Informed consent 
issues were the most frequent (31%), followed by respect for participants (19.6%) and scientific 
validity (13.5%).Other ethical issues raised by REC 2 included queries related to favourable risk-
benefit ratio (6.5%), independent ethics review (3.5%), fair participant selection (3.1%) and 
collaborative partnership (2.5%). The lowest percentage of ethical issues raised by REC 2 were 
about social value (1%) (Table 5 and Figure 2).  
  
Table 5: Emanuel et al. (2004) ethical issues raised by REC 2 




Percentage of queries 
(%) 
Rank of frequency 
Informed consent  158               31 Highest 
Respect for participants 100   19.6  
Scientific  validity 69               13.5  
Favourable risk-benefit ratio 33               6.5  
Independent ethics review 18               3.5  
Fair participant selection 16 3.1  
Collaborative partnership 13 2.5  

































Emanuel et al. (2004) ethical issues
REC 2
Figure 2: Ethical issues raised by REC 2 
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6.1.4.3 Comparison of Emanuel et al. (2004) issues raised by both RECs 
 
A comparison of the ranking/frequency of the Emanuel et al. (2004) ethical issues raised by each 
REC, as shown in Figure 3, is presented below in descending order. The most frequent issues 
raised by both RECs were informed consent (ranked 1st), respect for participants (ranked 2nd) and 
scientific validity (ranked 3rd).  It is clear from Figure 3, that other ethical issues were ranked 
differently between the two RECs. Specifically, the fourth ranked issue at REC 1 was 
collaborative partnership (8.1%) while at REC 2 it was favourable risk/benefit ratio (6.5%). 
Similarly, independent ethics review was ranked 5th at REC 2, while the 5th ranked issue at REC 
1 was fair participant selection (3.1%). Furthermore, the 6th ranked issue at REC 1 was 
favourable risk/benefit ratio (4.5%), while it was fair participant selection (3.1%) for REC 2. The 
principle of independent ethics review (3.5%) was ranked 7th at REC 1, while collaborative 
partnership was ranked seventh (2.5%) at REC 2. Social value was the least frequent issue, 




















6.1.5. Sub-analysis of Emanuel et al. (2004) ethical issues raised by REC 1 
Further sub-analyses of the eight broad categories of ethical issues (Emanuel et al., 2004) raised 
by both RECs were conducted in order to identify sub-themes and codes emerging from the data. 

















Emanuel et al. (2004) issues
REC 1
REC 2
Figure 3: Comparison of ethical issues raised by both RECs 
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6.1.5.1 Informed consent (23.9%) 
 
Table 6 below shows that the most frequent queries under informed consent were requests for 
adequate information (e.g., study procedures, risks, benefits, contact details of investigators) 
(50.8%), rewording and simplification of language in the consent documents (38.7%) and 
ensuring voluntary participation and withdrawal from the study without any penalties (10.4% ). 
Table 6: Informed consent queries raised by REC 1 (n=305) 
Ethical principle Specific queries raised 
 
Frequency  Percentage                     
 
Informed Consent  
Complete information  
 
155  50.8% 
Rewording and simplification of language 
 
118  38.7% 
Valid and voluntary consent  process    32 10.4% 
 
6.1.5.2 Respect for participants (18.9%) 
Table 7 below shows that under the principle of respect for participants, the majority of queries 
raised were related to participant care during and after research (29%), including post-trial access 
to interventions (26.1%). Additional queries that were commonly raised included issues related 
to privacy and confidentiality (23.2%), compensation and reimbursements (17.4%) and 
informing participants and the community of research findings in ways that are culturally and 





Table 7: Respect for participants queries raised by REC 1 (n=241) 











Privacy and confidentiality 
 
56  23.2% 
Reimbursements and compensation 
 
42  17.4% 
Dissemination of results to participants 10  4.1% 
 
6.1.5.3 Scientific validity (18%) 
Table 8 below shows that of the scientific validity issues identified, most concerns were related 
to methodology (34.9%), study design (25.3%), data collection instruments (15.7%), research 
questions and feasibility (13.1%), statistical validity (6.9%) and sample size (3.9%).  
Table 8: Scientific validity queries raised by REC 1 (n=229) 
Ethical principle 
 
Specific queries raised 
 












Data collection instruments 
 
36  15.7% 
Research question/ feasibility 
 
30  13.1% 
Statistical validity 
 
16  6.9% 






6.1.5.4 Collaborative partnership (8.1%) 
Table 9 below shows that of the overall queries under collaborative partnership, most (48.5%) of 
the concerns were about developing partnerships with researchers, and other research 
stakeholders in planning and conducting proposed research, as well as developing capacity for 
local researchers. This was followed by the need to respect local community cultural values and 
beliefs (41.7%).  Other issues emerging were concerns about ensuring that research results are 
disseminated to relevant stakeholders and used to enhance local health systems (9.7%).  
Table 9: Collaborative partnership queries raised by REC 1 (n=103) 
Ethical principle 
 
 Specific queries raised 
 







Develop partnerships and build local capacity 
 
50  48.5% 
Community consultation and respect for local 
culture and practices 
 
43  41.7% 
Integrating research results into local healthcare 
system 
10  9.7% 
 
 
6.1.5.5 Fair participant selection (4.8%)   
Table 10 below indicates that of the issues queried under fair participant selection, the most 
common were appropriate recruitment methods (50.8%), unbiased inclusion/ exclusion of study 





Table 10: Fair participant selection queries raised by REC 1 (n=61) 
Ethical principle 
 
Specific queries raised 
 





Appropriate recruitment method 
 
31  50.8% 
Unbiased inclusion/exclusion 
 
25  40.9% 
Safeguard vulnerable populations   5 8.1% 
 
6.1.5.6 Favourable risk/benefit ratio (4.5%)    
Table 11 below highlights that most of the queries under risk-benefit ratio were related to 
identification of study risks and burdens (50.8%) and ensuring that the risks are minimized to the 
greatest extent possible in relation to the potential benefits (49.1%). 
Table 11: Favourable risk/benefit ratio queries raised by REC 1 (n=57) 
Ethical principle 
 
Specific queries raised 
 




Identification of risk and burdens to participants 
 
29  50.8% 
Mitigation of risks 28  49.2% 
 
 
6.1.5.7 Independent ethics review (3.5%) 
Table 12 below shows that under independent review, most of the queries were related multisite 
ethical approvals in collaborative studies (52.2%) and regulatory approvals, for example 




Table 12: Independent ethics review queries raised by REC 1 (n=44) 
Ethical principle Specific queries raised 
 




Ethics approval by RECs 
 
23 52.2% 




6.1.5.8 Social value (1.3%)   
Table 13 below shows that for social value, most of the queries (12.2%) were related to the 
importance of proposed studies, as well as enhancing the value of research for enrolled 
participants and communities (4.4%).  
Table 13: Social value queries raised by REC 1 (n=17) 
Ethical Principle 
 
Specific queries raised 
 
Frequency Percentage              
Social Value  Importance and value of study  
 
11  64.7% 
Enhance value  for participants   6 35.3% 
 
 
6.1.6 Sub-analysis of Emanuel et al. (2004) issues raised by REC 2 
Further analyses were performed to identify sub-themes within each particular ethical category 
raised by REC 2. The results are described below in descending order of frequency, i.e., 
informed consent (31%), respect for participants (19.6%), scientific validity (13.5%), favourable 
risk-benefit ratio (6.5%), independent review (3.5%), fair participant selection (3.1%), 
collaborative partnership (2.5%) and social value (1%).  
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6.1.6.1 Informed consent (31%)  
Table 14 below shows that the most frequently discussed queries under informed consent were 
requests for adequate information (e.g. study procedures, risks, benefits, contact details of 
investigators) (42.4%), rewording and simplification of language in the consent documents 
(34.2% ) and ensuring voluntary participation and withdrawal from the study without any 
penalties (23.4%). 
Table 14: Informed consent queries raised by REC 2 (n=158) 
Ethical principle Specific queries raised 
 
Frequency    Percentage                         
 
Informed Consent  
Complete information 
  
67  42.4% 
Rewording and simplification of language 
 
54  34.2% 
Valid and voluntary consent  process  37 23.4% 
 
 
6.1.6.2 Respect for participants (19.6%) 
Table 15 below shows that under the principle of respect for participants, the majority of queries 
raised were related to participant care during and after research (36%), including post-trial access 
to interventions (24%). Other queries raised included privacy and confidentiality (19%), 
compensation and reimbursements (15%) and informing participants and the community of 




Table 15: Respect for participants queries raised by REC 2 (n=100) 












Privacy and confidentiality 
 
19 19% 
Reimbursements and compensation 
 
15 15% 
Dissemination of results to participants   6   6% 
 
6.1.6.3 Scientific validity (13.5%) 
Table 16 below shows that, of the scientific validity issues identified, the majority of concerns 
were related to methodology (40.6%), study design (21.7%), measuring instruments (14.5%), 
sample size (11.6%) and feasibility (11.6%). There was significance difference (p < 0.05) noted 
between the two RECs. 
Table 16: Scientific validity queries raised by REC 2 (n=69) 
Ethical principle 
 
Specific queries raised 
 















  8 11.6% 






6.1.6.4 Favourable risk-benefit ratio (6.5%)  
Table 17 below shows that the most frequent queries under risk-benefit ratio were related to 
identification of study risks and burdens (54.5%) and ensuring that the risks are minimized to the 
greatest extent possible in relation to the potential benefits (45.5%). 
Table 17: Favourable risk/benefit ratio queries raised by REC 2 (n=33) 
Ethical principle 
 
Specific queries raised Frequency Percentage                            
Favourable risk/ 
benefit ratio  
Identification of risk to participants 
 
18 54.5% 
Mitigation of risks 15 45.5% 
 
 
6.1.6.5 Independent ethics review (3.5%) 
Table 18 below shows that for independent ethics review, most of the queries were related to 
multisite ethical approvals in collaborative studies (55.6%) and regulatory approvals, for 
example approvals from the Medicines Control Council for all clinical drug trials (44.4%). 
Table 18: Independent ethics review queries raised by REC 2 (n=18) 
Ethical principle Specific queries raised 
 




Ethics approval by RECs 
 
10 55.6% 
MCC approvals  and other regulatory 
requirements 






6.1.6.6 Fair participant selection (3.1%) 
Table 19 below indicates that of the issues queried under fair participant selection, the most 
common were appropriate inclusion/ exclusion study population (56.3%), recruitment methods 
(31.2%), and safeguarding vulnerable participant groups (12.5%). 
Table 19: Fair participant selection queries raised by REC 2 (n=16) 
Ethical Principle 
 
Specific queries raised 
 




Unbiased inclusion/ exclusion 
 
9 56.3% 
Appropriate recruitment method 
 
5 31.2% 
Safeguard vulnerable populations 2 12.5% 
 
 
6.1.6.7 Collaborative partnership (2.5%)  
Table 20 below shows that, for collaborative partnership, most (13.3%) of the queries were about 
developing partnerships with researchers, and other research stakeholders in planning and 
conducting proposed research, as well as developing capacity for local researchers. This was 
followed by the need to respect local community cultural values and beliefs (6.6%).  Other issues 
emerging were concerns about ensuring that research results are disseminated to relevant 
stakeholders and used to enhance local health systems (2.2%). There was significant difference 





Table 20: Collaborative partnership queries raised by REC 2 (n=13) 











Community consultation and respect for local 
culture and practices 
 
5 38.5% 
Integrating research results into local healthcare 
system 
1   7.7% 
 
 
6.1.6.8 Social value (1%)  
Table 21 below shows that, for social value, most of the queries (60%) were related to the 
importance of proposed studies, as well as enhancing the value of research for enrolled 
participants and communities (40%).  
Table 21: Social value queries raised by REC 2 (n=5) 
Ethical Principle 
 
Specific queries raised Frequency   Percentage              
 
Social Value  
Importance and value of study  
 
3 60% 








6.1.7 Additional issues raised by RECs 
Furthermore, there were additional queries raised by both RECs that could not be coded using 
the eight categories in the Emanuel et al. (2004) framework. These were mostly coded as 
administrative queries and errors.   
 
6.1.7.1 Additional issues raised by REC 1 
 
The additional issues raised by REC 1 are summarised below in Table 22 and shown in Figure 4.  
The findings showed that most of the additional queries were administrative queries (68.2%) 
related to research budgets (34.9%), investigators’ CVs (34.2%), details about the research team 
(17.8%) and missing signatures, for example from the co-principal investigators (13%). 
Furthermore, the results showed that errors were identified in 31.8% (n=68) of the protocols 
sampled in this study. 
Table 22: Additional queries raised by REC 1 (n=214) 
Additional issues raised  Frequency Percentage  
Administrative issues  
    Research budgets                             
    Researchers’ CVs    
    Details about the research       
team    
     Missing signatures                                                                                                                                                                        
146 
     51 
                 50 
               26 








Errors 68   31.8% 
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6.1.7.2 Additional issues raised by REC 2 
 
Similarly, for REC 2, most of the additional issues raised were coded as administrative queries 
(69%) and errors (30.9%). Table 23 below and Figure 5 below summarizes the frequency of 




























Additional issues raised by REC 1
REC 1
Figure 4: Percentage of additional queries raised by REC 1 
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Table 23: Additional queries raised by REC 2 (n=97) 
Additional issues raised  Frequency  Percentage 
Administrative issues  
  Researcher’s CVs      
  Research budgets    
  Details about the research       
team                       
  Missing signatures 
67 
                23                  
                18 
 
                16 
                 10 
69.0% 
                       34.3% 
                       26.9% 
 
 
                       23.9% 
                       14.9% 




































Additional issues raised by REC 2
REC  2
Figure 5: Percentage of additional queries raised by REC 2 
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6.1.8 Comparison of additional issues raised by both RECs 
Figure 6 below is a comparison of the aggregated data on additional issues (i.e., not coded under 
the eight Emanuel et al. 2004 benchmarks) raised by the two RECs.  The data shows that REC 1 
most frequently raised additional queries related to administrative issues (8.1%) and errors (4%) 









































Additional issues raised by both RECs
Administrative issues
Errors
Figure 6: Comparison of additional queries raised by both RECs 
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6.1.9 Total issues raised by RECs 
The section below describes the total issues (i.e., Emanuel et al. (2004) plus those coded under 
additional queries) raised by both RECs. 
6.1.9.1 Total issues raised by REC 1 
 
Analysis of the total issues raised by REC 1, as shown in Figure 7 below, showed that the most 
frequent issues that emerged were related to the informed consent (23.9%), respect for 
participants (18.9%), scientific validity (18%), administrative queries such as CVs and funding 
(11.5%) and collaborative partnerships (8.1%). This was then followed by queries related to 
editorial errors (5.3%). Other ethical issues raised by REC 1 that emerged less frequently in this 
study were fair participant selection (4.8%), favourable risk-benefit ratio (4.5%), independent 





























Total (ethical) issues raised by REC 1
REC 1
Figure 7: Percentage total queries raised by REC 1 
159 
 
6.1.9.2 Total issues raised by REC 2 
 
Figure 8 below shows that of the total queries raised by REC 2, the most frequent were informed 
consent (31%), respect for participants (19.6%) and scientific validity (13.5%). Administrative 
issues emerged as fourth ranked (13.1%). Other ethical issues raised by REC 2, albeit less 
frequently, were queries related to favourable risk/benefit ratio (6.5%), errors (5.9%), 
independent ethics review (3.5%), fair participant selection (3.1%) and collaborative partnership 






































Total (ethical issues) raised by REC 2
REC 2
Figure 8: Percentage total queries raised by REC 2 
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6.1.10 Comparison of overall queries raised by both RECs 
When comparing aggregated data from both RECs, Figure 9 below shows that there were 
similarities and differences in the ranking of the issues raised by the two RECs. The ranking of 
the overall issues between the two RECs was similar for the following issues: informed consent 
(ranked 1st), respect for participants (ranked 2nd) scientific validity (ranked 3rd), administrative 
issues (ranked 4th), editorial errors (ranked 6th) and social value which was the least frequent 
issue (ranked 10th). Differences were observed in the ranking of the other remaining issues such 
as collaborative partnership ranked 5th at REC 1 and 9th at REC 2. Ranked seventh at REC 1 were 
fair participant selection issues, which were ranked 8th for REC 2. Queries related to favourable 
risk/benefit ratio were eighth and 5th ranked at REC 1 and REC 2, respectively. Independent 
ethics review was ranked 9th for REC1, while at REC 2 they were the seventh most frequent 




























Total (ethical) issues raised
REC 1
REC 2
Figure 9: Comparison of total ethical issues raised by both RECs 
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Figure 10 below shows the average combined percentage of issues raised by both RECs are 
presented. The results showed that for the aggregated data averaged, the most frequent issues 
raised were about informed consent (26%, top ranked), respect for participants (19%, ranked 
2nd), scientific validity (16.7%, ranked 3rd) and administrative queries (11.9%, ranked 4th). The 
other less frequent issues emerging in this study were collaborative partnership (6.5%, ranked 
5th), editorial errors (5.5%, ranked 6th), favourable risk/benefit ratio (5%, ranked 7th), fair 
participant selection (4.3%, ranked 8th), independent ethics review (3.5%, ranked 9th) and social 






































Overall (ethical) issues raised - RECs combined
Both RECs
Figure 10: Overall ethical issues raised – RECs combined 
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6.2 Qualitative description of ethical issues raised by both RECs 
In what follows, examples of anonymized quotes from the actual minutes and decision letters 
from both RECs are used to illustrate the types of ethical issues identified drawing from the 
Emanuel et al. (2004) framework. The combined data from both RECs are presented in 
descending order of frequency. The aggregated percentage (%) of queries in each category is 
displayed in brackets. Where a statistically significant difference in frequency was found 
between the two RECs, this is also indicated.  
6.2.1 Informed consent (26%) (Significant difference, p < 0.05) 
The top ranked issues identified by both RECs were informed consent (26%). Although ranked 
first by both RECs as the most frequently raised issue, there was a statistically significant 
difference between the frequencies of informed consent issues being raised by both RECs (p < 
0.05). The Emanuel et al. (2004) framework calls for participant information disclosure in 
culturally and language appropriate formats, obtaining supplementary community or familial 
consent where culturally appropriate and ensuring freedom to refuse participation or withdraw 
from the study without any penalties. Both RECs frequently raised informed consent issues. Of 
these, the majority were requests to applicants to provide more complete information.   
The consent forms should describe the intervention itself in more detail and mention that 
there will be non-intervention control comparisons (REC 1). 
The informed consent form should be revised to include…more information about the 
study and details of what will be required from participants… e.g. confidentiality, risks 




This was followed by requests for simplification of language in these consent forms.  
Language level of information and consent document needs to be simplified (REC 1). 
The informed consent form is too technical and more simple language should be used 
(REC 2).  
Finally, both RECs were concerned about ensuring appropriate and valid consent processes. This 
includes appropriate measures to ensure that vulnerable participants with limited or no capacity 
to provide valid consent are protected. 
Can valid informed consent be obtained from acutely ill patients? (REC 1). 
This is an acutely ill study population and they are unlikely to be able to provide rational 
informed consent upon admission to hospital…the protocol should provide procedures 
for assent by the patient and proxy consent, as well as retrospective consent by patients 
when stabilized (REC 2). 
 
6.2.2 Respect for recruited participants (19%) 
The second ranked issue raised by both RECs was about respect for participants (19%). There 
was no statistically significant difference between the two RECs. According to the Emanuel et al. 
(2004) framework, respect for recruited participants and study communities entails protecting 
their confidentiality, disseminating research results to participants and ensuring appropriate 
medical care during and after research, including research-related injuries. Both RECs were 
mostly concerned with ensuring appropriate medical care to participants, including research-
related injuries.    
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 The standard care package is not fully explained (REC 1). 
Briefly explain the procedure for referral for continued treatment and care outside of the 
study. What happens regarding ongoing HIV treatment for babies at the end of the study 
(REC 2). 
Furthermore, both RECs raised queries about post-trial access of the intervention to participants 
beyond completion of the study. 
 Will there be post-trial access to this drug? (REC 1). 
The post-trial options as well as the recourse in case of injury should also be in the 
summary (REC 2). 
   
Furthermore, RECs were also concerned about measures in place to protect the privacy and 
confidentiality of participants. Merely stating that confidentiality will be ensured seemed 
inadequate as both RECs often wanted a clear explanation or demonstration of how such 
confidentiality will be maintained and the sort of restrictions/measures in place to ensure that 
participant data is protected and not shared with third parties without appropriate consent.  
Confidentiality and privacy of mother and infant-describe measures to prevent 
stigmatisation (REC 1). 
What site-specific measures will be put in place to protect the privacy of participants and 




Furthermore, both RECs wanted to ensure that participants were provided with appropriate 
reimbursements and compensation. 
If the follow-up procedures for the study are more than required for routine care, 
participants should be reimbursed for travel (REC 1). 
You are kindly requested to clarify your remuneration or compensation of participants 
(REC 1). 
 
Finally, both RECs were also less concerned about the dissemination of study results to 
participants and communities in appropriate ways.  
 Describe the dissemination plan (REC 1). 
           Describe how results will be reported back to these participants/this community (REC 2). 
 
6.2.3 Scientific validity (16.7%) (Significant difference, p < 0.05).   
The third most frequent issue raised by both RECs concerned scientific validity (16.7%). 
Although this was the third most frequent issue raised by both RECs, there was a statistically 
significant difference (p < 0.05) between the RECs regarding the relative frequency of the issue 
being raised. According to Emanuel et al. (2004), scientific validity entails ensuring that the 
scientific design of the study realizes the scientific objectives.  Furthermore, the research study 
should be feasible and realizable within the context of the local research community. Both RECs 
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raised many queries on the methodology and study design - in some cases even requesting the 
applicant to consider an alternative study, for instance:  
The investigators plan to use a cohort study design… the proposed design will result in 
an unnecessary burden on the study participants… The investigators should consider 
using a cross-sectional design (REC 1). 
This is an open label study. The sponsors should indicate why it is not a double-blind 
study bearing in mind the greater weight which findings in these studies carry (REC 2). 
There were also frequent queries related to sample sizes and statistical validity.  
There are a multitude of aims and objectives that cannot be justified by the sample size 
and methodology (REC 1). 
Have you consulted with a statistician to ensure that the study is powered to answer your 
research questions? If not, please do so before approval can be granted (REC 2). 
 
6.2.4 Collaborative partnership (6.5%) (Significant difference p < 0.05) 
From the combined averaged data, collaborative partnership issues were ranked fifth by both 
RECs, but there was a statistically significant difference (p < 0.05) in the frequency of such 
queries being raised by both RECs. The Emanuel et al. (2004) framework defines collaborative 
partnerships as developing partnerships with researchers, makers of health policies, and the 
community. Furthermore, collaborative partnerships entail involving partners in sharing 
responsibilities for determining the importance of health problem, assessing the value of 
research, planning, conducting, and overseeing research, and integrating research into the 
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healthcare system. Additionally, collaborative partnerships involve respecting the community’s 
values, culture, traditions, and social practices and developing the capacity for researchers, 
makers of health policies, and the community to become full and equal partners in the research 
enterprise (Emanuel et al., 2004). This was evident in both RECs as most of the queries were 
about respecting the local community’s values and culture, and community engagement with 
community representatives. 
Principal Investigator need to get support from community leaders for support of this 
study as this is a low socio-economic/vulnerable group (REC 1). 
The committee recommend that researchers consult the Community Advisory Board 
(CAB) or equivalent community representative on appropriate entry into this community 
and… any cultural issues to consider (REC 2).  
 
Furthermore, RECs were concerned about establishing partnerships with researchers and 
developing the capacity for researchers, makers of health policies, and the community to become 
full and equal partners in the research enterprise. 
Please justify why laboratory work will be done in the US. Is this not a missed 
opportunity for technology transfer and capacity building in RSA (REC 1). 
Could you kindly clarify….why [laboratory tests] must be done in the USA (REC 2). 
Additionally, queries about human biological samples were also raised, in particular, the 
exportation of samples. RECs constantly requested international investigators to obtain export 
permits and material transfer agreements [MTAs] from the Department of Health.  
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Genetic material will be exported to UK and US for further analysis…MTA and export 
permits must be submitted prior to shipping (REC 1). 
The MTA is still pending and must be available before the transfer of study samples to 
non-South African labs (REC 2). 
 
Lastly, both RECs were concerned with how the results of the study would be integrated into 
local healthcare system and benefit public health. 
What is the likely availability of [name of drug] in RSA public health system if the study 
shows safety and efficacy? (REC 1) 
 
6.2.5 Favourable risk/benefit ratio (5%) 
Queries coded under the principle of favourable risk/benefit ratio were ranked seventh by both 
RECs. The Emanuel et al. (2004) framework says the study risks should be balanced against 
potential benefits to achieve a favourable risk-benefit ratio. Both RECs raised concerns with the 
potential risks and ways in which they can be minimized.  
Has the study drug any risk of triggering or aggravating neuro-psychiatric disorders 
such as depression or anxiety (REC 1). 
The committee is concerned that pre-term infants are being subjected to unnecessary 




Furthermore, both RECs were also concerned about the actual conduct of the research study, for 
example ensuring that medical procedures are conducted by appropriately qualified researchers.  
Venepuncture is required more than once, even in controls. Who will do it? A 
Phlebotomist was not identified in the proposal (REC 1).   
As the PI is not a medic, a clinician must be a co-investigator and be responsible for the 
investigation. For the purpose of this study we strongly recommend that a paediatric 
neurologist be recruited (REC 2). 
Additionally both RECs raised concerns about the need for independent data safety and 
monitoring board (DSMB) to monitor participant safety and adverse events in clinical trials.  
Who are the members of the Safety Monitoring Committee and how is their independence 
guaranteed? (REC 1). 
In research of this nature independent monitoring and oversight will be essential to 
protect participants (REC 2). 
 
6.2.6 Fair participant selection (4.3%) 
Queries related to fair participant selection were the eighth most frequent issue raised by both 
RECs.  The Emanuel et al. (2004) framework states that there should be fair and equitable 
selection of participants to ensure scientific validity of the research. Moreover, vulnerable 
populations should be identified and protected. This was evident in the data from both RECs as 
they were concerned with ensuring that participants are recruited fairly and that there is clear 
justification of enrolling particular populations. 
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Why was the enrolment only subjected to black women and not other races? (REC 1). 
Please state more details of how it will be decided which specific participants will be 
recruited/chosen (REC 2).  
 
6.2.7 Independent ethics review (3.5%) 
The principle of independent ethics review was ranked ninth for the combined averaged data 
from both RECs. The Emanuel et al. (2004) framework emphasizes the need for independent and 
competent review of research by RECs and other regulatory authorities mandated by national 
laws and regulations. As such, both RECs often wanted to see approvals mandated by law in 
their countries.   
Has Medicines Control Council [MCC] approval been obtained for the use of this drug in 
the phase 3 study? (REC 1). 
Kindly indicate whether the issue of [name of experimental drug] dosage been cleared up 
with MCC (REC 2). 
 
6.2.8 Social value (1.2%) 
The principle of social value was the least frequently raised issue by both RECs, ranked tenth 
(Figure 10). According to the Emanuel et al. (2004) framework, social value means the research 
should benefit participants and the community. This was clearly evident in data from both RECs 
as they were concerned about whether the research would be relevant to the well-being and 
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needs of the individual participants suffering from the disease under study or address the health 
problems of importance to the community. Essentially, both RECs were anxious that the findings 
emanating from the study should benefit participants and improve their health needs and the host 
community (35.3% vs 40%).  
Can more be done to maximise benefits to patients and to the study site (REC 1). 
The rationale for this study is to get [drug] registered in [foreign country] for patients 
with COPD. It is not clear why the South African population is being studied as there is 
no indication that [drug] will be marketed in South Africa (REC 2). 
 
6.2.9 Additional issues raised 
Furthermore, there were some additional REC queries that could not be accommodated by the 
Emanuel et al. (2004) framework. These were categorised as administrative issues –e.g., 
researchers’ CVs and budgets (ranked 4th) and errors (ranked 6th overall).  
The CVs, declarations and proof of GCP training should be submitted for all 
investigators and sub investigators (REC 1). 
A copy of the financial agreement for this project must be submitted to the ethics 





In summary, when data from the two South African RECs were integrated and averaged, the 
following emerged as the most frequent ethical issues overall in descending order: informed 
consent (26%, ranked 1st), respect for participants (19%, ranked 2nd), scientific validity (16.7%, 
ranked 3rd), administrative issues (11.9%, ranked 4th), collaborative partnership (6.5%, ranked 
5th), editorial errors (5.5%, ranked 6th), favourable risk/benefit ratio (5%, ranked 7th), fair 
participant selection (4.3%, ranked 8th), independent ethics review (3.5%, ranked 9th) and social 
value (1.2%, ranked 10th). This analysis of the data suggests that the Emanuel et al. (2004) 
framework was compatible with 83% of the ethical issues raised by both RECs overall, 
supporting it’s widely accepted applicability and utility for guiding research ethics training and 
informing ethics review systems and templates (Tsoka-Gwegweni & Wassenaar, 2014).  
 
6.3 Results for Work package 2: Interviews with REC members about 
findings of work package 1 
 
6.3.1 Response rate for semi-structured interviews  
A total of 66 REC members were invited to participate. Five out of 22 (22.7%) members at REC 
1 and four out of the 44 (9%) members at REC 2 consented to take part in the semi-structured 
interviews. Overall, there was a 14% (9 out of 66) response rate. The sample was skewed in 





6.3.2 Demographic characteristics of respondents 
Table 24 below summarizes the demographics of the respondents. In brief, the majority (77.7%) 
of respondents were white academics employed by the institution to which the REC is affiliated. 
All but one had obtained PhDs in different fields of health sciences. There were almost equal 
number of members from the medicine, public health and biomedical science. No lay members 
volunteered to take part in this study. There was a chair or co-chair at each REC sampled. In 
terms of gender, there were more males interviewed at REC 1 compared to REC 2. The duration 
as REC members was quite similar with members from both RECs having experience ranging 












Table 24: Demographic characteristics of respondents 
 REC 1   REC 2 Total 
Race         n (%)              n (%)     n (%)     
 Black African 
  Indian 




 0 (0) 
 0 (0) 




Gender    
 Female 
                    Male 
2 (40)   
3 (60) 
  3 (75) 
  1 (25) 
5 (56) 
4 (44) 
Age group    
 30-40 yrs 
                    41-50 yrs 
                    51-60 yrs 




 1 (20) 
 4 (80) 
        0 (0) 
  3 (75) 
  1 (25) 
 0 (0) 





                     PhD 
 Masters  
 
Area of specialization 
   5 (100) 
        0 (0) 
  3 (75) 
  1 (25) 
8 (89) 
1 (11) 
                     Medicine  
                     Public health 
                     Psychology 
                     Biomedical science 
 
Role in REC 
 3 (60) 
 1 (20) 
        0 (0) 
 1 (20) 
  2 (50) 
  1 (25) 
  1 (25) 







                    Chair/ Co-chair 
                    Internal member 
                    Lay member 
 
Duration as REC member 
  1 (20) 
        4 (80) 
        0 (0) 
  2 (50) 
  2 (50) 









      (2-6 years) 
 









6.3.3 Research ethics experience of respondents 
All respondents indicated that they had received some form of ethics training before or 
immediately after becoming a REC member. The research ethics training received by most 
(67%) members from both RECs was in the form of short course training and online courses. All 
respondents indicated that their training was based mostly on the Emanuel et al. (2004) 
framework. At REC 2, two members indicated that they had received ethics training at Masters 
and PhD level, respectively. When asked to rate their level of expertise/experience in research 
ethics review, more than half (67%) of the respondents ranked as intermediate while the 
remaining 33% of REC members were ranked advanced (Table 25).  
   
Table 25: Questions of REC members' experience in research ethics review 
 REC 1   REC 2   Total 
Have you ever received training 
in research ethics/bioethics 
            n (%)         n (%)        n (%) 
 Yes 
  No 
 
     5 (100) 
            0 (0) 
 
  4 (100) 
        0 (0) 
 
9 (100) 
        0 (0) 
If yes, what did your training 
comprise of? 
   
                    Short course 
                    Diploma 
                    Masters 
                    PhD                                                                           
             4 (80) 
             1 (20)  
             0 (0)                    
0 (0)                     
                 
                                     
         2 (50) 
         0 (0) 
  1 (25) 
1 (25) 
 
        6 (67) 
 1 (11) 
 1 (11) 
        1 (11) 
How would you perceive your 
level of experience/expertise in 
research ethics review 
   
                    Basic 
                    Intermediate 
                    Advanced 
                                            
 
  0 (0) 
    4 (80) 
   1 (20 
 




 0 (0) 
 6 (67) 





6.4 Qualitative views of REC members  
Semi-structured interviews using an interview guide (Appendix 2) were conducted with 9 REC 
members to explore ethical issues identified as previously described in detail in Chapter 5. This 
section presents the findings from these semi-structured interviews. The main themes emerging 
from the qualitative data are described below in order of decreasing frequency. 
 
6.4.1 Role of REC 
The first question asked from REC members was what they thought the main role of a REC was. 
All respondents clearly articulated that the primary task of REC was to protect research 
participants and provide adequate ethics oversight for research involving human beings. For 
example, two respondents said: 
I think it’s primarily to ensure participant protection, and I see it particularly from a 
medical point of view where there has been a history of abuse of research participants in 
medical science. So I think that the first reason we have research ethics committees is to 
protect participants. And then there are other reasons that come about to make sure that 
the research is of good quality, that the researchers actually know what they are doing 
when it comes to doing research… But I think it’s about participant protection…so we 
have ethics now because we don’t want participants to be ever abused again (REC 1). 
Well, I suppose the ethics committee is sort of a representative to protect the, I would say 
maybe the rights, but to try and use the [ethical] guidelines and legislation to protect the 
rights of the participants, the researcher and the institution. But the participant would be 
your main category that you want to provide protection (REC 2). 
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However, another respondent reiterated that while RECs are there primarily to protect 
participants and ensure that the goals of research do not supersede the rights and safety of 
participants, RECs should take precaution not to stifle research (Snooks et al., 2012). The 
respondent said: 
My way of looking at the ethics committee is that it’s there to protect participants, but at 
the same time not stifle research- which is where I end up conflicting often with some of 
my colleagues who seem to suggest that we [RECs] should be stifling research. But, so I 
like to look at it from, is this study in general going to be safe, doable and practicable 
without putting patient or participant’s identity, safety and outcome at risk (REC 2). 
In the next set of questions, respondents were asked to describe the kinds of ethical issues that 
they typically identify during ethics and their opinions on the findings from work package 1 
(Figure 9). These data are presented below in descending order of frequency. 
 
6.4.2 Informed consent 
Although the sample was relatively small (N=9), all respondents identified informed consent as 
one of the most frequent issues they find problematic in research protocols. As such, all 
respondents (100%) said they were not at all surprised at the distribution of informed consent 
issues in this study (Figure 9). REC members repeatedly identified informed consent as one of 




It’s almost common sense to think that if informed consent is not in place that’s probably 
not going to be ethical research….without it you can automatically say that this study is 
unlikely to be ethical unless of course if there are other circumstances that allow for 
waivers of informed consent. So for me it [informed consent] is the first step in actually 
making sure that research is ethical and the others [ethical issues] follow (REC 1). 
Well for me, the most important part is informed consent process and all the aspects... So 
I think informed consent is the most important issue that needs to be covered (REC 2). 
 
When asked to elaborate further exactly the key elements of informed consent that they 
identified, almost all respondents mentioned that the most frequent problems include the use of 
too much technical language and/or omitting sufficient details about the study, for example the 
risks, benefits, and contact details of researchers and the local REC.  Therefore, REC members 
stated that they often required changes to the informed consent document in terms of rewording 
and simplification of language, as well as every single detail pertinent to the research study. For 
example four respondents said:   
I think the biggest problem that people have with the ethics application form is the ability 
to include in the informed consent the aspects of the study… sometimes their form is so 
comprehensive that it becomes many many pages and difficult for someone to read 
[laughter]….When they do an informed consent they may not include all the aspects that 
are relevant to the ethics of the study, for instance they may not reveal that it’s being 
done for your Masters or PhD etc…, they may not say that the patient can withdraw from 
the study at any time that they wish, they may not say that there will be no penalties for 
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withdrawing, they may not say that they [participants] are not obliged to give consent, 
you know, that this is purely voluntary and at any stage they can withdraw their consent. 
And the last thing is that sometimes the investigators fail to reveal whether they are 
actually paying for the participants or not, and that’s very important that it’s noted in the 
consent form so that there is no perverse incentives.  So those are the things that we 
particularly look at [in the consent form] (REC 1). 
We tend to focus on informed consent it has to be thorough. Usually we receive a huge 
document, and the researcher says this is informed consent, and we say No, No, No! 
simplify it, simplify the language it’s too technical. It doesn’t matter whether the funders 
wanted it that way but we want it to be simple for the participants, so the language must 
be simplified and it must be shortened and list everything that that is there including the 
harms (REC 2). 
Yeah, the kind of informed consent queries that I can remember are the language issue, 
and then often the information is too complex for the lay person and that it’s too long. 
Those are the queries that come to mind that people [reviewers] ask, and those won’t be 
addressed in a REC application (REC 1). 
It is a lot about the wording and the phrasing, and sometimes it’s about not including 
details or contact details…making sure every single element of the procedures of that 
trial is explained to the participant (REC 2). 
REC members also believed that because of low levels of education and literacy in many South 
African samples, participants may not easily understand the study. Hence they often raised 
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comments related to understanding and comprehension of the informed consent by prospective 
participants. As mentioned by one respondent: 
Issues of informed consent form one of the biggest problems that we have. Researchers 
think that if they explain something to the participant in terms that they themselves 
understand, then their potential participants automatically are going to understand, and 
that’s a problem (REC 2). 
 
6.4.3 Respect for participants 
When it came to the principle of respect for participants, most respondents identified the need to 
protect the privacy and confidentiality of participants: For example two respondents stated that: 
Well first of all I think anonymity of data [is important] because any personal data can 
actually be used to harm someone. So I think if you protect the person’s identity in the 
research documents by not having any traceable information (REC 1). 
 
For instance most studies for students are chart reviews or they use previously collected 
samples. So… we want to ensure that issues of privacy and confidentiality are addressed 
in the protocol or in the informed consent, i.e. how are they going to ensure they protect 
the privacy of participants if they are interviewing participants? (REC 2). 
Furthermore, REC members believed that researchers should make plans for post-trial access of 
interventions to participants upon completion of the study. REC members said that they are often 
troubled when there is no clear indication from researchers and their sponsors on plans for on-
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going access to medical care for participants after the study has completed. For example one 
reviewer said: 
One of the common issues in terms of participant protection is the issue of post-trial 
availability of test drugs, okay. And that’s something I stare in horror with some of the 
commercial proposals that gets sent to me for review (REC 1). 
 
6.4.4 Scientific validity 
While all REC members acknowledged the importance of good scientific validity for any 
research study, there were divergent views about the overall distribution of scientific queries 
raised by RECs in this study (Figure 9). Most (77.7%) respondents said they were not surprised 
by the high frequency of scientific queries because they felt strongly that scientific reviews were 
in the remit of ethics review. To illustrate this, three respondents said: 
Scientific validity is at the roots of research and immediately if the scientific validity is 
wrong, is misinterpretable then…there is no point looking at the ethics. If it’s not 
scientifically valid, it’s immediately unethical to start the study (REC 1). 
We’re looking at ethical issues but we’re also looking at whether the study is well 
designed so that we can really make sure that we are not wasting participant’s time and 
resources by doing research that has no scientific value in the end because it’s been 
badly designed and the findings will be invalid.  So we look at whether it’s feasible in 
terms of the methodology and the design, but also whether the way that those things are 
being conducted is done in ethical ways (REC 2). 
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The primary focus of RECs is to look at the ethics of a study. But if you have poor science 
you gonna end up with poor ethics, right [laughter], and one is not mutually exclusive 
from the other. So you have to look at both aspects, if a study has poor science then how 
can you ethically justify doing that study especially if its invasive (REC 1). 
 
Interestingly, however, while acknowledging that the science of a project should be valid, a few 
other REC members (22.2%) strongly felt that there was often an over-emphasis on scientific 
issues. They believed that querying scientific issues was not the core function of an REC, hence 
it falls outside its purview. For example, two respondents said: 
One of the biggest issues that strike me the most….is the over-emphasis on the scientific 
validity…We tend to lose focus that we are ethics committees reviewing ethical issues, 
noting that the science should be ethical. But we are not there to ask all these questions 
about the scientific methodology (REC 2). 
As to the sort of scientific methodology, I think that’s where the REC needs to often take a 
step back and say, look this is not our discipline, let’s ask an expert to review the science 
and advise us, and I don’t think we do that often enough especially for some of the 
postgraduate studies (REC 1). 
 
When asked about their views on the criticism levelled against RECs that they lack expertise to 
review scientific issues for example, in qualitative designs, some respondents agreed strongly 
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and believed that this was fair criticism. They believed that RECs generally did not have the 
expertise to review qualitative designs: For example, one respondent said:  
Absolutely. It’s a very fair comment. In most medical work that gets done especially in 
clinical medicine schools, is quantitative…and there are limited people [REC members] 
that know what they are doing with qualitative research. So I think it’s a responsibility of 
any REC to have somebody on board who can understand qualitative research, who can 
understand that you can get away with a sample size of 10 because you have reached 
saturation. But a lot of clinicians don’t have the time to get their head around that. So I 
think that we have to look further and find people [REC members] who can grasp that 
work. And I have seen it in my work where I had a student’s work reviewed and the two 
reviewers had no clue what I was doing and in front of me they slated the work almost 
brutally [laughter] I realized afterwards that they actually just didn’t understand the 
work (REC 2).   
Finally, when asked to what they attribute such a high number of queries on scientific validity, it 
was concerning to note that most REC members attributed a high number of queries raised (for 
scientific validity and other ethical issues), to inadequate supervision or input from supervisors 
prior to submission to RECs for ethics approval particularly for postgraduate student projects:  
For example two respondents said: 
I’m afraid that there is very little support given to novice researchers and some of the 
stuff [proposals] that gets through [REC] and that gets slated is because it’s a novice 
researcher who hasn’t got adequate assistance from the supervisor. And things are just 
getting rubber stamped [by postgraduate committees] for turnover (REC 1) 
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It’s not necessarily that we have a particularly brusque ethics committee. It may just 
reflect the fact that we are suddenly getting an increased numbers of submissions by 
relatively inexperienced students with relatively inexperienced supervisors. And it needs 
to be set against a postgraduate review system which just rubber-stamped the 
applications (REC 2). 
 
6.4.5 Collaborative partnership 
Although issues of collaborative partnerships were not as frequently mentioned as compared to 
other ethical issues (consent: ranked 1st, respect for participants: ranked 2nd and scientific 
validity: ranked 3rd), there was a general concern by some REC that they would like to see more 
collaborative partnerships when researchers from more developed countries conduct research in 
local communities. In particular, REC members wanted developing country researchers to 
engage in consultative process with local researchers and respect the local context and culture, as 
opposed to imposing their own standards on the local community in which research is being 
conducted.  One respondent said:    
There are other studies that are more internationally funded studies, and bigger 
sponsors. So essentially the sponsor pushes through what is applicable in their settings, 
and these are from developed countries, and they push through the norms and standards 
they use and they expect that to be done here also with little regard to the local issues 




6.4.6 Reasons for low frequency of certain issues  
When asked for their views on perhaps why certain issues (e.g., social value) were not as 
frequent as others, respondents generally felt that the nature of their REC application forms 
influenced the distribution of ethical queries raised by reviewers. For instance, respondents 
believed that their application forms adequately addressed issues of risk benefit and fair 
participant selection, such that few queries arise from the REC deliberations. An illustration of 
that point was made by one respondent who said: 
I think that the application form itself makes sure that you answer the questions on 
participant selection and favourable risk benefit ratio and whether there has been 
another independent review. So if there is a tick box that covers these, and I think there is 
in the [name of REC] application form, of course these issues will be lower (REC 1). 
 
Also, some respondents said that the data did not necessarily mean that they neglect certain 
issues, but it could be that the issues are well described by researchers in the protocol. For 
example with social value, most respondents felt that because most studies addressed issues of 
national importance such as HIV. Therefore, there were likely to be very few queries asked on 
social value because the mere fact that it’s a biomedical study addressing a disease or condition 
affecting people in South Africa, then it means the study has social value: This was illustrated by 
one respondent who said:  
The nature [of studies reviewed by REC] is biomedical research and they are public 
health research. So when the researchers come, they study those issues that are of 
national priority, so they justify why they want to do their research. Like I said HIV and 
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TB is very topical in South Africa…So obviously once you[REC member] look at it [the 
proposal], the reviewer will know that this is a national priority and they will say ok 
there is social value because South Africa is battling with HIV, you know….the issues are 
easy to sort (REC 2).   
 
6.4.7 Additional issues  
The researcher also asked for respondents’ views on the overall ranking of administrative issues 
(ranked 4th) compared to ethical issues such as favourable risk/benefit (ranked 7th) and social 
value (ranked 10th) (Figure 10). Most REC members felt that querying administrative issues, 
such as investigator CVs and research budget occurred for valid reasons and not because 
reviewers were pedantic. They said that although these are not overtly ethical issues, they have 
ethical and scientific implications. To illustrate this point, two respondents said: 
For instance with CVs and qualifications, it comes back to, umm, are the researchers 
qualified or experts and experienced in what they are researching, okay. You don’t want 
to send out a boy to do a man’s job [laughter] because it’s not fair on the participants; 
you can’t send somebody [researcher] who doesn’t know what they are doing to do 
research on these people (REC 1). 
Some of the administrative issues may not be regulatory requirements, like a budget or a 
timeline. [But] for me again it speaks a little bit to the validity of the research (REC 2). 
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Importantly, most REC members reiterated that most of these administrative issues such as CVs, 
in fact, are regulatory requirements in accordance with national and international standards. This 
is what one respondent said: 
Quite a lot of these things [CVs] actually are regulatory requirements. The NHREC 
[National Health Research Ethics Council] and the regulations actually require that 
these things [CVs] are included in the applications and ethics review- and if they are not 
there they invalidate the application and it means the REC is doing something wrong by 
keeping on file an application that is incomplete without those things (REC 2). 
 
Furthermore, when asked for their views on whether the ranking of the issues between the two 
RECs (Figure 9), was expected or surprising, and/or reflected what RECs should be attending to, 
most respondents stated that the ranking was not at all surprising. They felt that indeed, these are 
the kinds of issues they would have expected their RECs to pick up. Some REC members also 
believed that they do not necessarily over-scrutinize protocols, but they raise issues simply 
because they would not have been properly addressed or are missing in the submitted proposals. 
As such, REC members cannot simply cast a blind eye to those issues.  One respondent said: 
I don’t think there is any terrible plot from the ethics committee to pick everybody up on 
these issues. It’s just that they are there, if it’s an issue it’s an issue. You can’t just say oh 
well I’m going to ignore this because I have been sending a lot of these queries back 
recently. You can’t say it’s wrong to pick up on it, you can’t say a lot of these are going 
back [to applicants] let’s try and decrease our numbers [of queries]…So this [data] 
reflects us doing our job- it’s not a policing thing (REC 1). 
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At the end of the semi-structured interviews, REC members were asked to suggest ways in which 
the protocols submitted for ethics review could have been improved. Almost all participants 
made specific comments about the need for better supervision in the case of student research. 
Furthermore, all REC members believed there is need for more research ethics training of 
researchers when it comes to addressing ethical issues in REC applications. Furthermore, some 
respondents also suggested that the use of electronic REC management review systems could 
improve the review process and circumvent the need for multiple submissions of documents such 
as CVs.  
 
6.5 Results for Work package 3: Alignment to national research ethics 
guidance  
This section provides an overview of results from work package 1 (Figure 10) and draws on the 
ethical statements in the South African national research ethics guidance (Department of Health, 
2015) to illustrate whether there is consistency between the issues identified by both RECs and 
existing guidance. 
 
Table 26 below shows that, when comparing the types of issues raised by both RECs (Figure 9) 
and the requirements of the national guidelines (Department of Health, 2004, 2015), the majority 
of issues identified by the RECs were compatible with the guidelines. Specifically, both RECs 
raised the following Emanuel et al. (2004) ethical issues in descending order of frequency: 
informed consent (top ranked), respect for participants, scientific validity, collaborative 
partnership, favourable risk/benefit ratio, fair participant selection, independent ethics review  
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and social value (least ranked) . Although they do not stipulate how much weight should be 
given to each issue, the national guidelines (Department of Health, 2004, 2015) require the work 
of RECs to be informed by the same principles as the Emanuel et al. (2004) principles identified 
in work package (1). Furthermore, Table 26 shows that in terms of the additional issues 
identified by both RECs, such as investigator CVs, these are requirements of the national 
guidelines, which states that the researcher must have the requisite qualifications and experience 
(Department of Health, 2015). In conclusion Table 26 shows that the issues raised by RECs in 
this study were in line with requirements in the national guidelines (Department of Health, 
2015).  
Table 26: Comparison of themes identified in work package (1) with national guidance 
Ethical issues identified in 
work package (1) 
 
What does the national ethical guidance say? 
Emanuel et al. (2004) 
issues (Ranked in 
descending order for 
combined REC data) 
 
 
Informed consent (26%) Ensure valid and voluntary informed consent is obtained from 
participants or their legally authorized proxies where the 
participants are not competent enough to provide valid 
consent 
 
Respect for participants 
(19%) 
This involves respecting the participants' rights, including but 
not limited to rights to dignity, privacy and confidentiality…. 
The researchers should ensure appropriate plans for provision 
for compensation for research-related injury, for more than 
minimal risk research 
 
Scientific validity (16.7%) The research should have a valid scientific methodology and 
be likely to provide answers for the specific research questions 




Researchers should engage key role players at various stages 
of planning and conducting research to improve the quality 
and rigour of the research, to increase its acceptability to the 
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key role players, to harness role player expertise where 
possible, and to offset power differentials where these exist. 
 
Favourable risk/ benefit 
ratio (5%) 
The proposed research must ensure that the research benefits 
outweigh the potential risks, i.e. a favourable risk-benefit 
analysis 
 
Fair participant selection 
(4.3%) 
Fair participant selection: The researchers should ensure that 
the recruitment and selection of potential participants is 
objective and fair 
 
Independent ethics review 
(3.5%) 
It is the obligation of the researchers to ensure that they 
submit protocols for independent review by a registered health 
research ethics committee. 
 
Social value (1.2%) Research should be responsive to the health needs or priorities 
of the population, participating community or proposed 
participants  
 
Additional issues  
Administrative queries 
e.g., CVs (11.9%) 
 
Researchers must be suitably qualified and technically 
competent to carry out the proposed research… Competence is 
demonstrated mainly by academic qualifications, credentials, 
scientific and technical competence as evidenced in previous 
publications or testimonials. 
 













6.6 Summary   
In in section, results from the three work packages were presented. In the first work package, a 
retrospective analysis of minutes showed that, in descending order, the two RECs in this study 
most frequently identified issues related to: 
• Informed consent (ranked first: 26%)  
• Respect for participants (ranked second: 19%), and  
• Scientific validity (ranked third: 16.7%).  
Although ranked first by both RECs as the most frequently raised issue, there was a statistically 
significant difference between the frequencies of informed consent issues being raised. Similarly, 
there was a statistically significant difference in the frequency of respect for participants and 
scientific validity queries raised by the two RECs (p < 0.05).  
In the second work package, qualitative interviews with REC members highlighted that generally 
respondents were not surprised with the ranking of the ethical issues queried (Figure 9) and saw 
them as compatible with what was expected as REC outcomes. However, there were some 
different views, especially regarding scientific validity. While most respondents agreed with the 
frequency with which scientific issues were raised by both RECs in this study, some felt that it 
was outside the remit of RECs to review scientific issues. The aim of work package 3 was then 
to do a review of national ethical guidelines and compare it with findings in work package (1) 
above to determine if there is alignment between the two and showed that the majority of issues 







The aim of this chapter is to relate the findings presented in the results sections to the existing 
relevant scholarly literature.  
There have been many calls for the evaluation of RECs (Abbott & Grady, 2011; Coleman & 
Bouesseau, 2008).  However, there is a lack of consensus on the assessment criteria for 
evaluating research ethics review (Nicholls et al., 2015). The present study described and 
evaluated the ethical issues raised by two biomedical RECs in South Africa from three 
perspectives: (i) content analysis of REC meeting minutes and decision letters, using the 
Emanuel et al. (2004) framework, (ii) semi-structured interviews with REC members, and (iii) 
comparison with findings in (i) above with current South African national research ethics 
guidance (Department of Health, 2015). Assessing the institutions’ research ethics capacity 
(instead of RECs themselves) (Hyder et al., 2013, 2015) or the effectiveness of ethics review 
(Abbott & Grady, 2011) was beyond the scope of this project. 
  
In what follows, the main findings of this study are discussed. The findings are discussed and 
interpreted in relation to the eight benchmarks described in the theoretical framework used in this 
study (Emanuel et al., 2004).  The discussion is structured according to the overarching themes 
presented in the results sections in descending order of frequency 1) informed consent, 2) respect 
for participants, 3) scientific validity, 4) collaborative partnership, 5) fair participant selection, 6) 
favourable risk benefit ratio, 7) independent review, and 8) social value. The section concludes 
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with a discussion of the administrative issues and other process errors identified by the two 
RECs in this study.  
  
7.1 Informed consent  
The findings suggest that the two RECs in this study most frequently identified problems with 
informed consent (26%) when reviewing proposals. These findings are comparable with previous 
South African studies in which informed consent were the most frequent ethical issues identified 
(Clarke, 2014; Cleaton-Jones, 2010; Tsoka-Gwegweni & Wassenaar, 2014). Furthermore, 
similar studies conducted in the United Kingdom (Angell et al., 2010; Dixon-Woods, Angell, 
Tarrant & Thomas, 2008), U.S (Lidz et al., 2012), France (Decullier, Lheritier & Chapuis, 2005), 
Brazil (Bueno et al., 2009) and Spain (Dal-Ré et al., 2004; Martin-Arrabis et al., 2012) also 
reported that informed consent issues were top ranked  by RECs in their settings. Another study 
in Germany reported that of the total 1299 queries identified, 53% concerned the patient 
information and consent document (Russ, Busta, Riedel, Zollner & Jost, 2009). A study of US 
IRBs reported that informed consent issues were discussed in 102/104 (98%) of protocols and 
changes to the informed consent were requested in 92/104 (88%) of protocols (Lidz et al., 2012). 
Similarly, a study that analysed 100 protocols submitted to two US IRBs found that 87% of those 
protocols had queries related to informed consent. Of those, omissions in the consent documents 
(40%), requests for better clarity (24%) and word-smithing (10%) were the most common 
queries requested (Blackwood et al., 2014).  These data suggest that RECs want to ensure that 
participants are provided with simple but comprehensive study details, including a statement that 
the study has been approved by a local REC.  
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There are several possible explanations for such a relatively high frequency of informed consent 
issues observed in this present study. Firstly, informed consent is a legislative requirement 
enshrined in the South African Constitution and National Health Act (Strode, Toohey, Singh & 
Slack, 2015). It is widely recognized that informed consent is the cornerstone for ethical research 
with human participants, and for it to be valid, consent should include information disclosure, 
comprehension, competence and voluntariness (Grady, 2015; Lindegger & Richter, 2000). 
Therefore RECs may feel pressured to be more rigorous when reviewing informed consent forms 
on both legal and ethical grounds. Another possible explanation is that local RECs probably 
worry about the vulnerability of local participants due to high illiteracy and lower levels of 
education – contextual factors which may compromise voluntary informed consent (Bull & 
Lindegger, 2011; Kamunya et al., 2011), although there is still a lack of consensus on the 
standards for conceptualizing and assessing voluntariness (Mamotte & Wassenaar, 2015, 2016).  
 
While the informed consent process should be interactive and on-going throughout the study, and 
not necessarily reliant on the ability to read (Horn et al., 2014), RECs may feel the need to be 
more vigilant when reviewing the readability of consent forms in order to ensure that potential 
participants are better informed through the use of simple language (Blackwood et al., 2014; 
Horn et al., 2014). Indeed, some empirical studies have reported limited understanding by 
participants during informed consent. One study found that participants had difficulties 
understanding technical terms such as randomization, double-blind and placebo, unless explained 
in simple local terms (Ndebele et al., 2014c). Another study also reported that participants’ 
understanding of HIV research could be impeded by linguistic and cultural differences. The 
authors found that RECs often raised concerns about the context (e.g., low literacy and less 
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familiarity with research procedures), content (e.g., length of forms and translation), and aspects 
of the consent process such as written vs. oral consent (Hanrahan et al., 2015). Therefore, these 
data thus seem to have useful educational implications for researchers, i.e., they should ensure, to 
the greatest extent possible, the use of simple understandable language in the informed consent 
forms. While research ethicists have called for improved readability, several researchers have 
criticized RECs for too much tinkering and word-smithing, sometimes requesting unreasonable 
demands to the informed consent documents (Paasche- Orlow, Taylor & Brancati, 2003). 
Informed consent documents submitted to Australian RECs were frequently too long to read, 
with mean readability of 47, and were too complex to comprehend at the recommended grade 8 
level (Biggs & Marchesi, 2015).  
 
Another study in New Zealand and Australia found a mean readability score of 11.9 (higher than 
the recommended 8), but the authors nevertheless concluded that this was more than the average 
readability requirements in their countries (Taylor & Bramley, 2012). While these data are from 
an international context, they could possibly justify why South African RECs also frequently 
requested changes to simplify language in the participant information sheet and consent forms as 
suggested by data from the present study. The qualitative interviews with members from the two 
South African RECs (described in detail in the previous Chapter 5) suggested that they also 
require readability of consent forms to be around grade 8 level.  An empirical study investigating 
how US IRBs viewed and made decisions about consent forms found that while IRBs generally 
strive to decrease the length and complexity of consent forms, some IRB members often 
experienced difficulty regarding what and how much the informed consent forms should include, 
i.e., how perfect should a consent form be? (Klitzman, 2013a).  
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7.2 Respect for participants  
Ongoing respect for participants emerged as the second most frequent issue (19%) raised by both 
RECs in this study, particularly participant care during and after research, confidentiality and 
compensation and reimbursements. With regard to participant care, most issues were related to 
adequate monitoring of medical conditions including research-related injuries. These data are in 
accordance with the South African GCP (Department of Health, 2006), which requires RECs to 
assess whether insurance cover for clinical trials is in place and valid. Furthermore, RECs were 
concerned about plans for post-trial access to treatment beyond the duration of the study.  
There is considerable debate in the literature about what is owed to participants after research 
completion and whether investigators have an obligation to provide post-trial access to 
medication and care beyond the duration of the study (Pace et al., 2006; Sofaer et al., 2011). 
While this argument is beyond the scope of this thesis, a possible explanation why local RECs 
often comment on post-trial access is because of lack of adequate healthcare systems and poor 
access to medical care by the majority of SA trial participants (Harris et al., 2011). Thus, based 
on the premise of beneficence, social justice and reciprocity (Slack, 2014), RECs may feel that 
participants should continue to receive medical care and treatment even after trial completion. 
Unfortunately, the national ethical guidelines are rather ambiguous regarding the matter 
(Department of Health, 2015). However, some international guidelines recommend that 
“sponsors, researchers and host country governments should make provisions for post-trial 
access for all participants who still need an intervention identified as beneficial in the trial” 
(WMA, 2013, p. 7). Furthermore, participants must be provided information regarding post-trial 




7.3 Scientific validity 
The findings highlighted that scientific validity emerged as the third frequent (16.7%) source of 
queries raised by both RECs in this study. Contrary to some reports that RECs do not pay 
sufficient attention to scientific rigor (Altman, 1994), data in this present study show that the two 
South African biomedical RECs in this study regularly raised scientific validity issues such as 
the study design, research questions, methodology, sample size, statistical validity and measuring 
instruments. This issue was the third most frequently ranked issue, overall. 
 
These findings are comparable to results reported in previous studies in South Africa. One study 
found that 21.3% of queries raised were related to scientific validity (second after informed 
consent) (Tsoka-Gwegweni & Wassenaar, 2014), while in the present study issues of scientific 
validity were the third most frequent issue. Another study found that of 142 queries, the majority 
were scientific issues: study design 31 (21.8%), methodology 29 (20.4%), statistics 14 (9.9%) 
(Clarke, 2014). A different study analysed 306 letters and found that queries about the study 
sample were raised in 15% of applications (Cleaton-Jones, 2010).  Elsewhere, 141 decision 
letters showed that scientific issues were raised in 104 (74%) of the letters. The most common 
issues were related to sampling (65%), methodology (50%), research question (28%), measuring 
instruments (27%), data analysis (22%), bias (15%) and feasibility (12%) (Angell et al., 2008). A 
recent study in Finland reported scientific issues, particularly the methodology, to be the most 




The findings of this study showed the importance accorded to the ethical importance of scientific 
validity and provided some data on the types of concerns arising under this general heading. 
While the majority (77.7%) of REC members sampled in this study indicated that they expected 
a high proportion of scientific validity issues, a smaller group others (22.2%) felt that it was not 
the duty of their RECs to query issues related to the scientific validity of proposed research. That 
there are divergent views about scientific validity reflects the on-going debate on the remit of 
RECs in relation to scientific reviews. Perhaps a question that remains unanswered is how far 
RECs should go in reviewing the science of proposed research? Qualitative interviews with 
RECs, researchers and policy makers could help explore these questions further. 
 
There are arguments on whether or not RECs should review the science of research proposals 
and the suitability of study designs and methodologies chosen by researchers to achieve their 
scientific objectives (Angell et al., 2008; Humphreys et al., 2014a). For some commentators, 
reviewing scientific validity is uncontroversial because enrolling participants in a scientifically 
invalid research poses unnecessary risks and burden to participants, i.e. bad science is bad ethics 
(Dawson & Yentis, 2007; Emanuel et al., 2004). Furthermore, most international (e.g., CIOMS, 
2002; WHO, 2011; WMA, 2013) and national guidelines (Department of Health, 2015) require 
review of the science of research proposals. 
 
There could be several interpretations for the high ranking and frequency of queries on scientific 
validity observed in this present study. That local RECs frequently raised scientific issues is in 
line with the national guidance (Department of Health, 2015) which explicitly obliges RECs to 
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ensure that propose research has scientific validity. Another possible explanation is that because 
of the composition of RECs, often dominated by medical scientists compared to lay members, it 
may be almost impossible for REC members not to comment on the scientific issues - even if 
they are tangential to the study (Humphreys et al., 2014b). As a result, the scientific expertise of 
most REC members may unintentionally dominate the deliberations of the entire REC, thus 
resulting in an over-emphasis on scientific issues (Humphreys et al., 2014b).  
 
7.4 Collaborative partnership  
The findings of this study showed that issues of collaborative partnership were ranked fifth 
(6.5%) for the combined REC data. These issues were raised particularly in international 
collaborative studies involving the collection, storage and export of human biological samples 
for future, and sometimes unknown and unspecified, research purposes. Both RECs often 
(ranked fourth among other categories of ethics query) requested clarifications on issues such as 
ownership of samples, benefit-sharing, material transfer agreement (MTAs) and export permits. 
Existing international ethical guidelines such as CIOMS, Declaration of Helsinki are ambiguous 
on several salient issues.  For example, there is no specific guidance on benefit-sharing and 
ownership - an important ethical issue emerging from this study. Therefore, current frameworks 
need to be revised to provide further guidance on concerns identified by RECs in this study such 





There are published reports suggesting that exportation of biological samples sometimes happens 
without appropriate REC approvals, MTAs and export permits (Langat, 2005; Sathar, Dhai & 
van der Linde, 2013). A study exploring the views of stakeholders about exportation of human 
biological samples from Ghana and Kenya found frequent concerns about developing 
meaningful partnerships through obtaining culturally appropriate permissions prior to 
exportation of samples, consideration of cultural sensitivities in the use of blood samples, and 
also building sustainable local scientific capacity and benefit-sharing (Tindana et al., 2014).  
These data emphasise the need for meaningful consultative collaborations, for example, through 
direct engagement with participants and communities, or involvement of community advisory 
boards (UNAIDS/AVAC, 2011). While there have been many efforts to produce guidance on 
promoting community engagement, there is a general lack of consensus on the ethical goals and 
strategies for community engagement, as well as appropriate indicators and metrics for 
evaluating the effectiveness of existing models of community engagement (MacQueen et al., 
2015).  
 
7.5 Favourable risk/benefit ratio  
The findings showed that the combined REC queries related to favourable risk/benefit ratio were 
ranked seventh (5%). These data are comparable to previous studies in South Africa and 
elsewhere. One South African study found that risk/benefit queries were ranked fifth, 
representing (9% of the total queries raised by the REC in their study (Tsoka-Gwegweni & 
Wassenaar, 2014). Another study reported that of the 142 queries identified, only four (2.8%) 
were issues of risk/benefit (Clarke, 2014). A separate study investigating how US IRBs apply the 
criteria in the Common Rule guidelines, found that they did not address risk-benefit issues in 
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52/91 (57%) of the protocols reviewed (Lidz et al., 2012). These data raise interesting questions 
about how thoroughly RECs systematically assess favourable risk/benefit ratio to ensure 
protection of research participants from excessive risks (Rid & Wendler, 2011). Although there 
were relatively fewer risk/benefit issues (ranked fifth) compared to informed consent (top 
ranked), respect for participants (second ranked), scientific validity (third ranked third) and 
collaborative partnership (fourth ranked), results of the qualitative interviews suggested that REC 
members believed that they gave adequate consideration to risk/benefit issues because these 
issues are detailed in the REC application forms, forcing applicants to consider them carefully. It 
is therefore possible that risk-benefit issues were well addressed in the research proposals. A 
study by Klitzman (2013b) found that some US IRBs encounter difficulties in assessing and 
balancing social risks and benefits of a study, and vary in whether and how to balance these 
against individual risks/benefits. Another study of 188 US IRB chairs found inconsistencies in 
how they assessed risk/benefit issues in paediatric research, at times in ways incongruent with 
federal regulations (Shah et al., 2004). 
 
7.6 Fair participant selection  
The findings revealed that issues regarding fair participant selection were not as frequently raised 
(ranked sixth)  as other previous ethical issues such as informed consent (ranked first: 26%), 
respect for participants (ranked second: 19%), scientific validity (ranked third: 16.7%) and 
collaborative partnership (ranked fourth 6.5%). These results are comparable to similar previous 
studies in South Africa. For example, Clarke (2014) found that of the 104 queries, only 3 (2.1%) 
were issues about fair participant selection. Another study reported that issues of fair participant 
selection were identified in 145/1040 (13.9%) of ethics queries, thus ranked third after informed 
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consent (27.4%) and scientific validity (21.4%) (Tsoka-Gwegweni & Wassenaar, 2014). A study 
in the US reported that IRBs did not consider fair participant selection in 60% of protocols (Lidz 
et al., 2012). That these issues were relatively infrequently raised does not mean that the RECs 
paid insufficient attention to fair participant selection. Qualitative data from REC members 
suggested that they are often concerned with ensuring that disadvantaged persons and 
communities are not unfairly included or excluded from ethically sound research on the sole 
basis of their vulnerable status, for example, supporting enrolment of homeless persons in 
research that otherwise stands to benefit wealthy communities only.  
 
7.7 Independent ethics review 
Independent ethics review issues were ranked ninth overall on aggregated data from both RECs 
(3.5% of total queries). The findings suggest that RECs in this study often requested 
investigators to provide relevant approvals mandated by laws in the host countries. For example 
in South Africa, it is mandatory to obtain MCC approval for clinical drug trials as well as 
approval by local RECs registered with NHREC (Department of Health, 2015). While 
acknowledging the value of independent ethical review, some commentators have criticized the 
practice of multiple REC reviews and approvals for multinational collaborative studies because 
the process results in duplication of effort, wastes time and resources and is often riddled with 
inconsistencies (Abbott & Grady, 2011). A review of African RECs identified that some RECs 
encounter several barriers (e.g., inadequate resources, difficulties interpreting international 
guidelines, limited ethics review expertise) in conducting effective and efficient ethical reviews 
(Silaigwana & Wassenaar, 2015). 
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7.8 Social value 
While it was the least frequent (1%) and lowest ranked issue raised by both RECs in the present 
study, social value is an important ethical benchmark underscored by key national and 
international guidelines (Emanuel et al., 2004). The principle of social value entails ensuring that 
proposed research is responsive to the health needs of the researched communities and is not 
exploitative (Department of Health, 2015; Emanuel et al., 2004). The data from qualitative 
interviews with REC members suggested that no member was surprised by the low frequency of 
social value queries raised by both RECs. The members felt that, because most studies reviewed 
by their RECs addressed important public health priorities such as HIV/AIDS and TB, they 
already were of social value to the community. This suggests that REC members believed that 
issues of social value would have been adequately addressed by the investigators in the research 
proposal under review, hence the low frequency of queries related to social value.  There are a 
few empirical studies that have explored stakeholder’s views on social value in research. A study 
in Kenya found that stakeholders viewed social value as benefit-sharing, for example, through 
post-trial access to research products and medical care, technology transfer and building local 
capacity, and societal benefits emanating from the successful completion of research (Lairumbi 







7.9 Additional issues  
Although most of the issues raised in the data analysed for the present study were compatible 
with principles articulated in the Emanuel et al. (2004) framework, there were additional issues 
raised by the two RECs that could not be accommodated by the Emanuel et al. (2004) 
framework. These issues were categorized into administrative queries and include CVs and 
certificates of investigators and funding/budget. At face value, these would seem like mere 
administrative queries, but qualitative data with REC members suggests that these issues have a 
bearing on the social value, favourable risk benefit ratio and scientific validity of a study. For 
example, a trial that is not sufficiently funded may suddenly come to a halt before completion- 
hence exposes participants to unnecessary burden and waste of time and resources (Tsoka-
Gwegweni & Wassenaar, 2014). Second, a study conducted by a scientifically poorly qualified 
PI is unlikely to yield valid results. 
 
Furthermore, research procedures conducted by an unqualified researcher could not only yield 
invalid results, but pose risk of harm to the participants.  Thus, RECs have to ensure that an 
appropriately qualified PI oversees the research and that appropriately qualified and skilled study 
personnel conduct relevant research and clinical procedures. This will improve the scientific 
validity as well as ensure that participants are attended to by qualified study personnel. Another 
category was editorial queries such as grammatical errors and typos. While these should not be 
encouraged, an interesting question is how far should RECs go in querying editorial issues? Are 
they important enough a reason to not approve a study? Should these issues even be queried in 
the first place? Considering the seemingly antagonistic relationship between RECs and 
researchers, particularly social science investigators (Mamotte & Wassenaar, 2012; Wassenaar & 
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Slack, 2016), it would be interesting to further explore the views of both REC members and 
researchers on these issues. A similar study in UK analysed 100 letters and found that errors 
were raised in 30% of letters (Angell & Dixon-Woods, 2009). There are some reported cases in 
the literature where research proposals have not been approved on the basis of poor editorial 
work (Stark, 2012). It could be argued that editorial issues reflect poor attention to detail by 
researchers, which could be a predictor of similar poor oversight in the study being proposed. 
Alternately or in addition, RECs could be briefed to attend only to editorial issues if they obscure 
key meanings of ethical import. Further work is needed to articulate and refine RECs’ concerns 
arising under this general additional category. 
 
7.10 Summary 
This chapter has interpreted and discussed the study findings in light of the literature and 
framework underpinning this study (Emanuel et al., 2004). Comparing with results of other 
previous studies conducted both in South Africa (Clarke, 2014; Cleaton-Jones, 2010; Tsoka-
Gwegweni & Wassenaar, 2014) and internationally (c.f., Adams et al., 2013, 2015; Angell et al., 
2008, 2010; Kent, 1999; Lidz et al., 2012; Novaes et al., 2009; van Lent et al., 2014), the 
findings showed that the three most frequent issues identified in the present study, ranked in 
descending order (informed consent, respect for participants and scientific validity) were similar 
and comparable, except that there were some differences in the ranking of the issues. For 
instance, when comparing the results of the present study and findings reported by Tsoka-
Gwegweni and Wassenaar (2014), issues of scientific validity were second ranked, whereas in 
the present study the second most frequent queries were respect for participants, followed by 
scientific validity in the third rank. In conclusion, the discussion chapter suggested that there is 
206 
 
some considerable similarity in the kinds of ethical issues raised by the two different RECs in the 
present study and previous studies conducted elsewhere, notwithstanding the different rankings 
and frequency of these issues. The next and concluding chapter highlights the limitations of the 
methodology and sample employed in this study, as well as the conclusions and 

















CONCLUSIONS AND RECOMMENDATIONS 
This final chapter provides a summary of the study as a whole and concluding remarks. The 
chapter begins by highlighting the limitations of this study. This is then followed by the major 
conclusions and recommendations for further research. 
 
8.1 Limitations of the study 
This study has several limitations. The study sampled only two South African biomedical RECs. 
Results may therefore not be generalizable to all 44 biomedical RECs in South Africa (NHREC, 
2015). However, both RECs are based at major South African universities that have highly active 
biomedical research portfolios, including many large clinical trials. Further, this study was a 
retrospective analysis of previous REC minutes and decision letters. The researcher did not 
prospectively observe the actual REC meetings. Thus, salient ethical issues raised by REC 
members during the rich conversational deliberations could have been omitted in the minutes 
analysed – even though many of the points in the minutes are transcribed by REC staff directly 
into the minutes, which in turn are extracted into decision letters to applicants. An ethnographic 
approach would possibly allow the more richly deliberated ethical issues be identified and 
provide in-depth insights into the review process (de Jong et al., 2012; Klitzman, 2015; Stark, 




Additionally, there was an untested assumption that the two RECs had comparable types of 
applications reviewed. Different workloads and types of protocols reviewed could influence the 
nature and frequency of ethical issues raised by RECs. Another limitation was that it was not 
possible to determine whether the low ranked ethical issues such as social value (ranked tenth 
overall), were well addressed in the research protocols or were thoroughly addressed through 
comprehensive ethics application forms, as suggested by some of the interviewees, or were 
caused by reviewers’ blind spots.  Furthermore, there is no agreed upon normative framework to 
interpret the ranking or frequency of queries, hence one of the reasons for qualitative interviews 
with REC members who confirmed that the distribution of the ethical issues was roughly what 
they would expect from such an analysis. A further critique of their commentary might be that 
they knew that they were indirectly reviewing their own REC’s work (plus that of one other 
anonymous REC) which could have inclined interviewees to be uncritical. A future study should 
seek commentary from independent REC members or research ethics experts.  
 
A further limitation is that members from both RECs stated that they had been trained using the 
Emanuel et al. (2004) framework, thus contributing to review outcomes compatible with this 
framework. Future work will explore REC outcomes from RECs whose members have not been 
trained using this popular framework. Hopefully these data would contribute to the development 
of a normative framework on how frequently these queries should be raised by RECs. A further 
multinational study is underway to collect, compare and aggregate similar data from several 
African countries. In addition, the coding of the minutes into the Emanuel et al. (2004) categories 
might have been unreliable, even though a co-rater attained 75% concordance with the researcher 




The analyses of REC minutes using the Emanuel et al. (2004) framework presented in this study 
focused on ethical issues raised by two South African biomedical RECs. The findings of this 
present study suggest that while the relative weight given to ethical principles varied slightly 
across the two different RECs, the core issues raised were very similar and consistent with 
established national guidance (Department of Health, 2004, 2015). For instance, the findings 
highlighted that informed consent was the most frequent ethical issue raised by both RECs, 
followed by ongoing respect for participants (ranked second) and scientific validity (ranked 
third). The other remaining Emanuel et al. (2004) issues were ranked differently by the two 
RECs (see Figure 9). For example, collaborative partnership was the fourth most frequent issue 
raised by REC 1, while it was seventh at REC 2. Similarly, fair participant selection was ranked 
fifth and sixth at REC 1 and 2 respectively. Likewise, favourable risk/ benefit ratio was the sixth 
most frequent issue raised at REC 1, but was ranked fourth at REC 2. Social value was the least 
frequent issue raised by both RECs in this study. The frequencies of ethical issues raised by the 
two RECs sampled in this study largely resemble the findings reported in a similar previous 
study (Tsoka-Gwegweni & Wassenaar, 2014). 
  
Furthermore, the present study also found that the frequency of additional queries raised by both 
RECs, coded as administrative queries e.g., funding and CVs (4th ranked) and editorial errors 
(ranked 6th overall) was higher compared to, perhaps more important, ethical issues such as 
favourable risk/benefit ratio and fair participant selection. This suggests that researchers really 
need to proof-read their ethics applications and check all of the information and additional 
documentation required before submission because the likelihood is that RECs will find 
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something in the application that is of (ethical) concern to them or that they want further 
information about.  Similar studies in the UK have also reported that RECs frequently identify 
errors such as missing information and discrepancies in applications for ethics approval (Angell 
& Dixon-Woods, 2009). 
 
The findings of the present study hopefully provide valuable empirical insight into some of the 
ethical issues raised by two South African biomedical RECs. Researchers submitting protocols 
need to be aware of, and address in advance, concerns about informed consent (ranked first), 
respect for participants (ranked second) and scientific validity (ranked third), as these were 
frequently raised and ranked highest by both RECs. While they were not as highly ranked in the 
present study, other ethical issues such as collaborative partnership (ranked 5th), favourable 
risk/benefit ratio (ranked 7th), fair participant selection (ranked 8th) and social value (ranked 
10th), are equally important and should be thoroughly addressed in applications for ethics 
approval. The data shows that, overall, the Emanuel et al. (2004) framework seems compatible 
(83%) with the type of ethical issues identified by both RECs in this study. Almost all 
respondents regarded the framework as an adequate, concise and comprehensive research ethics 
framework compatible with review activities of local RECs.  
 
However, certain limitations of the framework were noted. The framework does not explicitly 
mention issues related to storage and use of biological samples such as the need to have export 
permits or MTAs, yet these requirements are required by the South African national guidelines 
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(Department of Health, 2015). As such, this could be added as a benchmark of collaborative 
partnership in the Emanuel et al. (2004) framework.  
 
Secondly, the framework does not explicitly address administrative issues, such as funding and 
investigator CVs. These issues have a considerable bearing on the social value, favourable 
risk/benefit ratio and scientific validity of proposals as previously described and could be added 
as benchmarks under these respective headings in the Emanuel et al. (2004) framework.  The 
South African (Department of Health, 2015) and most international ethical guidelines such as 
CIOMS (2002) and Declaration of Helsinki (2013) explicitly require that research be conducted 
by a competent investigator - reflected in their certification, knowledge and experience. This 
concern could probably be included as a subsection of scientific validity.  
 
Overall, it is reassuring that the majority of ethical issues raised by the two index RECs in this 
study resonated well with  principles in the national research ethics guidance (Department of 
Health, 2004, 2015) as well as international guidelines such as the Declaration of Helsinki 
(WMA, 2013). Nonetheless, there is need for RECs to be constantly re-trained and kept abreast 
with ethical issues in international biomedical research to be able to apply the Emanuel et al. 
(2004) framework and national guidance (Department of Health, 2015) optimally in their 




This study has hopefully generated empirical data and highlighted some of the important ethical 
issues typically considered by two South African biomedical RECs during their ethics review 
work. It is hoped that findings of this thesis could be used to alert future investigators about the 
concerns raised by local RECs reviewing biomedical research and what issues should be 
addressed in their applications for ethics approval. It is also hoped that the findings will be of use 
in training REC members with regard to common and possibly neglected issues in ethics review.  
 
8.3 Recommendations for future research 
First, the study was based on a retrospective analysis of REC minutes. Further ethnographic 
studies of ethical issues raised during REC meetings would be very useful as they are more likely 
to give in depth insight into the kinds of issues discussed and the decision-making process 
(Klitzman, 2015; Stark, 2012). Secondly, the study involved only two South African RECs.  
Future studies comparing a bigger sample of RECs in South Africa would be worthwhile. Such a 
study is currently underway in about ten additional African countries.  
 
Second, the RECs sampled in this study stated that they mainly depend on the Emanuel et al, 
(2004) framework for ethics training of their REC members. This could have contributed to why 
the ethical issues identified in this study were compatible with this framework. Therefore future 
studies could explore ethical issues raised by RECs whose members have not been trained using 
this popular framework. Perhaps such studies might uncover a different pattern of ethical issues 




Furthermore, it was interesting to note the high ranking of certain issues e.g., informed consent 
and respect for participants. This may perhaps be due to lack of knowledge or limited 
understanding of these ethical issues among researchers or inadequate specification of 
requirements in the RECs’ application forms. It remains unclear how researchers view and 
understand the ethical issues identified in this study. Further in-depth interviews about these 
findings with such stakeholders will be useful. Importantly, researchers need to familiarise 
themselves with their institutional REC’s framework and national (Department of Health, 2015) 
and international ethical standards governing biomedical research such as the Declaration of 
Helsinki (WMA, 2013). When researchers familiarise themselves with principles of ethical 
research and really think about these ethical issues, and work closely with their local RECs, there 
is increased likelihood for fewer ethical queries on their applications because they would have 
submitted well-written protocols and improved informed consent documents that better address 
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Appendix 1: Data collection form 
Title: An empirical investigation of ethical issues raised by two Research Ethics Committees 
reviewing biomedical research in South Africa.  
1. General  
1.1 Research protocol unique code: ------------- 
1.2 REC unique code: ---------------------- 
1.3 Year of ethical review    
A. 2009   
B. 2010   
C. 2011   
D. 2012   
E. 2013 
 
1.4 Type of research    
A. Cross-sectional    D. Case-control 
B. Clinical Trial   E. Descriptive 
C. Cohort    F. Other: ------------------------------  
 
1.5 Area of Research: --------------------------  
1.6 Research participants  
A. Children  
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B. Adults  
C. Other: ________________________________________________________________ 
 
1.7 Vulnerable group 
A. Pregnant women  
B. Children 
C. Prisoners 
D. Mentally ill 
Other __________________________________________________________________ 
 











PRINCIPLE 1: COLLABORATIVE PARTNERSHIP  
Develop partnerships with researchers, makers of health 
policies, and the community 
   
Involve partners in sharing responsibilities for determining 
the importance of health problem, assessing the value of 
research, planning, conducting, and overseeing research, 
and integrating research into the health-care system 
   
Respect the community’s values, culture, traditions, and 
social practices 
   
Develop the capacity for researchers, makers of health 
policies, and the community to become full and equal 
partners in the research enterprise. 
   
Ensure that recruited participants and communities receive 
benefits from the conduct and results of research. 
   
Share fairly financial and other rewards of the research.    
PRINCIPLE 2. SOCIAL VALUE  
Specify the beneficiaries of the research—who.    
Assess the importance of the health problems being 
investigated and the prospective value of the research for 
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each of the beneficiaries—what 
Enhance the value of the research for each of the 
beneficiaries through dissemination of knowledge, product 
development, long-term research collaboration, and/or 
health system improvements 
   
Prevent supplanting the extant health system infrastructure 
and services 
   
PRINCIPLE 3. SCIENTIFIC VALIDITY  
Ensure that the scientific design of the research realizes 
social value for the primary beneficiaries of the research 
   
Applicability of results- Ensure that the scientific design 
realizes the scientific objectives while guaranteeing 
research participants the health-care interventions to which 
they are entitled. 
   
Ensure that the research study is feasible within the social, 
political, and cultural context or with sustainable 
improvements in the local health-care and physical 
infrastructure 
   
PRINCIPLE 4. FAIR PARTICIPANT SELECTION  
Select the study population to ensure scientific validity of 
the research. 
   
Select the study population to minimize the risks of the 
research and enhance other principles, especially 
collaborative partnership and social value 
   
Identify and protect vulnerable populations.    
PRINCIPLE 5. FAVOURABLE RISK-BENEFIT RATIO  
Assess the potential risks and benefits of the research to the 
study population in the context of its health risks. 
   
Assess the risk-benefit ratio by comparing the net risks of 
the research project with the potential benefits derived from 
collaborative partnership, social value, and respect for study 
populations. 
   
PRINCIPLE 6. INDEPENDENT  REVIEW  
Ensure public accountability through reviews mandated by 
laws and regulations. 
   
Ensure public accountability through transparency and 
reviews by other international and nongovernmental bodies, 
as appropriate 
   
Ensure independence and competence of the reviews.    
PRINCIPLE 7. INFORMED CONSENT  
Involve the community in establishing recruitment 
procedures and incentives 
   
Disclose information in culturally and linguistically 
appropriate formats. 
   
Implement supplementary community and familial consent 
procedures where culturally appropriate 
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Obtain consent in culturally and linguistically appropriate 
formats. 
   
Ensure the freedom to refuse or withdraw.    
PRINCIPLE 8. RESPECT FOR PARTICIPANTS  
Develop and implement procedures to protect the privacy 
and confidentiality of recruited and enrolled participants 
   
Ensure that participants know they can withdraw without 
penalty. 
   
Provide enrolled participants with information that arises in 
the course of the research study 
   
Monitor and develop interventions for medical conditions, 
including research-related injuries, for enrolled participants 
at least as good as existing local norms. 
   
Inform participants and the study community of the results 
of the research. 
   
 




















Appendix 2: Interview guide 
Topic guide: Semi-structured interviews with REC members 
General experience and views about REC ethics review 
1. Can you tell me about your experience with REC reviews?  
• What do you think is the core function of your REC? Can you tell me about issues/ 
benchmarks that you associate with ethical research? 
• Based on your experience reviewing research protocols, please identify common (ethical) 
issues or concerns that you see in proposals. [Probe for all types of ethical issues known]. 
Can you think of any other issues? 
• Can you please define/ tell me more about the categories/issues raised above. What are 
the most important considerations/indicators e.g. collaborative, social value, informed 
consent, respect for participants. etc. 
• What do you think are the main ethical issues that local RECs should consider when 
reviewing research?  [Why should these be raised or not?]  
• In general, what kind of issues (of those you have just mentioned) do you see as more 
important than others? Would you even argue that there are important issues than others? 
Why are these important? 
• Do you think all the relevant ethical issues are given adequate consideration by your 
REC?  
• Do you feel that there are issues that should be given more consideration than others 
during ethics review? [Probe for reasons why or why not] 
 
Views about the data summary [to be shown to each interviewee] 
2. What do you think about this distribution? 
• Would you expect such a distribution from your REC? [probe for reasons]  
• How would you compare these two sets of issues? Overall, do you think they reflect what 
local RECs should be doing?  [probe for reasons why or why not]? 
• Would you argue that there are any categories overemphasized or under-emphasized?  
• Are there any surprises? [why or why not] 
• Do you think some issues should be queried more than others? [probe for the type of 
issues and reasons why] 
• Could the above distribution be due to a bias in the application form?  
• Do you think your REC application form captures all the main ethical issues in the shown 
in the data? 
• Do you think there is a REC doing a better job at protecting participants than the other? If 
so why do you say this? In what way do you think one REC is doing better than the 
other? [draw on data explained in the graphs above] 
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• What would you, as a REC member/chair/administrator, ideally like to see addressed in 
the proposals that you review or during REC deliberations? Is there anything missing in 
the data presented? 
 
General views about the Emanuel framework 
3. What are your views about the Emanuel framework? 
 
• Are you familiar with the Emanuel framework? 
• Do you think the Emanuel benchmarks are important or relevant to your work? In what 
way do they seem important or pertinent to your REC? 
• Is the framework compatible with issues that you pick up in your typical review 
activities?  
• Are there any types of issues raised by your REC and not covered in the framework that 
you would like to see in the framework? [Why or why not. Probe around administrative 
queries]. 
 
Concluding remarks and reflections 













Appendix 3: Informed Consent Form 
PARTICIPANT INFORMATION LEAFLET  
 
 
TITLE OF THE RESEARCH PROJECT:  An empirical investigation of ethical issues raised by 
research ethics committees reviewing biomedical research in South Africa 
 
PRINCIPAL INVESTIGATOR: Mr Blessing Silaigwana 
 
ADDRESS: University of KwaZulu-Natal 
College of Humanities 
School of Applied Human Sciences 





   
Hello. My name is Blessing Silaigwana and I am a PhD student at the University of KwaZulu-
Natal. I would like to invite you to participate in a research project that aims to investigate the 
views of Research Ethics Committee (REC) members on the issues typically raised by local 
RECs. This study will help us to understand aspects of the ethical issues that RECs typically 
identify in their review activities. 
 
Please take some time to read the information presented here, which will explain the details of 
this project and contact me if you require further explanation or clarification of any aspect of the 
study. Also, your participation is entirely voluntary and you are free to decline to participate.  If 
you say no, this will not affect you negatively in any way whatsoever.  You are also free to 
withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the XXXXXX (REC) at XXXXXXX University (Ref 
XXXXX) and University of XXXXXX Research Ethics Committee (Ref XXXXX) and will be 
conducted according to accepted and applicable National and International ethical guidelines and 
principles, including those of the international Declaration of Helsinki 2013.  
 
What is this research study all about? 
 
The purpose of this component of my study is to explore the views of Research Ethics 
Committee (REC) members on the issues raised by local RECs. The investigator will present you 
with materials reflecting typical queries of RECs to applications for ethics approval. This study 
will help us understand perspectives on the ethical issues that RECs typically identify in their 
review activities. 
Your participating involves taking part in an in-depth interview lasting between 30-45 minutes. 
You will be asked some open-ended questions, based on the data presented, which will help us to 
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explore these ethical issues. The questions are not personal or sensitive in any nature, but you are 
free not to answer any specific question. 
The study will be conducted at your University and one other South African University. Details 
of both participating institutions will be anonymised in all reports and publications. Altogether 
15 participants will be recruited for this study. 
 
Why have you been invited to participate? 
You have been invited to participate because as a REC member who is familiar with the ethical 
review process of biomedical research studies, we would like to explore your views on the 
ethical issues typically raised by the two participating RECs. Your comments will help us 
understand the data from the first part of this study. 
 
What will your responsibilities be? 
Your responsibilities will be to voluntarily give your opinions and responses to some open-ended 
questions asked in the form of an in-depth interview. You will be presented with a synopsis of 
results obtained from the analysis minutes and letters of two South African RECs. You will be 
asked for your opinions and views about the ethical issues identified by RECs.  I would also like 
to ask your permission to audio record the interviews. 
 
Will you benefit from taking part in this research? 
There are no direct benefits that you will receive from participation in this study. However, your 
participation in the study has potential to contribute scientific knowledge to the research being 
conducted. We have also offered to present our findings to the two participating RECs. 
 
Are there in risks involved in your taking part in this research? 
Presently, there are no any foreseeable risks in your participation. All data will be completely 
anonymized and your name and the name of your institution will not be recorded anywhere nor 
revealed in subsequent publications. 
 
If you do not agree to take part, what alternatives do you have? 
Please note that participation is voluntary and completely based on your willingness. You are not 
being forced to take part in this study. The choice of whether to participate or not, is yours alone. 
If you choose not to take part, you will not be affected in any way whatsoever. If you agree to 
participate, you may stop participating in the research at any time. You are guaranteed that there 
will be no penalties or any action taken against you and you will not be prejudiced in any way 
should you decide to withdraw from the study. If you chose not to take part or chose to withdraw 
from this study, your welfare will not be affected in any way. 
 
If you are willing to participate in this study please sign the attached Declaration of 
Consent and hand it to the investigator.  
 




By signing below, I …………………………………..…………. agree to take part in a research 
study entitled An empirical investigation of ethical issues raised by Research Ethics 
Committees reviewing biomedical research in South Africa. 
 . 
 
I declare that: 
 
• I have read the attached information leaflet and it is written in a language with which 
I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
• I may be asked to leave the study before it has finished, if the researcher feels it is in 
my best interests, or if I do not follow the study plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. On (date) …………....……….. 2015. 
 
 




CONSENT FOR TAPE RECORDING  
I hereby agree to the tape-recording of my participation in the study.  
 
……………………………..  
Signature of participant       
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Appendix 5: Ethics approval from University 2 
Withheld to retain confidentiality. Available on request for audit purposes 
 
 
 
 
 
